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ABSTRACT OF DISSERTATION 
 
 
 
 
RAD GTPASE: IDENTIFICATION OF NOVEL REGULATORY MECHANISMS 
AND A NEW FUNCTION IN MODULATION OF BONE DENSITY AND 
MARROW ADIPOSITY  
 
 The small GTP-binding protein Rad (RRAD, Ras associated with diabetes) 
is the founding member of the RGK (Rad, Rem, Rem2, and Gem/Kir) family that 
regulates voltage-dependent calcium channel function. Given its expression in 
both excitable and non-excitable cell types, the control mechanisms for Rad 
regulation and the potential for novel functions for Rad beyond calcium channel 
modulation are open questions.  Here we report a novel interaction between Rad 
and Enigma, a scaffolding protein that also binds to the E3 ubiquitin ligase Smad 
ubiquitin regulatory factor 1 (Smurf1).  Overexpression of Smurf1, but not of a 
catalytically inactive mutant enzyme, results in ubiquitination of Rad and down 
regulation of Rad protein levels.  The Smurf1-mediated decrease in Rad levels is 
sensitive to proteasome inhibition and requires the ubiquitination site Lys204, 
suggesting that Smurf1 targets Rad for degradation.  Rad protein levels, but 
notably not mRNA levels, are increased in the hearts of Enigma-/- mice, leading 
to the hypothesis that Enigma may function as a scaffold to enhance Smurf1 
regulation of Rad. 
 
 In addition to ubiquitination, phosphorylation of RGK proteins represents 
another potential means of regulation.  Indeed, Rem phosphorylation has been 
shown to abolish calcium channel inhibition.  We demonstrate that β-adrenergic 
signaling promotes Rad phosphorylation at Ser39. Rad Ser39 phosphorylation is 
correlated with a decrease in the interaction between Rad and the CaVβ subunit 
of the calcium channel and an increase in Rad binding to 14-3-3.  Interestingly, 
Enigma overexpression promotes an increase in Rad Ser39 phosphorylation as 
well.  Despite an interaction between Enigma and the CaV1.2 calcium channel 
subunit, overexpression of Enigma had no effect on Rad-mediated channel 
inhibition.  Thus, Rad Ser39 phosphorylation alters its association with the 
calcium channel, but its impact on calcium channel regulation has yet to be 
determined. 
 
 Finally, we report a novel function for Rad in the regulation of bone 
homeostasis.  Rad deletion in mice results in a significant decrease in bone 
mass. Dynamic histomorphometry in vivo and primary calvarial osteoblast assays 
in vitro demonstrate that bone formation and osteoblast mineralization rates are 
depressed in the absence of Rad.  Microarray analysis revealed that canonical 
osteogenic gene expression is not altered in Rad-/- osteoblasts; instead robust 
up-regulation of matrix Gla protein (MGP, +11-fold), an inhibitor of mineralization 
and a protein secreted during adipocyte differentiation, was observed.  Strikingly, 
Rad deficiency also resulted in significantly higher bone marrow adipose tissue 
(BMAT) levels in vivo and promoted spontaneous in vitro adipogenesis of primary 
calvarial osteoblasts.  Adipogenic differentiation of WT osteoblasts resulted in the 
loss of endogenous Rad protein, further supporting a role for Rad in the control of 
BMAT levels.  These findings reveal a novel in vivo function for Rad signaling in 
the complex physiological control of skeletal homeostasis and bone marrow 
adiposity. 
 
 In summary, this dissertation expands our understanding of Rad 
regulation through identification of a novel binding partner and characterization of 
post-translational regulatory mechanisms for Rad function. This work also 
defines a new role for Rad that may not depend upon its calcium channel 
regulatory properties: regulation of the bone-fat balance.  These findings suggest 
that the regulation of Rad GTPase is likely more complex than guanine 
nucleotide cycling and that functions of Rad in non-excitable tissues warrant 
further study. 
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Chapter 1 
 
Introduction 
 
Ras superfamily of small GTPases 
The Ras superfamily of small monomeric GTP-binding proteins consists of over 
170 structurally related proteins that regulate a diverse array of signal 
transduction cascades and cellular functions [1].  All Ras-related GTPases 
contain five conserved domains known as G1-G5 and function as guanine 
nucleotide-dependent switches that are in an active state when bound to 
guanosine triphosphate (GTP) and an inactive state when bound to guanosine 
diphosphate (GDP) [2].  Guanine nucleotide exchange factors (GEFs) promote 
GTP loading of these small G-proteins by facilitating the release of GDP, while 
GTPase activating proteins (GAPs) catalyze the hydrolysis of GTP to GDP and 
thus promote inactivation [2].  The small GTPases of the Ras superfamily are 
divided into five large families, Ras, Rab, Rho, Arf, and Ran, which are further 
classified into subfamilies based on structural and functional conservation [1].  
The studies in this dissertation will focus primarily on Rad, a member of the RGK 
subfamily within the Ras family. 
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RGK subfamily of the Ras-related small GTPases 
The RGK subfamily of small GTPases consists of four members: Rad (Ras 
associated with diabetes; also known as Rrad) [3], Rem (Rad- and Gem-like; 
also known as Rem1 or Ges) [4], Rem2 (Rad- and Gem-like 2) [5], and Gem/Kir 
(gene expressed in mitogen-stimulated T-cells, or tyrosine kinase-inducible Ras-
like) [6].  RGK subfamily G-proteins share a number of unique structural features 
that are distinct compared to other Ras-related proteins [7-9].  For instance, RGK 
proteins contain non-conservative substitutions within regions of the Ras core 
domain that are required for nucleotide binding and hydrolysis.  Moreover, 
proteins of the RGK subfamily have long N- and C-terminal extensions compared 
to other members of the Ras superfamily, and the C-terminus of these proteins 
lacks the -CAAX motif that permits lipid modification and directs membrane 
association of most Ras-related GTPases [10].  Instead, RGK proteins have a 
conserved polybasic C-terminal motif that directs membrane association without 
lipid modification, and the C-terminal extension also serves to regulate RGK 
protein function.  The N-terminal extensions range in length from 44-88 amino 
acids and are not conserved within the RGK family, and the putative G2 effector 
domains also differ among RGK proteins [11].  This lack of conservation 
observed within RGK effector domains implies that the regulatory proteins and 
downstream effector proteins with which RGK proteins interact may be distinct.  
Established functions for RGK proteins include inhibition of the activity of voltage-
dependent calcium channels (VDCCs) through an interaction with the accessory 
CaVβ subunit [11-18] and regulation of cytoskeletal dynamics through control of 
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the Rho/Rho kinase signaling axis [19-22], and a growing literature suggests the 
potential for novel functions of RGK family proteins in processes including 
metabolism [23-27], tumorigenesis [24-39], transcriptional regulation [25, 40-42], 
and stem cell differentiation [42-46].  The means by which RGK protein function 
is regulated in each of these settings is an active area of investigation in the field.  
Interestingly, RGK proteins exhibit distinct tissue expression profiles [11], and 
expression of RGK proteins is regulated at the transcriptional and 
posttranscriptional levels in a variety of contexts [3, 4, 6, 20, 26, 30-32, 34, 35, 
37, 41, 43, 44, 46-74].  This chapter will review the structural and functional 
properties of RGK subfamily proteins, discuss the regulation of RGK proteins 
through subcellular localization, post-translational modifications, and expression 
level changes, and delve into the physiological significance of RGK proteins with 
a specific emphasis on the Rad GTPase.  Following an introduction to RGK 
proteins, osteoblast differentiation and bone biology will be briefly outlined as 
these are pertinent to data presented in Chapter 5 expanding our current 
understanding of Rad GTPase function.   
RGK proteins have a unique primary structure compared to other Ras 
family GTPases 
The amino acid sequences of RGK proteins contain a number of non-
conservative substitutions at positions important for guanine nucleotide binding 
and hydrolysis [4, 5] (Figure 1.1).  First, RGK proteins contain substitutions 
within the G1 motif involved in phosphate binding. The residue equivalent to 
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Gly12 in Ras is highly conserved among Ras-related GTPases, and mutation of 
this residue results in constitutive activation of Ras and Rho family GTPases.  
Notably, this residue is substituted in all four RGK proteins (to proline in Rad and 
Rem2, to serine in Rem, and to glutamine in Gem; Figure 1.1).  Moreover, the 
highly conserved Thr35 residue within the Ras switch I domain, which senses the 
γ-phosphate and facilitates the conformational change of Ras family proteins in 
response to nucleotide cycling, is absent in the RGK subfamily (Figure 1.1). 
Furthermore, the highly conserved phenylalanine residue in the switch I motif 
responsible for capping the guanine ring to promote high affinity nucleotide 
binding is substituted in each of the RGK proteins (Figure 1.1).  Mutation of the 
equivalent Phe28 in H-Ras to leucine resulted in a higher rate of nucleotide 
dissociation.  The RGK protein G2 and G3 domains, which promote the 
conformational change within Ras family proteins in response to GTP binding, 
also exhibit key sequence divergences compared to other Ras family GTPases.  
All four RGK proteins share a conserved DXWEX G3 motif with a bulky 
tryptophan and charged glutamate residue that are in striking contrast to the 
small alanine and glycine residues in the conserved DTAGQ motif of other Ras-
related G-proteins [75] (Figure 1.1).  The glutamine residue in this motif, which is 
critical for GTP hydrolysis in Ras, is conserved in Rad and Rem2 but is 
substituted for alanine and asparagine in Rem and Gem, respectively (Figure 
1.1).  Despite its conservation in Rad, however, mutation of this glutamine 
residue appears to have no effect on GTPase activity [76].  Finally, the G2 
domain, which serves as the primary docking site for downstream effector 
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proteins, is characteristically highly conserved within Ras subfamilies.  
Intriguingly, this putative G2 effector domain differs across the RGK subfamily, 
suggesting that individual RGK effector proteins may be distinct. The differences 
in RGK protein G2 effector domains also imply that interactions that are shared 
by each of the RGK proteins, such as binding to the CaVβ subunit of the calcium 
channel, may not be nucleotide dependent.  
The differences in RGK protein primary structure when compared to other Ras 
family GTPases first suggested that RGK proteins might not function as 
canonical GTPases subject to regulation by GTP/GDP cycling [11].  However, 
despite the sequence divergences observed in the RGK subfamily, all RGK 
proteins exhibit intrinsic, albeit low, GTPase activity and can bind to GTP and 
GDP.  Notably, nucleotide binding for RGK proteins is in the micromolar range, 
much weaker than what is observed for other Ras-related GTPases [3, 4, 6-9, 
77].  Despite efforts at identifying regulatory proteins, GEFs and GAPs for RGK 
protein regulation in vivo have not been found [11].  Early in vitro studies 
indicated that the nucleotide binding status of Rad is modified by the tumor 
suppressor nm23, which can phosphorylate GDP or dephosphorylate GTP bound 
to Rad, but it remains unclear whether nm23 regulates Rad, or other RGK 
proteins, in vivo [28, 78].  Evidence for RGK control through the classical 
GTPase cycle is lacking, and there is no clear indication to date that any known 
RGK binding partners associate in a GTP-dependent fashion [11]. These 
reasons, coupled with the identification of other unique means of RGK regulation 
including transcriptional control, post-translational modifications, and alteration of 
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subcellular localization, question the importance of GTP-binding to RGK 
activation and downstream signaling [11].  
Structure of RGK subfamily GTPases 
Crystal structures of the core G-domains of Rad, Gem, and Rem2 in the GDP-
bound state indicate that the overall RGK G-domain structure is similar to Ras 
and other small GTPases with a central β-sheet of six strands (β1-β6) and five 
surrounding α-helices (α1-α5) [7-9, 79].  In each of these structures, the GDP 
nucleotide was present in the canonical nucleotide-binding pocket observed for 
other Ras family GTPases; however, in contrast to Ras, there are fewer contacts 
between RGK proteins and the bound nucleotide.  In particular, the switch I 
region, which covers the bound nucleotide in Ras, is further from the bound 
nucleotide in the structures of Gem and Rad [7-9, 79].  The switch I and switch II 
regions of each of the RGK proteins are conformationally flexible in the GDP-
bound state [7-9, 79].  Intriguingly, the recent crystal structures of the Rad and 
Rem2 G-domains bound to GNP, a non-hydrolyzable GTP analog, revealed 
almost no difference in conformation compared to the GDP-bound structures 
[77].  Specifically, the conformational change in the switch I region of Ras in 
response to GTP binding was absent in the Rad:GNP and Rem2:GNP structures, 
suggesting that RGK proteins may not undergo the canonical nucleotide-
dependent molecular switching characteristic of other small GTPases [77].  One 
caveat to such a conclusion is that these structures were obtained from the 
isolated RGK GTP-binding domains, without the N- and C-terminal extensions.  
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The contributions of these extensions to the structure of RGK proteins, 
particularly of the switch regions, remain unclear.  It is worth noting that Splingard 
and colleagues reported the structure of the G-domain of Gem along with the 
majority of the C-terminal extension and observed that a portion of this extension 
folds into an α-helix that makes contacts with the G-domain [8] in a manner that 
is similar to the N-termini of GDP-bound Arf proteins and the C-terminus of Ran 
[80, 81].  While this region is conserved in Rad, it differs in Rem and Rem2, 
which instead contain a Src homology 3-binding motif (PXXP) that cannot form 
an α-helical fold.  The N- and C-terminal extensions of Gem influenced its 
intrinsic GTPase activity but not its affinity for nucleotides [8].  Additional crystal 
structures of full-length RGK proteins bound to GDP and GTP are necessary to 
clarify whether these extensions may undergo rearrangements in response to 
nucleotide binding and modulate the overall RGK structure.  
One other important observation in these biochemical and structural analyses is 
that the putative dominant negative mutation, equivalent to Ras S17N, in RGK 
proteins must be approached with caution.  The Ras S17N mutant is locked in a 
GDP-bound state and is thought to form non-productive, stable interactions with 
GEF proteins and thereby sequester them away from wildtype GTPases in the 
cell [82, 83].  This serine residue is conserved in RGK subfamily proteins and has 
been mutated to asparagine in order to generate a “dominant negative” RGK 
protein in a number of studies in the literature [84-90].  However, Opatowsky et 
al. and Sasson et al. reported that Gem S89N and Rad S105N may in fact be 
non-native proteins that fail to bind nucleotide or exhibit only partial occupancy of 
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nucleotide [7, 77].  In addition, they reported that these mutants express quite 
poorly [7, 77], which is an observation we have made in the laboratory as well.  
Hence, these mutants may not represent a dominant-negative protein as 
expected. 
RGK protein function: regulation of cytoskeletal dynamics 
RGK proteins, especially Rad and Gem, have been reported to promote cell 
shape remodeling through regulation of the cytoskeleton. Rad- and Gem-
mediated changes in cell morphology are mediated through direct and indirect 
modulation of Rho/Rho kinase signaling [19, 22, 91, 92].  Both Gem and Rad 
directly bind and antagonize Rho kinase (ROK), with Gem specifically binding 
and inhibiting ROKβ and Rad showing specificity for ROKα [19]. Ectopic 
expression of Rad or Gem induced cell flattening and neurite extension through 
inhibition of ROK-mediated cell rounding and neurite retraction [19, 93].  In 
epithelial and fibroblastic cells, blunting of ROK signaling through ectopic Rad or 
Gem expression caused disassembly of stress fibers and focal adhesions [19, 
20].  In addition to direct inhibition of ROK activity, recent yeast-two hybrid 
studies have identified another cytoskeletal regulatory pathway in which Gem 
associates with the novel Gem-interacting protein (Gmip), which serves as a 
GAP for Rho GTPase, and Ezrin, which is a membrane-cytoskeleton linker 
protein [22].  The interaction between Gem and Ezrin at the interface between 
the plasma membrane and the cytoskeleton is required for the recruitment and 
activation of Gmip, which in turn serves to inhibit Rho signaling [22].  More recent 
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studies have highlighted the importance of the Gem-Ezrin-Gmip interaction to 
Gem-mediated cytoskeletal rearrangements, as knockdown of Gmip or 
introduction of constitutively active RhoA rescued the Gem overexpression 
phenotype [92].  Notably, although Ezrin has only been reported as a binding 
partner for Gem [22], co-immunoprecipitation and mass spectrometry studies 
conducted in our laboratory suggest that Rad also associates with Ezrin and the 
related proteins Radixin and Moesin (data not shown).    
Gem has also been studied in its regulation of the microtubule cytoskeleton [94-
96]. Kinesin-like protein (KIF9) is a microtubule-associated protein that binds to 
Gem, and these two proteins together induce changes in cell morphology [95] 
and regulate spindle length and chromosome alignment during mitosis [94]. 
Interestingly, Gem expression is up regulated in the brains of tau-deficient mice, 
and Gem overexpression in Chinese hamster ovary cells induced cell elongation 
that was inhibited by the microtubule-associated tau protein [96], further 
suggesting a role for Gem in the microtubule cytoskeleton.   
Although they have been less studied, both Rem and Rem2 have been reported 
to regulate cytoskeletal dynamics as well [69, 89, 97-99].  Rem overexpression 
induced endothelial cell sprouting [89], and Rem2 is a negative regulator of 
dendritic complexity in neurons [69, 97-99].  Notably, Rem and Rem2 do not bind 
to or regulate either ROK isoform [19], and it remains unclear whether these 
proteins associate with Ezrin to control the activity of Gmip.  Thus, further studies 
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are necessary to clarify the mechanisms of RGK-mediated regulation of 
cytoskeletal dynamics.  
RGK protein function: inhibition of voltage-dependent calcium channels 
Voltage-dependent calcium channels (VDCCs) transduce changes in membrane 
potential at the cell surface into an increase in intracellular calcium concentration 
that can initiate a number of downstream physiological processes [100].  These 
processes include muscle contraction, hormone secretion, synaptic transmission, 
and gene transcription [100].  VDCCs are classified as high voltage-activated 
(HVA) channels or low voltage-activated (LVA) channels based upon their 
activation threshold [100].  HVA calcium channels are composed of a complex of 
proteins, which include a pore-forming CaVα1 subunit and auxiliary β, α2δ,  and in 
some cases γ subunits [100]. In contrast, LVA channels consist of only the CaVα1 
subunit [100].  
The pore-forming CaVα1 subunits are large, 190 kD proteins composed of four 
homologous domains (I-IV) that each include six transmembrane segments (S1-
S6) [100].  In HVA channels, the accessory CaVβ subunit binds with high affinity 
to a conserved region of CaVα1 in the intracellular loop connecting domains I and 
II (I-II loop) known as the α interaction domain (AID) [100].  There are ten genes 
encoding CaVα1 subunits, and these are divided into three families based upon 
sequence similarity and pharmacological properties [100].  The CaV1 family 
contains the L-type calcium channels CaV1.1 (α1S), CaV1.2 (α1C), CaV1.3 (α1D), 
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and CaV1.4 (α1F), and the CaV2 family contains the P/Q-type channel CaV2.1 
(α1A), the N-type channel CaV2.2 (α1B), and the R-type channel CaV2.3 (α1E) 
[100].  The CaV1 and CaV2 families are HVA calcium channels.  L-type calcium 
channels are expressed in skeletal muscle, smooth muscle, ventricular 
myocytes, neuronal dendrites, and osteoblasts in the bone, while P/Q-, N-, and 
R-type calcium channels are primarily expressed in the nervous system [100].  
The LVA calcium channels comprise the third family of CaVα1 subunits, the CaV3 
family, which contains the T-type calcium channels CaV3.1 (α1G), CaV3.2 (α1H), 
and CaV3.3 (α1I) [100].  T-type calcium channels are expressed in neurons, 
pacemaker cells, and osteocytes in the bone [100].   
There are four genes encoding CaVβ subunits, designated CaVβ1-4, and each of 
these has a variety of splice variants [101].  The CaVβ2a isoform is expressed 
highly in the heart and will be used for experiments in this dissertation.  Each of 
the CaVβ subunits contains three variable regions separated by conserved Src 
homology 3 (SH3)-like and guanylate kinase (GK)-like domains [102].  The AID 
domain of the pore-forming CaVα1 subunit, described above, binds with high 
affinity to a region within the CaVβ GK-like domain [100]. The interaction of 
auxiliary CaVβ subunits with CaVα1 contributes to the proper forward trafficking of 
CaVα1 to the plasma membrane and also modulates the gating properties of 
VDCCs resident at the membrane [100].  
The linkage between the RGK subfamily and voltage-dependent calcium 
channels was established when an interaction between Gem and CaVβ3 was 
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identified in MIN6 cells [14].  All four RGK proteins have since been shown to 
function as potent inhibitors of VDCCs, with ectopic expression of RGK proteins 
in a variety of experimental settings ranging from heterologous expression 
systems to primary cells consistently causing almost complete blockade of VDCC 
current (ICa) [12-14].  RGK protein-mediated inhibition has been reported for L-
type, P/Q-type, and N-type calcium channels [11].  Notably, RGK proteins have 
no effect on T-type calcium channels, which do not require CaVβ for current 
expression [12, 103].  In line with a physiological role for RGK proteins in 
inhibiting calcium current, RNA interference and transgenic knockout mouse 
models also indicate that loss of function of RGK proteins in cardiac myocytes 
promotes an increase in VDCC current [104, 105], although the effect was more 
pronounced with loss of function of Rad than Rem.   
The interaction between RGK proteins and the calcium channel complex and its 
likely contributions to RGK-mediated ICa inhibition have been further investigated.  
Each of the four RGK proteins has been shown to bind to CaVβ isoforms [14-16, 
106], and deletion-mapping studies indicate that RGK proteins, like CaVα1, bind 
within the GK-like domain of CaVβ [15].  However, the site for RGK binding to 
CaVβ is structurally distinct from the AID, as evidenced by the identification of 
CaVβ mutants that are null for CaVα1 binding yet retain Rem binding and by the 
observation of simultaneous binding of CaVβ to RGK proteins and CaVα1 [15, 
106]. Interestingly, RGK proteins were subsequently shown to interact directly 
with the CaVα1 pore-forming subunit [18, 107, 108].  Specifically, Gem co-
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immunoprecipitated with CaV2.1 in the absence of CaVβ subunit [108], and three 
RGK family proteins, Rem, Rad, and Gem, were shown to bind to the proximal 
and distal regions of the CaV1.2 C-terminus [107].  Yang and colleagues also 
reported a CaVβ-independent interaction between Rem and CaV1.2, but they 
identified a Rem-binding site within the N-terminus of CaV1.2 [18].  Interestingly, 
Rem2 and Gem failed to bind to the CaV1.2 N-terminus, and Rem did not bind to 
the N-terminus of CaV2.2, suggesting that distinct regulatory mechanisms may be 
at play for different RGK proteins and CaVα1 isoforms [18].  
While it is well established that RGK proteins physically associate with the VDCC 
complex and negatively regulate calcium current, there is debate as to the 
mechanism(s) responsible for this effect.  One model contends that RGK proteins 
inhibit ICa by preventing trafficking of the channel to the surface of the cell through 
interference with the interaction between CaVα1 and CaVβ subunits [14, 16, 64, 
90, 109].  Proponents of this CaVβ sequestration model cite the findings that 14-
3-3 and calmodulin binding alter the subcellular localization of RGK proteins, with 
RGK mutants that are null for binding to 14-3-3 or calmodulin accumulating in the 
nucleus along with co-expressed CaVβ [16].  A second, opposing model suggests 
that RGK proteins bind to and inhibit CaVα1 and CaVβ-containing channels 
present at the plasma membrane [12, 13, 15, 87, 103, 106, 110, 111].  This 
model is supported by the observations that RGK protein binding to CaVβ 
subunits does not block CaVα1 binding [15, 106] and that the C-terminus of RGK 
proteins, which targets them to the plasma membrane, is required for ICa 
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inhibition but not for CaVβ binding [12, 110]. Furthermore, biochemical studies 
demonstrate far higher binding affinity between CaVα1 and CaVβ subunits than 
between RGK proteins and CaVβ; thus, RGK proteins are not abundant enough 
to block or sequester CaVα1:CaVβ complex formation, and there is no evidence 
for a large pool of unbound CaVβ within the cell [15]. Notably, all of the studies in 
support of the decreased surface expression model involved investigation of L-
type calcium channels, or the CaV1 family.  In contrast, analysis of RGK-
mediated inhibition of N-type, or CaV2.1 family, calcium channels consistently 
revealed that RGK proteins inhibit ICa without altering the density of channels at 
the membrane [103, 106, 111].  Thus, it is possible that RGK proteins use distinct 
means of regulating channels from different CaVα1 families.   
Yang and colleagues performed an elegant study of Rem-mediated VDCC 
regulation that has begun to reconcile these seemingly disparate models by 
suggesting that Rem uses a combination of mechanisms to inhibit ICa [17].  First, 
ectopic expression of Rem in HEK293 cells was found to decrease the 
expression of recombinant CaV1.2 channels at the cell surface [17].  Interestingly, 
however, Rem was shown to decrease the surface density of CaV1.2 channels by 
enhancing dynamin-dependent endocytosis of the channel rather than by 
preventing its forward trafficking to the membrane [17].  While the co-expression 
of dominant-negative dynamin with Rem normalized the surface density of 
CaV1.2, Rem-mediated ICa inhibition was still observed, suggesting that Rem is 
also capable of inhibiting calcium channels resident at the cell surface [17].  This 
study and others are beginning to suggest that RGK proteins use multiple 
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mechanisms to inhibit proper localization of calcium channels at the plasma 
membrane as well as to inhibit calcium channels already present at the 
membrane [17, 18].  In summary, studies from many laboratories using diverse 
experimental systems indicate that RGK proteins are intrinsic negative regulators 
of calcium current; however, the mechanisms for regulation of RGK proteins are 
much less characterized, particularly since cells that endogenously express RGK 
proteins are still electrically active.  It also remains unclear whether the dominant 
physiological role for RGK proteins is to block calcium current or whether they 
may have additional roles in the regulation of calcium signaling or of other 
pathways altogether. 
Regulation of RGK subfamily GTPases 
Most Ras-related small GTPases function as molecular switches that are 
regulated by their nucleotide binding status, with nucleotide exchange facilitated 
by specific GEF and GAP regulatory proteins [112].  RGK subfamily proteins may 
be a novel exception, however, because as discussed earlier in this chapter, 
evidence for RGK control via the classical GTPase cycle is lacking [11].  Instead, 
studies from a number of systems indicate that RGK protein function may be 
modulated on a number of levels, through subcellular localization, post-
translational modifications, and even transcriptional control.  Further probing of 
the regulatory mechanisms for RGK proteins is critical to understanding how 
these proteins are controlled within the cell.   
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RGK regulation through subcellular localization 
One layer of regulation of RGK protein function appears to be at the level of 
subcellular localization, as RGKs have been reported to localize to the plasma 
membrane, the cytosol, and the nucleus in various contexts [5, 16, 40, 41, 106, 
109, 110, 113-117].  In particular, the C-terminus of RGK proteins, which is well 
conserved across the subfamily (Figure 1.1), plays an important role in the 
regulation of RGK subcellular distribution in part due to its interactions with other 
proteins [116-120] as well as with the phospholipid bilayer [106, 110].  Following 
its initial cloning, Rem2 was shown to have a punctate plasma membrane 
localization that was abolished upon deletion of the C-terminus [5], despite the 
lack of lipid modification of RGK proteins.  Our laboratory later determined that 
the polybasic motif at the C-terminus of RGK proteins directs them to the plasma 
membrane through association with phosphatidyl inositol phospholipids (PIP 
lipids) [106, 110], and our studies suggest that this plasma membrane targeting 
is essential for calcium current modulation [110], as outlined previously.  In 
addition to the polybasic motif, the C-terminal extension of RGK proteins also 
contains a nuclear localization sequence (NLS) that binds to importin proteins, a 
calmodulin binding site, and two serine residues that can be subject to 
phosphorylation [116].  One of these phospho-serine residues serves as a 14-3-3 
binding site [118], while the other serine residue that is two amino acids 
upstream impedes 14-3-3 binding when phosphorylated [117].  The many 
overlapping regulatory regions within the RGK C-terminus complicate our 
understanding of its role; however, Mahalakshmi et al. showed for all four RGK 
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proteins that importins can bind to the NLS sequence at the C-terminus of RGK 
proteins to facilitate their nuclear transport [116, 117], and mass spectrometry 
studies conducted in our laboratory have also identified an association between 
Rad and importin proteins (data not shown).  Work by Beguin and colleagues 
indicates that binding of 14-3-3 and calmodulin disrupts nuclear transport, likely 
by blocking the association of RGKs with importins [16, 109, 113].  In contrast, 
mutations that abolish 14-3-3 and calmodulin binding result in RGK protein 
accumulation in the nucleus [16, 109, 113].  Interestingly, 14-3-3 binding also 
interferes with PIP lipid binding [106]; hence, 14-3-3 binding to RGK proteins 
promotes cytosolic redistribution.   
While plasma membrane targeting seems to play a crucial role in RGK-mediated 
calcium channel modulation [106, 110], the role of nuclear targeting of RGK 
proteins is not entirely clear.  Beguin and colleagues argued that nuclear 
localization of RGK proteins constitutes a novel mechanism for calcium channel 
inhibition through sequestration of CaVβ [16, 109, 113]; however, it is plausible 
that RGK proteins may have a functional role in the nucleus, especially given 
recent reports that endogenous RGK proteins are localized predominantly in the 
nucleus [115, 117] and that Rad can bind to the transcription factors CCAAT-
enhancer binding protein-delta (C/EBPδ) and RelA/p65 within the nucleus and 
regulate their binding to DNA [40, 41]. 
While many of the earlier studies of RGK protein subcellular distribution 
employed overexpression of wildtype and mutant proteins to probe the roles of 
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various binding partners on RGK localization [16, 109, 113, 116], recent studies 
have suggested that Rem2 subcellular redistribution may be stimulus-dependent 
[98, 114].  In response to N-methyl-D-aspartate (NMDA) receptor activation and 
calcium influx, Rem2 redistributes from a diffuse to a highly punctate pattern that 
colocalizes with calmodulin-dependent protein kinase II (CaMKII) in neurons 
[114].  A subsequent study demonstrated that Rem2 is a novel substrate for 
CaMKII phosphorylation, with CaMKII phosphorylation promoting nuclear 
redistribution of Rem2 [98]. Hence, redistribution of the RGK protein Rem2 from 
the cytoplasm to the nucleus appears to be a physiologically relevant event, but 
the function of Rem2 within the nucleus and the possibility that other RGK 
proteins may undergo stimulus-dependent changes in subcellular distribution 
require further investigation. 
RGK regulation by post-translational modifications 
While evidence for the regulation of RGK proteins by the canonical guanine 
nucleotide cycle is lacking, there is a growing body of literature suggesting that 
RGK proteins may instead be regulated by post-translational modifications, most 
notably phosphorylation.  In particular, Rad phosphorylation at multiple distinct 
serine residues has been demonstrated by a variety of kinases including protein 
kinase A (PKA), protein kinase C (PKC), calmodulin-dependent protein kinase II 
(CaMKII), and casein kinase II [49].  Phosphorylation of RGK proteins has been 
reported to modulate their protein-protein interactions as well as their subcellular 
distribution [16, 49, 109, 113, 116-118, 121].  For instance, phosphorylation of N- 
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and C-terminal serine residues is required for RGK proteins to bind to 14-3-3 
dimers [109, 113, 118, 121].  Interestingly, 14-3-3 binding seems to increase the 
half-life of RGK proteins and to modulate their subcellular localization, specifically 
by excluding them from the nucleus [16, 109, 113, 116, 117, 121].  Moreover, an 
additional C-terminal serine phosphorylation site was identified for all RGK 
proteins that blocks 14-3-3 binding [117].  Phosphorylation of Rad by PKC or 
casein kinase II was shown to reduce binding to calmodulin [49].  Furthermore, 
phosphorylation of serine residues within the C-terminal nuclear localization 
signal of RGK proteins was reported to block association with importins to 
regulate nuclear accumulation [116]. The effects of phosphorylation on binding to 
CaVβ subunits had not yet been explored and will be described in Chapter 4 of 
this dissertation. 
Importantly, a number of recent studies have suggested that phosphorylation of 
RGK proteins at different serine residues may regulate their functions in both 
cytoskeletal reorganization and voltage-dependent calcium channel regulation.  
Phosphorylation of Ser261 and Ser289 in the Gem C-terminus was reported to 
regulate the cytoskeletal reorganization function of Gem separately from its role 
in calcium channel regulation [121].  Similarly, the phosphorylation of C-terminal 
serine residues within the nuclear localization signals that inhibited entry into the 
nucleus also blocked the effects of Gem on the cytoskeleton without impacting its 
ability to regulate calcium current [116].  The function of Rem2 in controlling 
dendritic complexity is also regulated by phosphorylation, as CaMKII 
phosphorylation of Rem2 triggered nuclear localization of Rem2 and was 
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required for its inhibition of dendritic arborization [98]. The physiological 
relevance of RGK phosphorylation is highlighted by the recent report that 
endogenous Rem2 is found in the nuclei of basal ganglia cells and is 
phosphorylated at multiple serine residues [115].  RGK phosphorylation has also 
recently been reported to afford regulation of calcium channel modulation.  Rem 
phosphorylation by protein kinase D1 (PKD1) was shown to reverse Rem-
mediated calcium channel blockade in heterologous expression systems and in 
primary cardiac myocytes [64]. Interestingly, PKA inhibition also partially relieved 
Rem-mediated calcium current inhibition [122], further suggesting that kinase 
cascades modulate RGK blockade of calcium current but that the nature of this 
regulation may be complex. These recent studies suggest that RGK 
phosphorylation is an important regulatory mechanism; however, the kinases that 
regulate RGK phosphorylation and the effects of phosphorylation on RGK 
function more broadly require more extensive study, particularly whether 14-3-3 
binding to phosphorylated RGK proteins may block association with other binding 
partners or whether phosphorylated RGKs may show enhanced binding to 
certain effectors.  It also remains unclear whether the same kinase cascades 
regulate each of the four RGK proteins or whether a diversity of regulatory 
pathways may exist. 
While phosphorylation is the best-studied post-translational modification of RGK 
proteins, mass spectrometry analysis has demonstrated that Rad protein can 
also be ubiquitinated at Lys204 [123, 124]. However, the E3 ubiquitin ligase 
enzyme(s) responsible for catalysis of Rad ubiquitination and the physiological 
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relevance of this modification remain to be determined. The possibility of 
ubiquitin-mediated proteostatic control of Rad will be investigated in Chapter 3 of 
this dissertation.  
Transcriptional regulation of RGK proteins 
In contrast to the regulatory mechanisms reported for most Ras-related small 
GTPases, RGK proteins are unique in their ability to be regulated at the level of 
expression [3, 4, 6, 20, 26, 30-32, 34, 35, 37, 41, 43, 44, 46-74].  Gem was 
initially discovered as a gene up regulated in human T cells following mitogen 
stimulation [6] and in BCR-Abl-transformed B cells [125].  Subsequent studies 
have shown that Gem expression is also up regulated in the context of heart 
failure [50], as well as following stroke [63], sciatic nerve injury [66], spinal cord 
injury [68], peripheral nerve injury [73], and optic nerve crush [70].  Moreover, 
Gem is down regulated in hepatocellular carcinoma, with expression levels 
negatively correlated with the histological grade, the size of the tumor, and the 
invasive and proliferative properties of the cancer [37].  In contrast, high 
expression of Gem in bladder cancer was correlated with decreased survival 
[36].  Expression of Gem as well as Rem2 is induced in MIN6 cells, a pancreatic 
β-islet cell line, following glucose treatment [13, 126].  Insulin and potassium 
chloride treatment of MIN6 cells also induced Gem expression [126].  Rem2 is up 
regulated in developing neurons and in human embryonic stem cells [42, 43], as 
well as in endothelial cells of stage IV pancreatic disease [56].  Rem2 is also 
regulated at the transcriptional level by calcium influx through VDCCs [69].  Rem 
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expression is up regulated in cardiomyocytes following isoproterenol treatment 
[127] and down regulated in mouse cardiac muscle following lipopolysaccharide 
injection [4].   
While all four RGK proteins have been shown to be under transcriptional control 
[3, 4, 6, 13], modulation of Rad expression has been described the most 
frequently, particularly in muscle.   Rad was initially identified as a gene 
overexpressed in the skeletal muscle of type II diabetic individuals [3], although 
analysis of Rad expression in Pima Indians and the Zucker diabetic rat model did 
not find such a correlation [128].  Subsequent studies indicated that Rad 
expression in muscle was positively correlated with body mass index and body 
fat percentage and negatively correlated with resting metabolic rate [129].  
Several independent studies have identified insulin as a stimulus for induction of 
Rad expression in muscle [47, 55, 57], and in the same vein, Rad expression 
was increased in pancreatic islets following exposure to type I diabetic serum 
[58, 65].  Rad expression also appears to be up regulated during muscle 
development and in response to muscle injury, as Rad levels are elevated in the 
progression of myoblasts to myotubes in vitro [128, 130], in regenerating limb 
muscle following amputation in the newt [46], in denervated mouse muscle [51, 
61], in ALS muscle [61], in vascular smooth muscle following balloon injury [20] 
and stimulation with platelet-derived growth factor [62], in dissecting aorta [72], 
and in the myogenic progenitor cell population during skeletal muscle 
regeneration [54].  In the heart, Rad expression is up regulated following 
ischemic preconditioning [60] and down regulated in heart failure [131, 132].  Rad 
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levels are also altered in a number of other tissues [34, 48, 52, 53, 67, 74], which 
will be described in more detail later.  Taken together, these studies indicate that 
RGK proteins, and Rad in particular, are regulated at the level of expression.  
Evidence suggests that much of this regulation occurs at the level of 
transcription; however, post-translational protein stability could provide an 
additional level of control that remains to be explored, especially given the 
observation that Rad protein is subject to ubiquitination [123, 124].   
Physiological significance of the RGK subfamily protein Rad 
While the functions of RGK proteins have been investigated in a variety of cell 
models, we are still working to understand the physiological roles of these 
proteins.  RGK proteins are expressed in a number of excitable tissues where 
their regulation of VDCCs may be particularly relevant [11].  For instance, Rem is 
expressed in the heart, Rem2 is expressed in neurons, Gem is expressed in 
pancreatic β-cells, and Rad, the focus of this dissertation, is present in cardiac 
and skeletal muscle [11].  Rad expression has also been recently found in non-
excitable cell types [34, 48, 52, 53, 67, 74], however, suggesting that its 
physiological significance extends well past its role in VDCC regulation. 
Roles of Rad in the heart 
Given its high expression in cardiac muscle [3, 128] and its role in the regulation 
of VDCCs [12], the function of Rad has been characterized most extensively in 
the heart.  Rad expression is decreased in human heart failure and in cardiac 
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hypertrophy induced by pressure overload in mice [131, 132].  A novel single 
nucleotide polymorphism (SNP) resulting in a Q66P mutation in the human Rad 
protein was correlated with congestive heart failure [133]; however, mutation of 
this residue does not alter the ability of ectopic Rad expression to block calcium 
current [134], suggesting that this mutation may contribute to cardiomyopathy 
through an alternative mechanism than calcium channel modulation.  Rad has 
also been reported to regulate apoptosis of cardiomyocytes through p38 protein 
kinase activation [135] and to regulate excitation-contraction coupling and β-
adrenergic signaling in cardiac myocytes [86].   
The first loss-of-function studies for Rad in heart were performed using the 
putative dominant negative mutant Rad S105N [84-86].  Overexpression of this 
mutant in guinea pig cardiomyocytes was reported to cause an increase in 
calcium current and a prolonged QT interval resulting in arrhythmias [85].  
Another study found that transgenic mice overexpressing Rad S105N exhibited 
increased phosphorylation of the Ryanodine receptor, the channel by which 
calcium is released from the sarcoplasmic reticulum (SR) in response to calcium 
influx through VDCCs, and a subsequent increase in the frequency of 
inappropriate calcium release from the SR, termed calcium sparks, and of 
arrhythmias [84].  Furthermore, Wang et al. reported that overexpression of Rad 
S105N resulted in a comparable increase in ICa compared to Rad knock down 
[86]. However, other studies have suggested that the “dominant negative” 
mutations in RGK proteins are not effective [88], and the lack of solid evidence of 
GTP cycle regulation of Rad makes interpretation of these data difficult.  The 
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generation of Rad-/- mice helped to circumvent this issue.  Initial studies in these 
mice indicated that loss of Rad results in more severe cardiac hypertrophy 
following pressure overload [132] and more extensive cardiac fibrosis through 
enhanced extracellular matrix (ECM) deposition [41], but the impact of Rad loss 
on calcium channel dynamics had not been investigated in these earlier studies. 
Over the past several years, the Andres and Satin laboratories have collaborated 
to further study the role of Rad GTPase in the heart through analysis of the 
cardiac phenotype of Rad-/- mice.  I have contributed data to a number of these 
studies and am a co-author on several manuscripts, but this work will not appear 
in a chapter of this dissertation [104, 131, 136].  Briefly, we have shown that 
cardiac myocytes from Rad-/- mice have higher calcium current [104], suggesting 
that Rad is indeed an endogenous inhibitor of VDCCs.  Rad-/- cardiomyocytes 
also exhibited elevated diastolic and twitch calcium levels, higher sarcoplasmic 
reticulum calcium load, and elevated sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA2a) expression, and the Rad-/- cardiac phenotype closely resembled 
tonic β-adrenergic stimulation of the calcium channel complex [104, 136].  In 
keeping with this sympathomimetic phenotype, we went on to establish that Rad-
/- mouse hearts are hypercontractile relative to wildtype hearts, and that this 
improved cardiac function is maintained in aging [136].  Notably, unlike the Rad 
S105N overexpression studies, we did not observe arrhythmias in Rad-/- mice.  
Finally, we have replicated the finding that Rad protein levels are significantly 
lower in human failing hearts [131]; however, while more work is needed, our 
data from Rad-/- mice suggest that the loss of Rad may be a compensatory 
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response to the need to increase cardiac output in this setting rather than a 
pathological consequence of heart failure.  In summary, our work suggests that 
loss of Rad does not exacerbate cardiac hypertrophy or induce cardiac 
arrhythmias as may be expected with an increase in calcium current; instead, 
Rad deletion appears to generate a stable increase in cardiac function that 
renders protection upon cardiac insult [136], (unpublished data).   
Emerging roles of Rad in non-excitable tissues 
While Rad, as a putative inhibitor of VDCC function, has primarily been studied in 
excitable tissues, especially the heart where it is highly expressed, a number of 
recent reports suggest that there is value in exploring the function of Rad in non-
excitable tissues.  In addition to the changes in Rad expression in muscle 
described above, Rad levels are also altered in other systems that require further 
investigation.  For instance, Rad expression is induced in the suprachiasmatic 
nucleus following stimulation with light [59, 71], in peripheral blood mononuclear 
cells following heat shock [48] or polychlorinated biphenyl (PCB) exposure [74], 
in cirrhotic livers relative to normal livers [52], in human placenta following 
hypoxia [53], and during erythropoiesis to confer erythroid survival [67].  In each 
of these cases, the mechanism for up regulation of Rad expression and the 
functional implications of this up regulation require further investigation. 
Interestingly, modulation of Rad levels has also been reported in a diverse 
assortment of cancers. Rad silencing has been reported in breast [28], lung [24, 
25, 30, 34, 137], ovarian [38], cervical [138], liver [26, 27], nasopharyngeal [32], 
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and esophageal cancer [35], as well as in glioblastoma [39]. In many of these 
cases, Rad silencing is correlated with aberrant methylation of its promoter 
region [32, 35, 38, 39, 138]. Notably, elevated Rad expression was also 
observed in some cancers, especially in highly invasive tumors and in drug-
resistant tumors [28, 29, 33, 139].  Mechanistically, the frequent down regulation 
of Rad in cancer has been attributed to a novel role of Rad in inhibiting the 
Warburg effect [25, 27], suggesting a role for Rad in metabolism.  Interestingly, 
Rad was found to repress glycolysis primarily through inhibition of glucose 
transporter translocation to the plasma membrane [24].  In the same vein, earlier 
studies also implicated Rad in the regulation of glucose uptake, as Rad 
overexpression inhibited glucose uptake in muscle and fat cells [140], and Rad 
silencing promoted glucose uptake in an ovarian cancer model [38].  The role of 
Rad in mediating these changes, however, remains unclear. 
The ability of Rad to localize to the nucleus in addition to the cytosol and plasma 
membrane is well established [16, 29, 40, 117], and the nuclear localization of 
Rad was initially thought to provide a means of sequestration of Rad to inhibit its 
activities in cytoskeletal reorganization and/or VDCC control [16, 117].  However, 
recent studies suggest that Rad may play a direct role in the regulation of gene 
transcription.  Following the observation that Rad-/- mice exhibited more severe 
cardiac fibrosis, Zhang et al. identified up regulation of connective tissue growth 
factor (CTGF) as a key factor in the observed phenotype, and further analysis 
indicated that Rad associates with CCAAT-enhancer binding protein-δ (C/EBP-δ) 
and inhibits its binding to the CTGF promoter [41].  Similarly, Hsiao et al. recently 
	   28 
reported a direct interaction between Rad and the p65/RelA subunit of nuclear 
factor kappa B (NFκB) that occurs in the nucleus and inhibits DNA binding of 
RelA [40]. Notably, overexpression of Rad decreased NFκB transcriptional 
activity, whereas Rad deletion resulted in up regulation of NFκB target genes 
[40].  Thus, it is plausible that Rad localization in the nucleus extends beyond a 
means of sequestering the protein to inhibit its regulation of VDCCs and the 
cytoskeleton; rather, Rad may actively bind to and activate or inhibit transcription 
factors and co-activators/co-repressors to influence gene expression.  
Finally, similar to the reports of Rem2 regulating embryonic stem cell self-
renewal and pluripotency [42, 43], Rad was also recently identified to have a 
potential role in embryonic stem cell differentiation [45] and to contribute to 
expression of stem factors enhancing self-renewal ability [139]. The involvement 
of Rad in regulation of stem cell maintenance and differentiation has also been 
extended to mesenchymal stem cells (MSCs), as Satija and colleagues recently 
reported that lithium priming of human MSCs toward the osteoblast lineage 
resulted in a significant up regulation of Rad expression, and that Rad silencing 
reversed the osteogenic effects of lithium [44]. The idea that RGK proteins, and 
Rad in particular, may influence MSC differentiation and osteogenesis will be 
explored in Chapter 5 of this dissertation.  In preparation for Chapter 5, a brief 
introduction of bone biology and osteoblast differentiation will now be described. 
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Bone remodeling 
Bone remodeling is a physiological process in which old or damaged bone is 
removed by osteoclasts and replaced by new bone formed by osteoblasts 
(Figure 1.2) [141].  This process occurs throughout life, with the entire skeleton 
of a child being replaced every four years and the entire adult skeleton being 
replaced every ten years [141].  The bone remodeling cycle can be broken into 
five stages: the resting state, resorption, reversal, formation, and mineralization 
[142]. 
In the resting state, the surface of the bone is covered with bone-lining cells, 
which are aged osteoblasts that no longer play a role in synthesis of bone matrix 
[143].  These bone-lining cells cover all non-metabolically active areas of the 
bone and thereby close it off to other cells, including osteoclasts [143].  The 
peeling back of the bone-lining cells stimulates and allows attachment of 
osteoclasts to the bone surface.  Osteocytes, which comprise 90% of all bone 
cells, are also derived from old osteoblasts that have been incorporated into the 
mineralized bone [144].  Osteocytes sense mechanical force and bone strain and 
respond to these forces by secreting factors that regulate osteoclast and 
osteoblast generation, thereby initiating the remodeling process on the bone 
surface [144].   
The bone remodeling cycle begins with osteoclast generation and recruitment to 
a particular site.  Under physiological conditions, this site may be in need of 
repair, while under pathological conditions it may be randomly and 
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inappropriately targeted.  Osteoclasts are giant, multinucleated cells derived from 
the hematopoietic lineage, and they have a specialized plasma membrane 
domain known as a ruffled border that attaches to the bone surface [145].  The 
osteoclast degrades mineralized extracellular matrix by secreting acid and 
lysosomal proteins, and the osteoclast then reabsorbs, packages, and secretes 
the minerals and proteins [145]. 
After osteoclastic resorption is complete, there is a reversal phase in which 
mononuclear cells migrate to the bone surface.  These cells put down a layer of 
glycoprotein-rich material known as the cement line to which osteoblasts can 
adhere, and they provide necessary signals for osteoblast differentiation and 
migration in the bone formation phase [142].  In this phase, successive waves of 
osteoblasts adhere to the cement line and lay down bone until the resorbed bone 
is completely replaced [142].  During the final stage, the newly formed bone 
matrix becomes mineralized, and the bone then returns to its resting state with 
little cellular activity on the bone surface until a new remodeling cycle begins. 
In normal bone remodeling, a balance between bone resorption mediated by 
osteoclasts and bone formation mediated by osteoblasts is tightly regulated and 
maintained in order to ensure that, in mature healthy bone, there are no major 
net changes in bone mass or mechanical strength after each remodeling cycle.  
Nonetheless, an imbalance between bone resorption and bone formation may 
occur under certain pathological conditions, such as osteoporosis, and this 
imbalance results in reduced bone density, or osteopenia [141].  Some of the 
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factors that can lead to dysregulation of the bone remodeling balance include 
aging, hormonal changes associated with menopause, changes in physical 
activity, medications, and secondary diseases [141].  Interestingly, many of these 
factors that are correlated with osteopenia are also associated with an increase 
in bone marrow adipose tissue, an idea that will be expanded in Chapter 5. 
Osteoblast and osteoclast differentiation  
As described above, the osteoblast is the cell type responsible for new bone 
formation through synthesis and secretion of collagen matrix and calcium salts 
[146].  Osteoblasts are derived from MSCs, which are pluripotent stem cells that 
can differentiate into a variety of tissues including adipocytes (fat), chondrocytes 
(cartilage), and myocytes (muscle) in addition to osteoblasts (bone) [146].  
Differentiation of MSCs toward the osteoblast lineage is controlled by a variety of 
cytokine signaling pathways including the Hedgehogs, transforming growth 
factor-β (TGF-β), parathyroid hormone (PTH), Wnts, and bone morphogenetic 
proteins (BMPs) [146].  Although there are a variety of upstream signals that can 
initiate the process of osteoblast differentiation, they each converge on the 
activation of Runt-related transcription factor 2 (Runx2), which is considered the 
master transcription factor for the regulation of osteoblast differentiation [147].  
Deletion of Runx2 in mice results in the complete absence of osteoblasts and a 
cartilaginous skeleton that lacks mineralized matrix [148].  Runx2 interacts with a 
number of co-regulatory proteins to positively or negatively regulate the 
expression of osteoblastic genes such as type I collagen, alkaline phosphatase, 
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osteocalcin, and osterix [149, 150].  Osterix is itself a transcription factor with a 
critical function in osteoblast differentiation, as Osterix-/- mice fail to develop 
osteoblasts [151].  The osteoblast differentiation process can be divided into the 
stages of proliferation of MSCs and osteo-chondrocyte precursors, maturation of 
these precursors into osteoblasts, and termination in which osteoblasts no longer 
function in bone formation and rather terminally differentiate into bone lining cells 
or osteocytes or undergo apoptosis [147]. Runx2 plays an early role in the 
differentiation of osteogenic precursors into immature osteoblasts, while Osterix 
promotes the maturation of these osteoblasts [147].   
Osteoclasts are the cells responsible for bone resorption, or break down.  Unlike 
osteoblasts, osteoclasts are multi-nucleated cells derived from the hematopoietic 
lineage, specifically from monocytes and macrophages near the bone surface 
[145].  Notably, differentiation of these macrophage precursors into osteoclasts 
requires two cytokines, receptor activator of nuclear factor-kappa B ligand 
(RANKL) and macrophage-colony stimulating factor (M-CSF), both of which are 
produced by osteoblasts [145, 152].  Hence, a direct regulatory linkage exists 
between osteoblasts and osteoclasts that is important for controlling bone 
homeostasis. 
Bone morphogenetic protein signaling 
The bone morphogenetic protein (BMP) signaling pathway is one of the 
pathways implicated in the regulation of osteoblast differentiation. BMPs are 
members of the transforming growth factor-β (TGF-β) superfamily that were 
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initially identified for their capacity to induce bone formation at ectopic sites in 
rats [153].  Since their discovery, the role of BMPs in bone homeostasis has 
been confirmed by their expression in skeletal tissues and their roles in skeletal 
development as well as in fracture healing [154].  Notably, conditional deletion of 
BMPs in mouse bone results in skeletal defects [154, 155], and inherited 
mutations in BMPs or their receptors are observed in skeletal disorders in 
humans [156].  BMPs are also utilized therapeutically in certain settings such as 
for the repair of open fractures of long bones and for spinal fusions [157]. 
BMP ligands bind as dimers to type-I and type-II serine/threonine receptor 
kinases, allowing receptor oligomerization.  This oligomerization allows the 
constitutively active type-II BMP receptors to phosphorylate and thereby activate 
the type-I receptors (Figure 1.3).  Type-I BMP receptor kinases activated by the 
type-II receptor kinases then phosphorylate the C-terminus of the receptor-
associated Smads (R-Smads) 1 and 5 (Figure 1.3).  Phosphorylated R-Smads 
can heterodimerize with the common-partner Smad (co-Smad) Smad4 and 
translocate into the nucleus (Figure 1.3), where they regulate the transcription of 
genes including Runx2 that are associated with bone development via interaction 
with various transcription factors and transcriptional co-activators or co-
repressors.  Meanwhile, C-terminally phosphorylated R-Smads in the nucleus are 
also subject to phosphorylation within the linker region by mitogen activated 
protein kinases (MAPKs) and glycogen synthase kinase-3 (GSK3) [158] (Figure 
1.4).  This linker phosphorylation allows R-Smad binding to E3 ubiquitin ligases 
such as Smurf1, which ubiquitinate the R-Smad proteins and target them for 
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degradation in the proteasome [158] (Figure 1.4).  Smurf1 thus regulates 
osteoblast differentiation by providing negative feedback on BMP signaling.    
Skeletal anatomy 
Bone tissue in mammals is classified into two different types of bone tissue: 
cortical and trabecular bone.  Cortical bone, sometimes also referred to as 
compact bone, forms the dense, outer shell (Figure 1.5) and is responsible for 
the majority of the weight of the skeleton (~80%).  Important functions of the 
cortical bone include supporting the weight of the body, protecting vital organs 
such as the brain and bone marrow, storing calcium, and providing leverage for 
movement.  Trabecular bone, also known as cancellous or spongy bone, is 
enclosed by the cortical bone and forms a less dense meshwork of bony plates 
and rods (Figure 1.5).  Trabecular bone is primarily found at the ends of long 
bones near joints and within vertebrae and flat bones.  Trabecular bone has a 
much higher surface area than cortical bone and is the primary site of bone 
remodeling associated with metabolism and maintenance of calcium 
homeostasis.  Trabecular bone is often impacted more severely than cortical 
bone in the setting of osteoporosis.  
The ends of long bones are known as the epiphyses.  The proximal epiphysis is 
the end that is closest to the center of the body (for instance, the top end of the 
femur which forms part of the hip joint), and the distal epiphysis is that farthest 
from the center of the body (the lower end of the femur which forms part of the 
knee joint) (Figure 1.5).  The majority of the histology presented in this 
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dissertation, as well as the trabecular bone µCT, utilizes the distal femur.  The 
shaft of long bones, or the portion between the two epiphyses, is called the 
diaphysis.  The diaphysis consists of a tube of cortical bone that encloses the 
medullary cavity (Figure 1.5).  Cortical analyses in this dissertation are 
performed at the mid-diaphysis of the femur.   
The medullary cavity is surrounded by a delicate membrane known as the 
endosteum (Figure 1.5), and the inner surface of the cortical bone is similarly 
called the endocortical surface.  A fibrous membrane called the periosteum 
surrounds the outer surface of the bone and is the site of tendon and ligament 
attachment to bones, as well as for blood vessels, nerves, and lymphatic vessels 
(Figure 1.5).  The outer surface of the cortical bone is thus referred to as the 
periosteal surface.  The bone formation rates of cortical bone in this dissertation 
will be presented for both the periosteal and endocortical surfaces. 
Scope of dissertation 
In summary, Rad is a member of the RGK subfamily of Ras-related small 
GTPases. This unique family of G-proteins binds to guanine nucleotides despite 
unusual amino acid substitutions within regions associated with nucleotide 
binding and hydrolysis. Rad has established functions in the regulation of 
cytoskeletal remodeling and of voltage-dependent calcium channel modulation, 
but it is unclear whether these functions are regulated through nucleotide binding 
status, subcellular distribution, post-translational modifications, transcriptional 
regulation, or proteostatic control mechanisms.  Rad expression has also been 
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reported in non-excitable cell types, and roles of Rad beyond its documented 
functions in regulating the cytoskeleton and calcium current are emerging.  In this 
dissertation, I seek to advance our understanding of how Rad might be 
regulated, both in excitatory and non-excitatory cells.  I will investigate the role of 
a novel Rad-interacting protein and an associated E3 ubiquitin ligase in the 
regulation of Rad protein levels in Chapter 3, followed by an examination of the 
role of Rad phosphorylation in the regulation of protein-protein interactions and 
calcium current regulation in Chapter 4.  Finally, I will explore the role of Rad in 
the regulation of bone homeostasis and osteoblast function in Chapter 5 of this 
dissertation. 
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Figure 1.1: Sequence alignment of the RGK subfamily 
The amino acid sequence of each of the four RGK subfamily proteins and H-Ras 
are aligned to illustrate regions of conservation and the lack thereof.  The G1-G5 
boxes of H-Ras, which are typically highly conserved among Ras-related 
GTPases, are enclosed in red boxes.  Black arrows indicate residues in H-Ras 
important for nucleotide binding and hydrolysis that are absent in RGK proteins. 
Amino acid residues depicted in orange represent sequence identity across the 
RGK subfamily, those in green represent sequence similarity across the RGK 
subfamily, and those in blue represent sequence similarity among three of the 
four RGK proteins. The lack of conservation in the N-terminal extensions of RGK 
proteins is readily observed.  The N- and C-terminal serine residues involved in 
phosphorylation-dependent 14-3-3 binding are enclosed in black boxes, and the 
site for calmodulin binding, the polybasic membrane targeting region, and the 
nuclear localization sequence within the conserved C-terminus of RGK proteins 
are also denoted. 
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Figure 1.2: The bone remodeling cycle 
Bone is a dynamic tissue that is constantly undergoing cycles of bone 
remodeling.  The five stages of bone remodeling are the resting state, osteoclast-
mediated bone resorption, reversal, osteoblast-mediated bone formation, and 
mineralization. 
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Figure 1.3: Bone morphogenetic protein signaling pathway 
Bone morphogenetic protein (BMP) ligand binding to BMP type I and type II 
receptors facilitates their oligomerization.  BMPRII phosphorylates and activates 
BMPRI, which then phosphorylates the C-terminus of receptor-associated Smad 
proteins such as Smad1.  Phosphorylated Smad1 then heterodimerizes with 
Smad4, and this complex translocates into the nucleus where it regulates gene 
transcription.  
	   40 
 
Figure 1.4: Smurf1-mediated ubiquitination of R-Smad proteins 
Following C-terminal phosphorylation of R-Smads by the BMP receptor, 
dimerization with Smad4, and nuclear translocation, R-Smad proteins are subject 
to phosphorylation at two serine residues within their linker region by MAPKs and 
GSK3. Linker phosphorylation allows recruitment of the Smurf1 E3 ligase, 
polyubiquitination of R-Smads, and proteasomal degradation. 
Modified from Fuentealba et al. 2007 [159]  
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Figure 1.5: Long bone anatomy 
This diagram of a long bone indicates the locations of important anatomical 
structures, such as cortical versus trabecular bone, diaphysis versus epiphysis, 
and periosteum versus endosteum. 
Modified from OpenStax College, Anatomy and Physiology. OpenStax CNX. 
http://cnx.org/contents/14fb4ad7-39a1-4eee-ab6e-3ef2482e3e228.81. 
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Chapter 2 
 
Materials and Methods 
 
HEK293 cell culture and transfection 
HEK293 cells were obtained from American Type Cell Culture (ATCC) and were 
cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 
units/mL penicillin, and 100 µg/mL streptomycin. The day prior to transfection, 
HEK293 cells were split into 6-well dishes at a density of 1x106 cells/well.  Cells 
were transfected using Transgin DNA Transfection Reagent (America Pharma 
Source, Gaithersburg, MD).  For each well of a 6-well plate, a total of 2 µg of 
plasmid DNA and 2 µL of Transgin were added to 100 µL of Opti-Mem and 
incubated at room temperature for 20 minutes.  HEK293 cells were incubated in 
1 mL of Opti-MEM per well plus the 100 µL transfection reaction for 4-6 hours, 
after which the Opti-MEM was replaced with 2 mL of standard growth media per 
well.  Cells were serum-starved for six hours prior to application of stimuli.  Cells 
were harvested 48 hours after transfection for immunoprecipitation or Western 
blotting analysis, or split 24 hours after transfection at low density into 35-mm 
dishes for electrophysiology experiments. 
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Plasmids and reagents 
Rat Enigma, mouse Enigma homolog 1 (ENH1), and human Cypher cDNA 
constructs were obtained from the DNASU plasmid repository and were 
subsequently subcloned into the p3XFLAG-CMV10 vector (Sigma) using the 
oligonucleotides in rows 1-6 of Table 2.1.  An N-terminal truncation of Enigma 
lacking the PDZ domain (ΔPDZ) was generated using the 5’ oligonucleotide in 
row 7 and the 3’ oligonucleotide in row 2 of Table 2.1, and a C-terminal 
truncation of Enigma lacking the three LIM domains (ΔLIM1-3) was generated 
using the 5’ oligonucleotide in row 1 and the 3’ oligonucleotide in row 8 of Table 
2.1.  
pKH3-Rem WT, pKH3-Rad WT, pKH3-Rem2 WT (long isoform), and pKH3-Gem 
WT have been previously described [12, 13].  pKH3-Rad K204R was generated 
by site directed mutagenesis using the QuikChange II Site-Directed Mutagenesis 
Kit (Agilent) and the oligonucleotides in rows 9 and 10 of Table 2.1.  pKH3-Rad 
S39A, S39D, and S301A were also generated by site directed mutagenesis by 
Dr. Hongge Jia.  
pRK-Myc-Smurf1 and pRK-Myc-Smurf2 were gifts from Dr. Ying Zhang 
(Addgene plasmids #13676 and 13678).  pCMV5B-Flag-Smurf1 WT, pCMV5B-
Flag-Smurf1 C699A, pCMV5B-Flag-Smad3, and pCMV5B-Flag-Smad4 were 
gifts from Dr. Jeff Wrana (Addgene plasmids #11752, 11753, 11742, and 11743). 
pCMV5 Flag-Smad1 was a gift from Dr. Joan Massague (Addgene plasmid 
#14044).  pRK-Myc-Ubiquitin was a gift from Dr. Tianyan Gao.  The β2-
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adrenergic receptor mammalian expression construct was a gift from Dr. John 
Kehrl (National Institute of Allergy and Infectious Diseases, National Institutes of 
Health).  LNCX BMP-RII was a gift from Dr. Rik Derynck (Addgene plasmid 
#12641).  pcDNA3.1-C/EBP α, β, and δ were gifts from Dr. Peter Johnson 
(Addgene plasmids #12550, 12557, and 12559). 
GFP-CaV1.2 (rabbit) was a gift from Dr. Kurt Beam (University of Colorado Health 
and Sciences Center, Aurora, CO).  HA-tagged CaV1.2 truncations (amino acids 
1507-2171, 1507-1906, and 1906-2171) have been described previously [107]. 
CaVβ2a was subcloned into the PiggyBac system vector PB514B-1 to generate a 
dual expression vector for CaVβ2a and RFP. The sequences of all constructs 
were confirmed using ACGT, Inc. or Eurofins MWG Operon. 
MG-132 (Selleckchem, Cat No. S2619) was used at a concentration of 10 µM for 
16 hours.  Recombinant BMP-2 protein (R&D Systems, Cat No. 355-BM-010) 
was used at a concentration of 100 ng/mL for 2 hours (HEK293 cells) or 7 days 
(primary osteoblasts), adding fresh growth media with BMP-2 every third day.  H-
89 (Calbiochem, Cat No. 371962) was used at a concentration of 1 mM.  
HEK293 cells were pre-treated with H-89 for 30 minutes prior to transfection, and 
H-89 was replenished in the media throughout the experiments, including during 
serum starvation, until the cells were lysed.  Isoproterenol (Sigma, 1351005) was 
used at a concentration of 100 ng/mL for 15 minutes.  Forskolin (Sigma, Cat No. 
F6886) was used at a concentration of 1 µM for the indicated amounts of time. 
Phorbol 12-myristate 13-acetate (PMA) (Sigma, Cat No. P1585) was used at a 
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concentration of 1 µM for the indicated amounts of time.  Macrophage-colony 
stimulating factor (M-CSF, Sigma, Cat No. M9170) and Receptor activator of 
nuclear factor kappa-B ligand (RANKL, Sigma, Cat No. R0525) were used as 
described in the osteoclast differentiation subsection of this chapter. 
Co-immunoprecipitations (Co-IPs) 
For co-IPs in chapters 3 and 5 of this dissertation, HEK293 cells were washed 
with PBS and harvested in ice-cold lysis buffer (20 mM HEPES (pH 7.4), 50 mM 
KF, 50 mM β-glycerophosphate, 150 mM NaCl, 2 mM EGTA (pH 8.0), 0.5% 
Triton X-100, 10% glycerol, 1x protease inhibitor (Calbiochem)) 48 hours after 
transfection. Lysates were cleared by high-speed centrifugation at 4oC, and 
protein concentrations were measured using BioRad Quick Start Bradford 1x Dye 
Reagent. For co-immunoprecipitations, 1 mg of protein was brought up to 500 µL 
total volume with lysis buffer, and 15 µL of Protein G Plus Agarose Suspension 
(Calbiochem) and 4 µg of anti-Flag M2 monoclonal antibody (Sigma) or anti-HA 
monoclonal antibody (Sigma) were added.  Tubes were rotated at 4oC for two 
hours, and the agarose beads were pelleted and washed once with 500 µL lysis 
buffer, twice with lysis buffer plus 150 mM NaCl, and twice more with lysis buffer.  
The bound fraction and the input were resolved on 10% SDS-PAGE gels, 
transferred to nitrocellulose, and subjected to Western blotting analysis.   
For CaVβ2a co-IPs in Chapter 4 of this dissertation, HEK293 cells were instead 
harvested in ice-cold Cavβ IP buffer (20 mM Tris (pH 7.5), 250 mM NaCl, 1% 
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Triton X-100, 10 mM MgCl2, 1x protease inhibitor (Calbiochem)), and co-IPs were 
otherwise performed as described in the above paragraph.  To probe for the 
effects of free calcium and of phosphorylation on the association between Rad 
and Cavβ2a, 2 mM EGTA (stock solution pH 8.0) or 50 mM β-glycerophosphate, 
respectively, were added to the Cavβ IP buffer and co-IPs were performed. 
Western blotting 
Membranes were blocked with casein in PBS-tween for one hour prior to 
incubation with primary antibodies (Table 2.2) for one hour at room temperature 
or overnight at 4oC. Membranes were then subjected to three 10-minute washes 
with PBS-tween and incubated with peroxidase-conjugated secondary antibodies 
(AffiniPure Goat Anti-Mouse IgG, Light Chain Specific, Jackson 
ImmunoResearch; Monoclonal Mouse Anti-Goat IgG, Light Chain Specific, 
Jackson ImmunoResearch; ECL Donkey Anti-Rabbit IgG, GE Healthcare) or 
peroxidase-conjugated streptavidin (Thermo Scientific) for one hour at room 
temperature (1:20,000 dilution). Signals were developed with Hyglo 
chemiluminescent reagent (Denville Scientific) and visualized on a ChemiDoc 
MP (Bio-Rad).   
Animals 
All animal procedures were reviewed and approved by the Institutional Animal 
Care and Use Committee at the University of Kentucky.  Global Rad knockout 
(Rad-/-) mice were obtained from Dr. C. Ronald Kahn and have been described 
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previously [132].  Global Enigma knockout (Enigma-/-) mice (also known as LIM 
mineralization protein (LMP)-/- mice) were obtained from Dr. Scott Boden at 
Emory University and have been described previously [160].   
Heart tissue homogenization 
Four-week-old male Enigma-/- mice and WT littermate controls were sacrificed, 
and hearts were excised, dissected into ventricles and apex, and snap frozen in 
liquid nitrogen.  The ventricles were pulverized under liquid nitrogen and 
homogenized in ice-cold lysis buffer (20 mM HEPES (pH 7.4), 50 mM KF, 50 mM 
β-glycerophosphate, 150 mM NaCl, 2 mM EGTA (pH 8.0), 0.5% Triton X-100, 
10% glycerol, 1x protease inhibitor (Calbiochem)).  Heart homogenates were 
centrifuged, and lysates were prepared at a concentration of 4 µg/µL, resolved 
on 10% SDS-PAGE gels, transferred to nitrocellulose, and subjected to Western 
blotting analysis.  The apices were stored at -80oC for RNA isolation. 
RNA isolation 
Samples for RNA isolation were first homogenized in TRIzol reagent.  Mouse 
heart tissue, specifically the apex of the heart, was pulverized under liquid 
nitrogen and homogenized in 0.5 mL of TRIzol in a microcentrifuge tube using a 
polypropylene pestle, after which an additional 0.5 mL of TRIzol was added to 
the tube.  For calvarial osteoblast cultures, 0.5 mL of TRIzol was added to each 
well of a 6-well plate, and the wells were scraped with a cell scraper and contents 
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were transferred into a microcentrifuge tube along with an additional 0.5 mL of 
TRIzol.  Samples were kept on ice during this time. 
For phase separation, 200 µL of chloroform was added to each tube.  Samples 
were vortexed vigorously for 15 seconds, incubated at room temperature for 3 
minutes, and then centrifuged at 11,500 rpm for 15 minutes at 4oC.  The 
colorless upper aqueous phase, which contains RNA, was transferred to a fresh 
microcentrifuge tube.  RNA was precipitated by adding 500 µL of isopropanol to 
each sample, inverting the tubes to mix, and incubating at room temperature for 
10 minutes.  The tubes were then centrifuged at 11,500 rpm for 10 minutes at 
4oC.  The supernatant was aspirated, and the pellet was washed with 1 mL of 
75% ethanol.  Samples were then vortexed and centrifuged at 6700 rpm for 5 
minutes at 4oC twice, removing as much ethanol as possible after each spin.  
The RNA pellet was then air-dried for 10 minutes and dissolved in 100 µL of 
DEPC-treated water.  DNase I and the appropriate buffer were then added to 
each sample, and the tubes were incubated at 37oC for one hour to allow 
digestion of DNA in the samples. 
To precipitate RNA, 12 µL of 5M ammonium acetate, 1.2 µL of linear acrylamide, 
and 240 µL of 100% ethanol were added to each sample, and the tubes were 
incubated at -20oC overnight.  The samples were then centrifuged at high speed 
for 20 minutes at 4oC, and the supernatant was aspirated before another 5-
minute high-speed centrifugation at 4oC.  The supernatant was carefully 
removed, and RNA pellets were air-dried for 5-10 minutes to evaporate additional 
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ethanol.  The pellets were then re-suspended in 10 µL of nuclease-free water, 
and concentrations were recorded and RNA quality was assessed using a 
Nanodrop instrument (Thermo Scientific). 
cDNA synthesis 
Total RNA (1 µg) was used as a template for cDNA synthesis using the RT2 First 
Strand kit (SABiosciences).  Briefly, 1 µg of total RNA was brought up to a 
volume of 10 µL with nuclease-free water in a 0.2 mL tube.  To each sample, 2 
µL of Buffer GE was added to facilitate degradation of any contaminating 
genomic DNA, and samples were heated at 42oC for 5 minutes.  Samples were 
then placed on ice, and the remaining kit components were added.  The tubes 
were then incubated at 42oC for 15 minutes and 95oC for 5 minutes to allow 
cDNA synthesis to proceed. 
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
cDNA from WT and Enigma-/- heart tissue was diluted 1:50 in nuclease-free 
water and amplified via RT-PCR using Taqman probes from Life Technologies: 
Gapdh (Mm99999915_g1) and Rrad (Mm00451053_m1).  Each RT-PCR 
reaction consisted of 10 µL of Taqman universal PCR master mix (Life 
Technologies, Cat No. 4304437), 1 µL of the appropriate Taqman primers, 7 µL 
of nuclease-free water, and 2 µL of diluted cDNA for a total of 20 µL per assay.  
RT-PCR was performed in triplicate for each sample and primer. Threshold 
values (CT) for Rrad were normalized by subtraction from Gapdh.  WT was then 
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subtracted from Enigma-/- to determine ΔΔCT values, and fold changes were 
calculated as 2-ΔΔCT. 
Fetal ventricular cardiomyocyte isolation and culture 
Timed pregnant females were obtained from Jackson Laboratories and sacrificed 
at embryonic day 18.  The embryo sac was removed, and pups were extracted 
from the sac.  Hearts were dissected from each pup and placed in PBS + 0.1 M 
MgCl2.  Atria were removed, and ventricles were cleared of blood and placed in a 
15 mL tube with PBS + 0.1 M MgCl2.  The tubes were centrifuged, and ventricles 
were re-suspended in 1 mL of filtered 0.5 mg/mL type II collagenase in PBS + 0.1 
M MgCl2 and transferred into a culture dish.  Hearts were mechanically torn apart 
using forceps, transferred back into a 15 mL tube, and brought up to 10 mL with 
filtered collagenase.  The tube was then incubated at 37oC for 10 minutes and 
centrifuged for 5 minutes.  Cells were re-suspended in fresh filtered collagenase 
solution, and the process of mechanical disruption, incubation at 37oC, and 
centrifugation was repeated.  The cell pellet was then re-suspended in DMEM + 
10% FBS and pre-plated in a 10-cm culture dish for 2 hours at 37oC to remove 
contaminating fibroblasts.  Cells were seeded in a 24-well plate onto laminin-
coated cover slips and maintained in DMEM + 10% FBS for 48-72 hours.  Cells 
were treated with vehicle, forskolin, or isoproterenol and harvested in ice-cold 
lysis buffer (20 mM HEPES (pH 7.4), 50 mM KF, 50 mM β-glycerophosphate, 
150 mM NaCl, 2 mM EGTA (pH 8.0), 0.5% Triton X-100, 10% glycerol, 1x 
protease inhibitor (Calbiochem)) and subjected to Western blotting analysis. 
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Electrophysiology 
HEK293 cells were transiently transfected with GFP-tagged CaV1.2, a PiggyBac 
dual promoter vector (PB514B-1) expressing CaVβ2a and RFP, HA-tagged 
empty vector or Rad WT, and Flag-tagged empty vector or Enigma.  Cells were 
split at low density into 35-mm dishes 24 hours post-transfection, and recordings 
were made 6-24 hours later.  The whole-cell configuration of the patch clamp 
technique was used to measure ionic current, selecting isolated GFP+/RFP+ 
spherical cells.  Patch electrodes were pulled from glass capillary tubes to 
resistances of 1-2 MΩ, and the tips were flame-polished.  The external bath 
solution contained 112.5 mM CsCl, 30 mM BaCl2, 1 mM MgCl2, 10 mM 
tetraethylammonium chloride, 5 mM glucose, and 5 mM HEPES (pH 7.4).  The 
internal recording solution contained 110 mM K-gluconate, 40 mM CsCl, 1 mM 
MgCl2, 5 mM Mg-ATP, 3 mM EGTA, and 10 mM HEPES (pH 7.35).  Recordings 
were performed at room temperature, and only those cells with seal resistances 
exceeding 1 GΩ were used for recording.  pCLAMP 10.0 (Axon Instruments) 
software was used to generate the voltage-clamp protocols and to acquire and 
analyze data. 
Alizarin Red / Alcian Blue skeletal stain 
Neonatal mice at one day of age were sacrificed and dissected to remove all the 
skin and organs. Scalding the specimens in a 70oC water bath facilitates this 
process.  The specimens were fixed in 95% ethanol in 50 mL conical tubes for 24 
hours at room temperature with gentle rocking.  All following incubations were 
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also performed at room temperature with slow rocking for the indicated amounts 
of time.  After fixation, the ethanol was replaced with Alcian Blue staining solution 
(0.03% Alcian Blue in 80% ethanol/20% acetic acid), and specimens were 
incubated in this solution for three days to allow staining of cartilage.  Skeletons 
were washed with 95% ethanol for six hours and then incubated in 2% KOH for 
24 hours.  The specimens were then stained in Alizarin Red S solution (0.03% 
Alizarin Red S in 1% KOH) for 12 hours.  Finally, the skeletons were cleared in a 
solution of 1% KOH/20% glycerol for 24 hours, incubated in a 1:1 solution of 
glycerol and 95% ethanol for 24 hours, and then analyzed and photographed. 
Bone collection 
The right femora were dissected from 4-month-old male and female WT and  
Rad-/- mice immediately after sacrifice, taking care to remove all soft tissue.  For 
microcomputed tomography and bone histology, femora were fixed in a ten-fold 
volume of 10% neutral buffered formalin for three days with rocking and then 
transferred to 70% ethanol until analysis.  For four-point bending analysis, bones 
were snap frozen in liquid nitrogen and stored at -80oC in saline-soaked gauze 
prior to analysis. 
Microcomputed tomography 
Microcomputed tomography (µCT) was performed in collaboration with the µCT 
core facility at Rush University.  Femora were scanned (Scanco Model 40; 
Scanco Medical AG, Basserdorf, Switzerland) in 70% ethanol at 55 kV and 145 
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mA, 0.3-second integration time with a 10 µm isotropic voxel size in plane and a 
10 µm slice thickness. The overall femur length was recorded and used to guide 
the cortical and trabecular analyses.  Specifically, the trabecular region of interest 
ranged from just proximal of the distal growth plate to 30% of the bone length as 
measured from the distal end.  The trabecular output variables included total 
volume (TV), bone volume (BV), bone volume fraction (BV/TV), connectivity 
density (Conn.D), structural model index (SMI), trabecular number (Tb.N), 
trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), apparent density 
(Ap.Dens), material density (Mat.Dens), specific bone surface (BS/BV), and 
degree of anisotropy (DA). Trabecular analyses utilized a sigma value of 0.8, 
support of 1, and threshold at 270. Cortical data at the midshaft of the femur 
were also analyzed, including cortical bone area (Ct.Ar), total cross-sectional 
area (Tt.Ar), medullary area (Ma.Ar), cortical thickness (Ct.Th), and cortical area 
fraction (Ct.Ar/Tt.Ar). Cortical analyses used a sigma value of 1.5, support of 2, 
and threshold at 350. 
Four-point bending analysis 
Four-point bend testing was performed in collaboration with Dr. Matthew Allen at 
Indiana University School of Medicine to measure whole bone mechanical 
properties [161].  Because four-point bending produces pure bending between 
two loading points, fractures occur at the weakest location in the region [162], 
making it superior to three-point bending which uses a single loading point.  
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The anterior surface of each femur was placed on two lower supports with a span 
length of 9 mm and an upper span length of 3 mm.  Each femur was loaded at a 
rate of 2 mm/min until failure occurred, and a force-displacement curve was 
generated and used to determine structural properties including ultimate force, 
stiffness, displacement, and energy absorption for each specimen.  Derivation of 
apparent material properties utilized the cross-sectional moments of inertia and 
the distances from the centroid to the tensile surface using standard beam-
bending equations for four-point bending. The 0.2% offset criterion was used to 
define yield points, and a custom MATLAB (Version 11) program was used for all 
mechanical analyses [163]. 
Preparation of femur sections for histology 
Following fixation in 10% neutral buffered formalin as described above, femora 
were dehydrated through a graded series of ethanols for 4 hours at each step 
and cleared in xylenes for 4 hours.  For plastic embedding, the specimens were 
incubated in unpolymerized methyl methacrylate for 4 hours, in unpolymerized 
methyl methacrylate containing 4% dibutyl phthalate as a softening agent for 7 
days, and finally embedded in methyl methacrylate containing 4% dibutyl 
phthalate and 0.25% Perkadox 16 as a catalyst and allowed to polymerize at 
room temperature.  A band saw was used to remove excess plastic from the 
blocks, and the blocks were then shaped with a dental model trimmer.  A rotary 
microtome with a tungsten-carbide knife was used to cut thin sections (4-10 µm, 
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mostly trabecular bone), and a diamond wire saw was used to cut thick sections 
(80+ µm, mostly cortical bone).   
All histological measurements were made using a semiautomatic analysis 
system (Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a 
Nikon Optiphot 2 microscope with both visible and ultraviolet light sources.  
Tartrate-resistant acid phosphatase stain 
Three thin sections per animal were de-plasticized in acetone and stained for 
tartrate resistant acid phosphatase (TRAP) as previously described [164] in 
collaboration with Dr. Keith Condon and the Bone Histology core facility at 
Indiana University School of Medicine.  Briefly, thin sections were incubated in 
0.2 M acetate buffer (pH 5.0), rinsed, and incubated in a warmed acid 
phosphatase solution.  Sections were then counterstained with Gill’s Hematoxylin 
No. 3 and coverslipped with an aqueous mounting media after air-drying.  TRAP 
staining was quantified as the percentage of the bone surface occupied by 
osteoclasts (% Oc.S/BS) using Bioquant OSTEO 7.20.10. 
Calcein labeling and dynamic histomorphometry 
To prepare the 0.6% calcein injection solution, 0.9 g NaCl was dissolved in 90 
mL of distilled water, followed by 2.0 g NaHCO3 and 0.6 g calcein. The calcein 
must be added slowly to avoid foaming of the solution.  The pH of the calcein 
solution was adjusted to 7.4 using 1 N NaOH or 1 N HCl, and the volume was 
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brought up to 100 mL with distilled water.  The solution was then filtered into a 
sterile glass vial and stored at 4oC in the dark. 
Mice were injected intraperitoneally with 30 mg/kg calcein (0.05 mL of 0.6% 
calcein for every 10 grams body weight) at 7 and 2 days prior to sacrifice.  The 
minimum dose used was 0.15 mL regardless of weight to ensure visualization of 
the label in bone, and each dose was administered as two half-doses. 
Thin sections for dynamic histomorphometry were kept in plastic and 
coverslipped using Eukitt mounting reagent to analyze trabecular bone formation 
rates.  Thick sections were briefly cleared in xylenes and coverslipped with Eukitt 
mounting reagent to analyze cortical bone formation rates at the periosteal and 
endocortical surfaces.  Slides were stored in the dark prior to analysis. 
Fluorochrome labels were quantified using Bioquant OSTEO 7.20.10.  First, the 
bone surfaces containing a single label (sLS), double labeling (dLS), and no label 
(noLS) were measured.  The mineral apposition rate (MAR) was calculated as 
the average distance between the two labels divided by the time interval of five 
days. The percent mineralizing surface (MS/BS), or the percentage of the bone 
surface that is actively forming bone, was calculated as the sum of the double-
labeled surface and half of the single-labeled surface divided by the total bone 
surface, or (dLS + ½ sLS)/(dLS + sLS + noLS) * 100%.  Finally, the bone 
formation rate (BFR/BS) in µm3/µm2/year was calculated as the mineral 
apposition rate multiplied by the percent mineralizing surface and 365 days/year, 
or MAR * MS/BS (as a decimal) * 365. 
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In vitro osteoclast isolation and culture 
Spleens were dissected from two-month-old mice and kept on ice in sterile PBS.  
Spleens were then transferred to sterile culture medium (α-MEM + 10% FBS + 
100 units/mL penicillin and 100 µg/mL streptomycin).  Spleens were crushed in 
culture medium using a 70-µm filter mesh, followed by pipetting to generate a 
single cell suspension.  This suspension was centrifuged 5 minutes at 1500 rpm, 
and the cell pellet was re-suspended in pre-osteoclast culture medium (α-MEM + 
10% FBS + 100 units/mL penicillin and 100 µg/mL streptomycin + 10 ng/mL 
macrophage colony stimulating factor (M-CSF)).  Cells were plated in untreated 
Petri dishes in pre-osteoclast medium for 5 days, changing the medium every 
other day.  Cells were washed three times with PBS and then incubated in PBS + 
0.25 mM EDTA for 15 minutes at 37oC.  EDTA was inactivated through the 
addition of an equal volume of culture medium, and cells were detached using a 
cell scraper and transferred into conical tubes.  Cell suspensions were 
centrifuged for 5 minutes at 1000 rpm, and the cells were re-suspended in a 
small volume of complete osteoclast culture medium (α-MEM + 10% FBS + 100 
units/mL penicillin and 100 µg/mL streptomycin + 5 ng/mL M-CSF + 50 ng/mL 
receptor activator of nuclear factor kappa-B ligand (RANKL)).  Cells were 
counted and seeded in 24 well plates at a density of 25,000 cells/well in complete 
osteoclast culture medium for 7 days, changing the media every other day, prior 
to osteoclast differentiation analysis. 
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Osteoclast differentiation assay 
Osteoclast differentiation was assessed using a tartrate-resistant acid 
phosphatase (TRAP) staining kit (Takara, Cat No. MK300).  Briefly, cells were 
fixed for five minutes at room temperature in the sodium citrate fixation solution 
supplied with the kit.  Cells were then stained with the substrate solution for acid 
phosphatase + 0.1 volume sodium tartrate solution at 37oC for 20 minutes.  This 
solution was discarded, and cells were washed three times with sterile water to 
stop the reaction.  Stained cells were analyzed using the Axiovert 100 
microscope.  The number of osteoclasts, defined as multinucleated (at least 
three nuclei) cells positive for TRAP staining, per well were counted. 
Neonatal calvarial osteoblast isolation and culture 
Calvariae, or skullcaps, were isolated from pooled litters of 3-day-old neonatal 
mice, taking care to remove all conjunctive tissues.  Calvariae were washed with 
ice-cold PBS and transferred to pre-warmed, filtered digestion media (α-MEM + 
1.5 mg/mL Type 2 Collagenase + 0.00625% Trypsin-EDTA).  The calvariae were 
digested with rotation at 37oC for 5 minutes, followed by 20 seconds of vigorous 
shaking.  The suspended cells, primarily fibroblasts, were discarded, and the 
medium was replaced with 10 mL of fresh digestion media.  The calvariae were 
digested with rotation at 37oC, shaking vigorously for 20 seconds every 10 
minutes for a total of 30 minutes.  The cell suspension was transferred to a new 
tube on ice, taking care to avoid large bone pieces.  Fresh digestion media was 
added to the calvariae, and they were digested at 37oC with rotation once more, 
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again shaking vigorously for 20 seconds every 10 minutes for a total of 30 
minutes.  The cell suspension was again transferred to a new tube on ice, and 
the two suspensions were centrifuged at 1300 rpm for 3 minutes at 4oC.  The cell 
pellets were re-suspended in growth media (GM; α-MEM + 10% FBS + 100 
units/mL penicillin and 100 µg/mL streptomycin) and plated in 10-cm dishes.  
After 72 hours, the cells were split into 6-well dishes at a density 15,000 cells/cm2 
and maintained in growth media for 72 hours.  Upon confluence, cells were either 
maintained in growth media or switched to osteogenic media (OM; α-MEM + 
10% FBS + 100 units/mL penicillin and 100 µg/mL streptomycin + 5 mM β-
glycerophosphate + 100 µg/mL ascorbic acid) or adipogenic media (AM; α-MEM 
+ 15% FBS, 5 µg/mL insulin, 50 µM indomethacin, 0.5 µM 3-isobutyl-1-
methylxanthine (IBMX), and 1 µM dexamethasone). The media was changed 
every 2-3 days until endpoint assays were performed. 
Alkaline phosphatase (ALP) stain 
WT and Rad-/- primary calvarial osteoblasts were assayed for alkaline 
phosphatase activity on day 0 (upon confluence) and day 7 of culture in 
osteogenic media or adipogenic media using a premixed 5-bromo-4-chloro-3-
indolyl phosphate (BCIP)/nitroblue tetrazolium (NBT) solution (Sigma, Cat No. 
B6404).  A sodium citrate (pH 5.4) fixation solution was prepared by combining 
45 mL of acetone, 10 mL of ethanol, 11.5 mL of 0.1 M citric acid monohydrate, 
and 33.5 mL of 0.1 M sodium citrate and was stored at -20oC. Cell monolayers in 
6-well dishes were incubated in 1 mL of sodium citrate fixation solution for 5 
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minutes and washed twice with distilled water.  The monolayers were then 
incubated with the BCIP/NBT solution for 10 minutes at room temperature, 
washed four times with distilled water, and maintained in PBS for imaging.  BCIP 
is a substrate for alkaline phosphatase, and dephosphorylation of BCIP 
generates an intermediate that dimerizes under alkaline conditions.  Hydrogen 
ions released during this dimerization reaction result in reduction of NBT, 
generating a bluish-purple precipitate that is indicative of alkaline phosphatase 
activity in these cells. 
Alizarin Red S (ARS) stain 
WT and Rad-/- osteoblasts were assayed for calcium deposition on day 21 of 
culture in osteogenic media using Alizarin Red S (ARS).  The working solution for 
this stain is 2% ARS, adjusted to pH 4.1-4.3 using NH4OH.  This solution must be 
filtered and stored in the dark and the pH checked prior to each use.  Cell 
monolayers were washed with PBS and fixed with 10% neutral buffered formalin 
for at least 30 minutes.  Cell monolayers were then incubated with the ARS 
working solution for 45 minutes at room temperature in the dark and then 
carefully washed four times with 1 mL of distilled water.  The last wash was 
replaced with PBS, and the cell monolayers were imaged using the Axiovert 100 
microscope. 
To quantify the ARS staining, which is proportional to the amount of calcium 
deposition, the ARS was solubilized and the optical density was measured.  ARS 
was solubilized from the osteoblast monolayers by adding 800 µL of 10% acetic 
	   61 
acid to each well and incubating for 30 minutes at room temperature with 
agitation.  The cells were scraped, transferred into a tube, and vortexed for 30 
seconds.  Samples were then heated at 85oC for 10 minutes, placed on ice for 
five minutes or until fully cooled, and centrifuged at high speed at 4oC for 15 
minutes.  Five hundred microliters of the supernatant were transferred to a new 
tube and neutralized with 200 µL of 10% NH4OH.  Samples were mixed well, and 
the pH was tested to ensure it fell between 4.1-4.5.  The absorbance at 405 nm 
was measured for each sample in triplicate by aliquoting 150 µL of each sample 
per well into an opaque-walled, transparent-bottomed 96-well plate.  The 
absorbance is directly proportional to the amount of ARS staining in the sample.   
Microarray analysis 
Total RNA was isolated from confluent WT and Rad-/- calvarial osteoblast 
cultures using the standard TRIzol and chloroform method described above, and 
RNA quality was assessed using RNA 6000 Nano-LabChip (Agilent).  The 
University of Kentucky Genomics Core Laboratory performed labeling of the RNA 
and hybridization to the chip. Total RNA (100 ng per sample) was labeled and 
hybridized onto the Affymetrix Clariom D mouse array. The arrays were 
hybridized for 16 hours at 45oC and 60 rpm.  The arrays were washed and 
stained on the Affymetrix Fluidics 450 station and scanned on the Affymetrix 
GeneChip7G scanner to quantify the signal intensity of hybridized probes.  Data 
were analyzed using the Affymetrix Command Console software. 
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Semi-quantitative RT-PCR 
For RT-PCR, cDNA from WT and Rad-/- osteoblast cultures was prepared from 1 
µg of total RNA using the RT2 First Strand Kit (Qiagen) as described above.  RT-
PCR reactions consisted of 12.5 µL of DreamTaq Green PCR Master Mix (2X) 
(Thermo Scientific), 2 µL of cDNA, 1 µL of the appropriate primers, and 9.5 µL of 
nuclease-free water.  Primers for mouse matrix Gla protein (MGP) and 18S were 
obtained from Real Time Primers, and RT-PCR cycling parameters followed the 
manufacturer’s instructions. PCR products were separated on 1% agarose gels, 
and band intensities were measured using ImageJ. 
Oil Red O (ORO) stain 
A stock solution of 0.3% Oil Red O (ORO) was prepared in isopropanol and 
stored in the dark.  Oil Red O staining was performed on osteoblast monolayers 
after 14 days in culture to quantify adipogenesis.  Cell monolayers were washed 
with PBS and fixed with 10% neutral buffered formalin for at least 30 minutes.  
During fixation, three parts of the ORO stock solution were combined with two 
parts distilled water and filtered to generate the working ORO solution.  This 
working solution must be used within 30 minutes of its preparation.  Cells were 
washed with distilled water and incubated in 60% isopropanol for 5 minutes at 
room temperature.  The cell monolayers were then incubated in ORO working 
solution for 15 minutes at room temperature, after which they were washed with 
distilled water four times.  Nuclei were stained purple by incubating the 
monolayers with Harris Hematoxylin solution for one minute at room temperature 
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and washing four times with distilled water.  Cell monolayers were kept in PBS 
for imaging on the Axiovert 100 microscope.  The number of ORO-positive cells 
per 20X field were quantified. 
Echo-MRI 
The body composition of live, unanesthetized WT and Rad-/- mice was measured 
using an EchoMRI-100 whole body composition analyzer (Echo Medical System, 
Houston, TX). 
Von Kossa / MacNeal’s tetrachrome stain 
Three thin sections per animal were de-plasticized in acetone and stained using 
a modification of the Von Kossa / MacNeal’s (VKM) tetrachrome protocol [165] in 
collaboration with the Bone Histology core facility at Indiana University School of 
Medicine.  Briefly, mineralized bone was stained using the Von Kossa silver 
method and unmineralized tissue was counterstained with MacNeal’s 
tetrachrome.  Slides were blinded, three random fields per section were imaged 
at the distal femur just proximal to the growth plate, and adipocyte number and 
size were quantified using ImageJ software. 
Statistics 
Statistical analysis was performed using Student’s t test, with p<0.05 considered 
significant, and all data are reported as mean +/- SEM. 
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Table 2.1: Primers 
 
Oligo Name Sequence 
1. Enigma 5’ HindIII -> Flag AATTAAGCTTATGGATTCCTTCAAGGT 
2. Enigma 3’ NotI -> Flag AATTGCGGCCGCTCATACGTGGGAAA 
3. ENH1 5’ HindIII -> Flag AATTAAGCTTATGAGCAACTACAGTG 
4. ENH1 3’ NotI -> Flag AATTGCGGCCGCTCAAAAATTCACAG 
5. Cypher 5’ HindIII -> Flag AATTAAGCTTATGTCTTACAGTGTGAC 
6. Cypher 3’ NotI -> Flag AATTGCGGCCGCTCACAAGTTGATGG 
7. Enigma ΔPDZ 5’ HindIII -> Flag AATTAAGCTTATGCACATGAAGCCC 
8. Enigma ΔLIM1-3 3’ NotI -> Flag AATTGCGGCCGCTCATACAGGCGTCT 
9. Rad K204R Sense CTCGTGGGCAACAGGAGTGACCTGGTG 
10. Rad K204R Antisense CACCAGGTCACTCCTGTTGCCCACGAG 
 
  
	   65 
Table 2.2: Primary antibodies 
 
Antibody Species Company and Catalog 
Number 
Dilution 
C/EBP alpha Rabbit  Cell Signaling, 8178 1:1000 
C/EBP beta Rabbit  Cell Signaling, 3087 1:1000 
C/EBP delta Rabbit  Cell Signaling, 2318 1:1000 
FLAG Mouse  Sigma, F1804 1:2000 
Gapdh Rabbit  Cell Signaling, 2118 1:1000 
GST Rabbit  Santa Cruz, sc-459 1:1000 
HA Mouse Sigma, H9658 1:2000 
Myc Mouse  Sigma, M4439 1:2000 
Phospho-Rad S39 Rabbit  Custom antibody 1:1000 
Rad Goat  Abcam, ab136865 1:1000 
Smad1 Rabbit  Cell Signaling, 6944 1:1000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Catherine N. K. Withers 2017 
	   66 
 
 
 
Chapter 3 
 
Rad levels are regulated through a novel interaction with Enigma and the 
associated E3 ligase Smurf1 
 
Introduction 
Ras-related GTPases function as guanine nucleotide-dependent switches that 
cycle between an active guanosine triphosphate (GTP)-bound state and an 
inactive guanosine diphosphate (GDP)-bound state [2].  This classical regulatory 
cascade is facilitated by the activities of guanine nucleotide exchange factors 
(GEFs), which promote GDP release and GTP loading, and GTPase activating 
proteins (GAPs), which catalyze GTP hydrolysis and promote inactivation [2].  
Unlike most other small GTPases, the nucleotide dependence of Rad and the 
other RGK (Rad, Rem, Rem2, Gem/Kir) subfamily protein function has not been 
established, and they instead share the unique property of regulation at the level 
of expression [11].  Briefly, Rad levels are significantly decreased in human heart 
failure [131, 132] and in a variety of human cancers [24-28, 30, 32, 34, 38, 39], 
while Rad expression is up regulated in developing and regenerating muscle [20, 
46, 51, 54] and during osteoblast differentiation [44]. Although most of these 
alterations in Rad expression have been attributed to transcriptional changes, it 
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is unclear whether Rad protein levels may also be regulated post-translationally. 
Specifically, Rad protein turnover presents a potential, as of yet unexplored 
regulatory mechanism in light of recent mass spectrometry studies that have 
revealed that Rad protein is subject to modification by ubiquitination [123, 124]. 
In this chapter, I will describe the association of RGK proteins with a scaffolding 
protein known to interact with E3 ubiquitin ligases and demonstrate that Rad 
protein is subject to ubiquitination and degradation following ectopic expression 
of one of these E3 ubiquitin ligases.  
Plasma membrane localization of RGK proteins is essential for their function in 
voltage-dependent calcium channel (VDCC) inhibition [110], and data suggest 
that the C-terminus of RGK proteins is required for calcium channel blockade and 
for proper localization to the plasma membrane, at least in part through binding 
to phosphatidyl inositol phospholipids [12, 106].  Moreover, the independent 
observations by our laboratory and the Colecraft laboratory that RGKs can bind 
directly to the CaV1.2 pore-forming subunit of the calcium channel suggest 
another means of localization of these GTPases at the cell membrane [18, 107].  
We were interested in defining other potential regulatory partners for RGK 
proteins, and for Rad in particular, and we began looking for candidate binding 
partners that are expressed in the heart and that might link RGK proteins to the 
plasma membrane and/or the calcium channel complex. 
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A recent network map of 14,000 protein-protein interactions identified Enigma 
(also known as PDLIM7 or LIM mineralization protein (LMP)) as a novel Gem-
binding protein [166].  Enigma contains an N-terminal PDZ (Postsynaptic density 
95, discs large, and zonula occludens-1) domain and three C-terminal LIM 
(Lin11, Isl-1, and Mec-3) domains. Proteins containing PDZ and LIM domains 
play important roles as scaffolding proteins that allow the formation of multi-
protein complexes to provide spatial and temporal regulation of signaling [167].  
Both PDZ and LIM domains mediate protein-protein interactions.  PDZ domains 
recognize and bind to short motifs usually found at the C-terminus of other 
proteins [168]. For instance, class I PDZ binding motifs are found at the C-
terminus of proteins whose last three amino acid residues are S/T-X-Φ, where X 
is any amino acid and Φ is a hydrophobic residue [168].  It should be noted that 
Rad, Gem, and Rem2 end in class I PDZ binding motifs (-SVL), while Rem does 
not (-AVL).  LIM domains consist of two adjacent zinc finger domains separated 
by a short hydrophobic linker, and a specific recognition motif has not been 
identified for these domains [169].  There are ten genes in the mammalian 
genome that encode proteins containing both PDZ and LIM domains [167].  Of 
these, the Enigma subfamily of PDZ-LIM proteins consists of three members, 
each of which contains an N-terminal PDZ domain and three C-terminal LIM 
domains [170]: Enigma (LIM mineralization protein (LMP), PDLIM7) [171], 
Enigma homolog (ENH, PDLIM5) [172], and Cypher/Z-band associated protein 
(ZASP, PDLIM6) [173].  These proteins are highly homologous in sequence to 
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one another, with the main differences lying in the region between the PDZ and 
LIM domains.   
The potential for an interaction between RGK proteins and Enigma was of 
interest for several reasons.  First, each of the Enigma subfamily proteins is 
expressed in the heart [173-175], and ENH and Cypher have been reported to 
bind to and regulate voltage-dependent calcium channels [176-179].  Moreover, 
deletion of Cypher or ENH in mice results in dilated cardiomyopathy [180, 181], 
Cypher and ENH play roles during cardiac development [182], and Enigma-null 
(Enigma-/-) mice exhibit cardiac structural and functional abnormalities [183]; 
thus, Enigma subfamily proteins appear to have important roles in the heart and 
in VDCC regulation.  In addition to its potential role in the heart, Enigma also 
binds to and alters the activity of several different E3 ubiquitin ligases, including 
Smad ubiquitin regulatory factor 1 (Smurf1) [184], murine double minute 2 
(MDM2) [185], and Cbl-c [186].  It remains unclear whether Enigma directly 
regulates the activity of these proteins or whether Enigma, through its multiple 
protein-protein interaction domains, may act as a scaffolding protein to regulate 
ubiquitin ligase activity by directing substrate specificity via proximity.  Based on 
the properties of PDZ-LIM family proteins described above and the report of a 
putative interaction between Gem and Enigma [166], the work in this chapter 
aims to confirm the Gem interaction and ask whether the association with 
Enigma is shared by the other RGK subfamily proteins, particularly Rad, and 
whether the E3 ubiquitin ligases reported to bind to Enigma might regulate Rad 
protein stability.   
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Of the E3 ubiquitin ligases that bind to Enigma, I chose to focus on Smurf1 
because of its established role in the regulation of osteoblast differentiation [158, 
187] given the report of Rad up regulation during osteogenic differentiation of 
mesenchymal stem cells (MSCs) [44] and the bone density phenotype of Rad-/- 
mice that will be described in detail in Chapter 5. Briefly, Smurf1 regulates 
osteoblast differentiation by providing negative feedback on bone morphogenetic 
protein (BMP) signaling through polyubiquitination of Smad proteins, thereby 
targeting them for degradation in the proteasome [158]. Enigma, or LIM 
mineralization protein (LMP) in the bone literature, has an established role in the 
regulation of osteoblast differentiation that is thought to occur through its 
regulation of Smurf1 [184, 188, 189], and Enigma-/- mice have documented 
deficits in bone density as a result [160].  As mentioned previously, Rad levels 
are up regulated when MSCs are primed for osteoblast differentiation using 
lithium [44]. Notably, Satija et al. have found that RNAi-mediated Rad silencing 
impaired lithium-dependent osteogenic priming [44], suggesting that the loss of 
Rad may result in a similar phenotype to increased Smurf1 activity. This chapter 
will describe studies defining the interaction of RGK proteins with Enigma and 
provide evidence that Rad is subject to ubiquitination and that Rad protein levels 
are reduced following ectopic expression of the Smurf1 E3 ligase and in 
response to prolonged BMP signaling.  Taken together, these studies suggest 
that ubiquitination may serve as a novel regulatory mechanism to permit dynamic 
control of Rad, and perhaps other RGK, protein levels.  
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Results 
RGK subfamily proteins co-immunoprecipitate with Enigma 
To determine whether Gem and other RGK proteins associate with Enigma [166], 
HEK293 cells were transfected with HA-tagged RGK proteins (Rad, Rem, Rem2 
and Gem) and Flag-tagged empty vector (EV), Enigma, ENH1, or Cypher, and 
interactions between these proteins were assessed by anti-Flag co-
immunoprecipitations. While each of the RGK proteins co-immunoprecipitated 
with Enigma, no interaction was detected between RGK proteins and either 
ENH1 or Cypher (Figure 3.1).  Thus, Enigma serves as a common interacting 
partner for all members of the RGK subfamily, joining calmodulin, 14-3-3, and 
CaVβ  [12, 14, 16, 109, 118-120].  As Enigma has been shown to have a role in 
heart development [183], and a focus of our laboratory is to examine the 
physiological role of Rad signaling in the heart, further studies were directed at 
examining whether Enigma plays a role in the control of Rad GTPase. 
Rad association with Enigma does not require the PDZ domain 
I next sought to determine which of the protein-protein interaction domain(s) of 
Enigma were required for interaction with Rad. Given that the C-termini of Rad, 
Gem, and Rem2 consist of a putative PDZ-binding motif and that Rem, the only 
RGK protein without a PDZ-binding motif, consistently displayed the weakest 
interaction with Enigma (Figure 3.1), I hypothesized that the PDZ domain might 
mediate, or at least enhance, the interaction between Rad and Enigma. 
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Truncations of Enigma were generated to lack either the N-terminal PDZ domain 
(ΔPDZ) or the three C-terminal LIM domains (ΔLIM1-3) to determine which 
domain in Enigma is required for the interaction with Rad (Figure 3.2A).  Co-
immunoprecipitation analyses using these truncations revealed that the 
interaction between Enigma and Rad was maintained when the PDZ domain was 
removed; however, deletion of the three LIM domains completely abolished the 
interaction between these two proteins (Figure 3.2B). Therefore, Rad likely 
interacts with Enigma through its LIM domain(s), whereas the PDZ domain is 
dispensable for Rad-Enigma complex formation. 
Rad protein levels are elevated in the hearts of Enigma-/- mice  
Unlike ENH1 and Cypher [178, 179], Enigma has not been studied in the 
regulation of calcium channels.  However, Enigma has an established role in E3 
ubiquitin ligase regulation that sets it apart from the other members of the PDZ-
LIM scaffold family [184-186].  Studies by our lab and others have reported that 
Rad protein levels are decreased in human heart failure [131, 132], but the 
mechanism underlying the down regulation of Rad expression is unclear.  Thus, I 
next asked whether the interaction between Rad and Enigma might serve to 
modulate Rad levels.  Hearts from Enigma-/- mice and WT littermates were 
homogenized and subjected to Western blotting analysis to probe the impact of 
Enigma deletion on Rad protein levels. Enigma-/- hearts exhibited significantly 
higher levels of Rad protein than WT controls (Figure 3.3A).  RNA was extracted 
from the apices of these hearts and quantitative RT-PCR analysis indicated a 
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modest increase in Rad mRNA levels in Enigma-/- hearts that did not reach 
statistical significance compared to WT hearts (Figure 3.3B).  These data, while 
preliminary, suggest that Enigma deletion may result in an increase in Rad 
expression through post-transcriptional mechanisms, and we next investigated 
the potential contribution of the E3 ubiquitin ligases bound to Enigma in 
regulating Rad protein levels. 
Smurf1 overexpression results in decreased Rad levels 
Smad ubiquitin regulatory factor 1 (Smurf1) is one of the E3 ubiquitin ligases that 
binds to Enigma [184].  Given the observation that Enigma deletion imparts a 
significant increase in Rad protein, but not mRNA, levels in the heart, I next 
assessed the ability of Smurf1 to regulate Rad post-translationally.  Transfection 
of HEK293 cells with Smurf1, but not the related E3 ligase Smurf2 which does 
not bind to Enigma, resulted in a significant reduction in Rad protein levels 
(Figure 3.4A). Ectopic expression of Enigma was not required for this down 
regulation of Rad; however, we cannot rule out the possibility that endogenous 
Enigma in HEK293 cells may act as a scaffold for Rad and Smurf1. To determine 
whether Rad is ubiquitinated following Smurf1 overexpression, HEK293 cells 
were transfected with Myc-tagged ubiquitin along with HA-tagged Rad and either 
Flag-tagged EV or Smurf1.  Cells were treated with MG-132 prior to lysis to 
inhibit proteasomal degradation, and N-ethylmaleimide was added to the lysis 
buffer to block cellular deubiquitylating enzyme activity.  In support of a role for 
Smurf1 in the proteostatic regulation of Rad function, Rad ubiquitination was 
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increased in the context of Smurf1 overexpression (Figure 3.4B).  Moreover, 
treatment of these cells with the proteasome inhibitor MG-132 maintained Rad 
levels in the presence of Smurf1 overexpression (Figure 3.4B). This observation 
suggests that the E3 ubiquitin ligase activity of Smurf1 followed by proteasomal 
degradation is responsible for the decline in Rad levels observed upon Smurf1 
overexpression.  Notably, Smurf1 overexpression resulted in a decrease in the 
expression of the other RGK proteins Rem and Gem, but not of the unrelated Rin 
GTPase, suggesting that Smurf1 regulation may be a common feature across the 
RGK subfamily (Figure 3.5).  
Rad Lys204 is required for Smurf1-mediated turnover 
In keeping with the notion that ectopic Smurf1 expression promotes 
polyubiquitination and targeting of Rad for proteasomal degradation, 
overexpression of the catalytically inactive Smurf1 C699A mutant failed to alter 
Rad protein levels [190] (Figure 3.6).  Previous mass spectrometry analysis 
indicates that Rad protein can be ubiquitinated at lysine-204 (Lys204) [123, 124]. 
To test whether Lys204 is required for Smurf1-mediated Rad regulation, site 
directed mutagenesis was performed to change this lysine to arginine (K204R) to 
prevent site-selective ubiquitination. Importantly, Rad K204R was insensitive to 
Smurf1 overexpression, suggesting that ubiquitination of Rad at this residue is 
required for Smurf1-mediated turnover of the protein (Figure 3.6).  Taken 
together, these data suggest that Smurf1 ubiquitinates Rad at Lys204, targeting it 
for proteasomal degradation.   
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Rad co-immunoprecipitates with receptor-associated Smad (R-Smad) 
proteins 
The studies described above suggest that Rad is a substrate for Smurf1, like the 
receptor-associated Smad (R-Smad) proteins in the BMP signaling pathway, 
Smad1 and Smad5 [190].  Given the regulation of Rad and Smad proteins by 
Smurf1-mediated ubiquitination as well as the recent reports of Rad binding to 
transcription factors [40, 41], co-immunoprecipitation experiments were 
performed to probe for a potential interaction between Rad and Smad proteins.  
HEK293 cells were transfected with HA-Rad WT and either Flag-tagged Smad1, 
Smad3, Smad4, Enigma as a positive control, or EV as a negative control.  
Smad1 is an R-Smad in the BMP signaling pathway and is targeted by Smurf1 
[190], Smad3 is an R-Smad in the transforming growth factor β (TGFβ) signaling 
pathway and is targeted by the Smurf2 and ROC1 E3 ubiquitin ligases [191, 
192], and Smad4 is the common Smad partner (co-Smad) that dimerizes with 
phosphorylated R-Smads to facilitate nuclear translocation and transcriptional 
activation and is not subject to Smurf-mediated turnover [193].  Co-
immunoprecipitation analyses suggested that Rad forms a complex with Smad1 
as well as, unexpectedly, Smad3 (Figure 3.7).  Thus, the data suggest that Rad 
associates with R-Smads from both the BMP and TGFβ pathways, but not with 
the co-Smad, Smad4. 
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BMP-2 treatment decreases Rad levels 
BMP receptor activation results in increased downstream Smurf1 activity toward 
R-Smad proteins [158], whether through activation of the Smurf1 enzyme or 
generation of a recognizable substrate in phosphorylated R-Smad proteins.  For 
this reason, I next examined whether BMP-2 signaling might control Rad levels. 
HEK293 cells were transfected with HA-Rad WT and treated with vehicle or 
BMP-2 for two hours and probed for changes in Rad levels.  Western blotting 
analysis indicated that BMP-2 treatment results in a decrease in Rad protein 
levels (Figure 3.8A).   Since Enigma has been reported to inhibit Smurf1-
mediated ubiquitination of Smad proteins [184], I next asked whether Enigma 
overexpression might alter the effects of BMP-2 signaling on Rad protein levels. 
Notably, the previously observed decrease in Rad protein levels following BMP-2 
treatment was rescued when Enigma was overexpressed (Figure 3.8A).   
In addition to the change seen by our laboratory and others in Rad protein levels 
during human heart failure [131, 132], we and others have also recently observed 
changes in Rad expression during MSC differentiation toward the osteoblast [44] 
and adipocyte lineages (see Chapter 5).  Since BMP/Smad signaling plays a 
central role in the regulation of MSC differentiation toward the osteoblast lineage 
[153, 155, 194], and since Enigma has been recently implicated in the regulation 
of this process as well [184], I next assessed the impact of BMP-2 signaling on 
endogenous Rad levels in wildtype primary calvarial pre-osteoblasts.  
Interestingly, treatment of these cells with BMP-2 for one week resulted in a 
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marked reduction in Rad protein levels (Figure 3.8B).  As confirmation that 
Smurf1 activity is detectable at this time point and at this dosage of BMP-2, 
Smad1 levels were also found to be decreased (Figure 3.8B). These data are 
preliminary, but they suggest that Smurf1 activation may be a physiological 
means of regulating Rad protein levels that warrants further investigation both in 
osteoblasts and cardiac myocytes. 
Discussion 
RGK GTPases comprise a unique subfamily of Ras-related GTPases in many 
ways, especially in the means by which these G-proteins are regulated.  Unlike 
the majority of small GTPases, Rad and the other related RGK proteins do not 
appear to be predominantly controlled via the canonical GTP/GDP cycle, and 
attempts to identify GEF and GAP regulatory proteins have to date been largely 
unsuccessful [11].  Instead, regulation of RGK proteins via phosphorylation [64, 
98] and expression levels [11] has been reported.  We and others have reported 
that Rad levels are significantly lower in human failing hearts compared to 
healthy controls [102, 131], but the mechanism of Rad down regulation is 
unknown. In many cases, Rad down regulation has been attributed to 
transcriptional changes, but the potential for post-translational control of Rad 
levels has not been explored, despite the observation that Rad protein is subject 
to ubiquitination [123, 124]. 
The studies described in this chapter have identified a novel interaction between 
Rad GTPase and Enigma, a scaffolding protein containing an N-terminal PDZ 
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domain and 3 C-terminal LIM domains that can bind to and regulate the activity 
of E3 ubiquitin ligases [184-186].  Deletion of Enigma results in an increase in 
Rad protein, but not mRNA, levels in mouse heart tissue, and overexpression of 
Smurf1, an E3 ubiquitin ligase that binds to Enigma, results in ubiquitination of 
Rad protein at Lys204 and proteasomal degradation.  While further studies are 
necessary and will be discussed below, we propose a working model in which 
Enigma acts as a scaffold to bring Smurf1 and its substrate Rad into close 
proximity to promote Rad ubiquitination and turnover (Figure 3.9A).  According 
to this model, deletion of Enigma would result in less efficient ubiquitination of 
Rad by Smurf1 (Figure 3.9B), and resting Rad levels would therefore increase 
as we observed in Figure 3.3 due to a loss of cellular proteostatic control.  While 
the observation that Enigma overexpression rescued the BMP-mediated decline 
in Rad levels (Figure 3.8A) seems at the surface to be at odds with such a 
model, this finding could also be explained if Enigma is required to scaffold Rad 
and Smurf1.  Overexpression of the scaffold may result in cases where Rad is 
sequestered away from limiting amounts of endogenous Smurf1; thus, 
paradoxically Enigma overexpression would result in Rad protection from 
Smurf1-dependent turnover (Figure 3.9C). We acknowledge that further studies 
are necessary to confirm our proposed model, some of which will be described in 
the following paragraphs.   
First, the co-immunoprecipitation analyses in Figure 3.1 indicate that RGK 
proteins associate with Enigma, but we cannot conclude whether this interaction 
is direct or indirect. Binding studies using purified recombinant proteins are 
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required to probe for direct binding of Rad to Enigma.  If the interaction is direct, 
identification of a minimal domain or region of Enigma necessary for Rad binding, 
beyond the preliminary analysis performed in Figure 3.2, would be useful to test 
the requirement of Enigma binding for Rad turnover.  The Smurf1 overexpression 
studies in HEK293 cells in Figures 3.4 and 3.6 indicate that Rad is subject to 
ubiquitination at Lys204 and proteasome-dependent turnover, but the role of 
Enigma in this process requires further investigation that would be assisted by 
such additional insights into the Rad-Enigma interaction. For instance, 
overexpression of the minimal domain of Enigma required for Rad binding would 
likely out-compete Rad binding to endogenous, full-length Enigma scaffolds and 
would thus be expected to block Smurf1-mediated Rad turnover if Enigma 
scaffolding is indeed a requirement.  Enigma knock down or overexpression of 
an Enigma construct lacking the Rad-binding region would be expected to have 
the same effect.  The regions of Enigma and Smurf1 required for their binding 
interaction have been modeled [188] and could be exploited in a similar manner.  
The nature of the ubiquitin linkage on Rad also warrants further investigation. 
Moreover, while the data in Figure 3.3 indicating a significant increase in Rad 
protein, but not mRNA, levels in Enigma-/- hearts is consistent with the model 
presented above, the requirement for Smurf1 and for proteasomal turnover in 
general has not directly been tested.  Primary calvarial osteoblasts present a cell 
system that expresses endogenous Rad and can be manipulated more readily 
than cardiac myocytes.  Rad levels should be probed in WT and Enigma-/- 
calvarial osteoblast cultures to determine whether the increase in Rad levels is 
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also observed in this cell type.  If so, overexpression of Enigma and Smurf1 may 
be expected to rescue this phenotype, and a pulse-chase experiment could be 
utilized to examine Rad turnover in these cells.  To confirm that the increase in 
Rad protein in Enigma-/- cells is indeed the result of hampered protein turnover, 
primary calvarial osteoblasts from WT and Enigma-/- mice could be treated with 
vehicle or MG-132 prior to probing Rad protein levels by Western blotting.  If the 
increase in Rad levels in cells lacking Enigma is due to a decrease in 
proteasomal degradation of Rad protein, then we would expect a more robust 
elevation in Rad levels in WT cells following proteasomal inhibition than in 
Enigma-/- cells.  Finally, probing Rad levels in tissues from Smurf1-/- mice would 
be expected to show a significant increase in Rad protein, but not mRNA levels. 
Furthermore, the observation that prolonged BMP-2 signaling results in 
decreased Rad levels in Figure 3.8 requires further studies to confirm the role of 
Smurf1 in this process.  To test for a direct role of Smurf1 in the down regulation 
of Rad, Smurf1 knock down could be performed in HEK293 cells or primary 
osteoblasts with the expectation that BMP treatment would no longer result in 
lower Rad or Smad1 expression.  We observed that Enigma overexpression 
rescued the BMP-mediated decrease in Rad levels in HEK293 cells, but 
interpretation of this experiment is difficult as discussed previously.  It would be 
worthwhile to ask whether Enigma knock down in HEK293 cells might also 
rescue Rad levels in the context of Smurf1 overexpression or BMP-2 treatment.  
In the same vein, BMP-2 treatment of WT calvarial osteoblasts in Figure 3.8B 
should be repeated in Enigma-/- osteoblasts with the expectation that BMP-2 
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would no longer promote a decrease in Rad levels, but perhaps that the 
decrease in Smad1 would be maintained since Enigma is not thought to 
associate with Smad proteins. To confirm that the BMP-2 mediated down 
regulation of Rad results from altered proteostatic control, HEK293 cells or 
primary osteoblasts should be treated with MG-132 in combination with BMP-2 to 
determine whether Rad levels are rescued, and analysis of Rad mRNA 
expression in BMP-treated cells should also be performed.  
The potential significance of the interaction between Rad and Smad proteins 
identified in Figure 3.7 is intriguing, especially in light of the recent reports of Rad 
binding to and regulating the DNA binding of other transcription factors [40, 41].  
The observation that Rad associates with R-Smads but not with Smad4 suggests 
two potential models.  First, Rad may associate with the R-Smad proteins in a 
manner that displaces Smad4, thereby inhibiting Smad dimerization and 
downstream transcriptional activation.  Alternatively, Rad may associate with the 
R-Smad/Smad4 complex through a direct association with the R-Smad, but we 
could not identify an interaction between Rad and Smad4 because of limiting 
endogenous R-Smad levels.  In this case, co-overexpression of the R-Smad (1 or 
3) along with Rad and Smad4 would be expected to allow co-
immunoprecipitation of Rad and Smad4 that was not observed in our studies.  
The potential impact of Rad on BMP/Smad signaling needs to be investigated 
further.  Preliminary studies suggest no change in BMP-responsive luciferase 
activity in Rad-/- osteoblasts compared to WT, and both genotypes were 
comparably responsive to BMP-2 stimulation in this assay (data not shown).  We 
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also fail to see a significant change in total Smad levels in Rad-/- hearts compared 
to WT (data not shown).  Zhang and colleagues did, however, find an increase in 
Smad3 expression in cardiac myocytes after infection with Rad adenovirus, along 
with a trend towards increased transcription from a Smad reporter construct [41]. 
Hence, the significance of the Rad-Smad interaction remains unclear.  
While the work presented in this chapter identifies Smurf1 as a novel regulator of 
Rad protein levels, Smurf1 may not be the only E3 ubiquitin ligase that regulates 
Rad stability.  Enigma has also been shown to bind c-Cbl and MDM2 and to 
regulate their E3 ubiquitin ligase activities [185, 186]; thus, future studies 
investigating the ability of these E3 ligases to target Rad are worthwhile.  Studies 
determining the specificity of the Enigma interaction and Smurf1 regulation to 
Rad are also of interest.  Each of the RGK proteins co-immunoprecipitates with 
Enigma and is down regulated by Smurf1 (Figures 3.1 and 3.5), but it remains 
unclear whether each of the RGKs binds to Enigma with the same affinity.  To 
date Rad is the only RGK protein for which ubiquitin modification has been 
identified, but further studies are necessary to determine whether modulation of 
the other RGK proteins by Smurf1 is ubiquitin-dependent and which lysine 
residue(s) are required. It is also unclear whether interactions with Enigma have 
additional functions beyond scaffolding RGKs to an E3 ubiquitin ligase enzyme.  
The reason for the specificity of RGKs for Enigma, and not the other PDZ-LIM 
family scaffolds that were investigated, also requires further assessment. 
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In the next chapter, we will also see that Enigma alters Rad phosphorylation 
status; hence, while we have uncovered a novel interaction between Rad and 
Enigma that likely plays an important regulatory role, there is much that remains 
to be determined. 
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Figure 3.1: RGK subfamily proteins co-immunoprecipitate with Enigma 
HEK293 cells were transfected with HA-tagged RGK proteins (Rem, Rad, Gem, 
or Rem2) and either Flag-tagged Enigma, ENH1, Cypher, or empty vector. 
Immunoprecipitation with anti-Flag antibody and Western blotting with 
biotinylated anti-HA antibody indicates that each of the RGK proteins interacts 
with Enigma, but not ENH1 or Cypher.  Immunoprecipitates were probed with 
anti-Flag antibody to confirm expression and pull down of PDZ-LIM proteins, and 
whole lysates were probed with anti-HA antibody to confirm equal loading of HA-
Rad. Results are representative of three independent experiments. 
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Figure 3.2: Rad interaction with Enigma is independent of the PDZ domain 
Panel A) Schematic showing the domain structure of Enigma and of the 
truncation mutants generated for domain binding analysis.  
Panel B) HA-Rad co-immunoprecipitates with Flag-Enigma WT and the ΔPDZ 
mutant but not with the ΔLIM1-3 mutant, suggesting that Rad may interact with 
Enigma through one or more of the LIM domains. Results are representative of 
three independent experiments. 
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Figure 3.3: Rad protein levels are elevated in the hearts of Enigma-/- mice 
Panel A) Rad protein levels normalized to Gapdh are higher in hearts from 4-
week-old male Enigma-/- mice compared to WT littermate controls. N=4 mice per 
genotype, * p<0.05 by Student’s t test. 
Panel B) Rad mRNA levels normalized to Gapdh are not significantly different in 
hearts from 4-week-old male Enigma-/- mice compared to WT littermate controls.  
N=3 mice per genotype. 
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Figure 3.4: Smurf1 overexpression results in Rad ubiquitination and 
turnover 
Panel A) HEK293 cells were transfected with HA-tagged Rad and Myc-tagged 
EV, Smurf1, or Smurf2. Overexpression of Smurf1, but not Smurf2, in HEK293 
cells results in a significant decrease in HA-Rad levels. * p<0.05 compared to 
Myc-EV by Student’s t test.  
Panel B) HEK293 cells were transfected with HA-tagged Rad, Flag-tagged EV or 
Smurf1, and Myc-tagged ubiquitin. Treatment of HEK293 cells with 10 µm MG-
132 for 16 hours prior to lysis protects Rad from Smurf1-mediated down-
regulation.  Immunoprecipitation of HA-Rad WT and immunoblotting with anti-
Myc antibody demonstrates ubiquitination of Rad protein when Smurf1 is 
overexpressed.  
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Figure 3.5: Smurf1 overexpression results in lower levels of RGK proteins 
Overexpression of Myc-Smurf1, but not Smurf2, in HEK293 cells results in a 
decrease in the levels of other HA-tagged RGK proteins, Rem and Gem, in 
addition to Rad.  Another small GTPase, Rin, was used as a negative control and 
does not appear to be modulated by Smurf1 overexpression.  
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Figure 3.6: Smurf1-mediated Rad turnover requires Lys204 
Panel A) Overexpression of Flag-Smurf1 WT, but not the catalytically inactive 
mutant C699A, results in a decrease in Rad protein levels.  
Panel B) Mutation of the proposed ubiquitination site Lys204 to arginine results in 
protection of Rad from Smurf1-mediated turnover.  
Panel C) Quantitation of the results of three independent experiments. * p<0.05 
compared to Flag-EV by Student’s t test.  
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Figure 3.7: Rad co-immunoprecipitates with Smad1 and Smad3 
HEK293 cells were transfected with HA-tagged Rad WT and Flag-tagged empty 
vector, Smad1, Smad3, Smad4, or Enigma (positive control). Co-
immunoprecipitation analysis indicated that Rad associates with the receptor-
associated Smads (Smad1 and 3), but not the co-Smad4 protein. 
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Figure 3.8: Bone morphogenetic protein stimulation results in decreased 
Rad levels 
Panel A) HEK293 cells were transfected with HA-tagged Rad WT and Flag-
tagged empty vector (left) or Enigma (right).  Cells were serum-starved prior to 
stimulation with 100 ng/mL BMP-2 for one hour.  BMP-2 treatment resulted in a 
decrease in Rad levels that was rescued when Enigma was overexpressed. 
Panel B) Primary mouse calvarial osteoblasts were stimulated with 100 ng/mL 
BMP-2 or vehicle for one week, refreshing media every other day prior to 
harvest.  Western blotting analysis indicated that Rad and Smad1 levels are 
decreased after prolonged BMP-2 stimulation.  Results of two independent 
isolations are shown. 
  
	   92 
 
Figure 3.9: Proposed model in which Enigma serves as a scaffold for 
Smurf1 and Rad GTPase 
Panel A) Proposed model in which Enigma serves as a scaffold to facilitate 
Smurf1-mediated Rad ubiquitination and turnover 
Panel B) This model would suggest that Enigma deletion would result in 
uncoupling of Smurf1 and Rad, and thus less efficient Rad ubiquitination. 
Panel C) This model may also suggest that Enigma overexpression may 
sequester overexpressed Rad away from limiting amounts of endogenous 
Smurf1, thus resulting in less efficient Rad ubiquitination and turnover. 
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Chapter 4 
 
Regulation of Rad phosphorylation by β-adrenergic signaling 
Introduction 
RGK (Rad, Rem, Rem2, and Gem/Kir) proteins, and Rad in particular, have 
established roles in voltage-dependent calcium channel (VDCC) control [11, 12], 
cytoskeletal remodeling [19], cardiac contractility [104, 136], and more recently, 
tumorigenesis [24-28, 30, 32, 34, 38, 39] and stem cell differentiation [44, 45].  
As detailed in Chapter 3, an outstanding issue in the RGK field that is central to 
this thesis is how these proteins are regulated, since evidence for nucleotide-
dependent control is lacking [11]. In addition to regulation at the level of 
expression, whether by transcriptional or post-transcriptional mechanisms 
explored in Chapter 3, phosphorylation also represents a novel means of 
regulation for RGK subfamily G-proteins [49, 64, 98, 116, 118, 121]. Early in vitro 
studies revealed that Rad protein is phosphorylated at multiple serine (Ser) 
residues by a variety of kinases including protein kinase A (PKA), protein kinase 
C (PKC), calmodulin-dependent protein kinase II (CaMKII), and casein kinase II 
[49].  Previous studies in our laboratory and others have shown that RGK 
proteins are subject to phosphorylation-dependent 14-3-3 binding [109, 113, 
118], and studies across the RGK family indicate that phosphorylation can 
regulate the subcellular localization [16, 109, 113] and the biological functions of 
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these proteins [64, 98, 121].  Some issues that remain unclear, however, are the 
nature of the upstream pathways that mediate RGK phosphorylation and the 
interplay of complex phosphorylation at multiple residues in RGK proteins, some 
of which are conserved across the family and others of which are unique.  
The only report to date of RGK phosphorylation impacting VDCC regulation is the 
recent finding that Rem phosphorylation at Ser18 by protein kinase D1 (PKD1) in 
the α1-adrenergic signaling cascade inhibited Rem-mediated blockade of calcium 
channel current [64]. The α1-adrenergic receptor is a G-protein coupled receptor 
(GPCR) that signals through Gq to activate phospholipase C, which cleaves 
phosphatidyl inositol 4,5-bisphosphate (PIP2) lipids to generate the second 
messenger molecules inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
[195].  IP3 binds to receptors on the endoplasmic reticulum to induce intracellular 
calcium release, while DAG activates PKC, PKD1, and downstream signaling 
[195].  In addition to activation of the α1-adrenergic receptor with phenylephrine, 
PKC can be activated downstream using phorbol esters such as phorbol 12-
myristate 13-acetate (PMA).  Jhun and colleagues showed convincingly that 
activation of this pathway, and specifically of PKD1, resulted in Rem 
phosphorylation and reversal of Rem-mediated calcium channel inhibition, while 
the Rem S18A point mutant was resistant to these treatments [64].  Notably, 
phosphorylated Ser18 is the N-terminal binding site for 14-3-3 within Rem [118]; 
however, the contribution of 14-3-3 binding to the reversal of channel block with 
Rem Ser18 phosphorylation is unclear.   
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While a role for Rem Ser18 phosphorylation in VDCC regulation has been 
documented [64], the impact of phosphorylation on the VDCC regulatory function 
of other RGK proteins remains to be tested.  Notably, the N-terminal extensions 
of RGK proteins are not well conserved across the family (see Figure 1.1), and 
we hypothesized that different kinase cascades could be involved in the 
regulation of distinct RGK proteins.  In this vein, intersections between Rad and 
the β-adrenergic signaling pathway have been reported in the literature [86, 104, 
131].  Briefly, β-adrenergic receptors are also GPCRs, but they signal through Gs 
to activate adenylyl cyclase, which converts adenosine triphosphate (ATP) to 
cyclic adenosine monophosphate (cAMP) to activate PKA and downstream 
signaling [196].  Experimentally, activation of the β-adrenergic receptor can be 
achieved using isoproterenol (ISO), and stimulation of cells with forskolin serves 
to activate adenylyl cyclase and PKA downstream of the receptor.  The first 
connection between Rad and β-adrenergic signaling in the literature was a report 
that overexpression of Rad in cardiac myocytes rendered the cells unresponsive 
to β-adrenergic stimulation of the calcium channel, as treatment with the general 
β-adrenergic agonist isoproterenol failed to elicit an increase in calcium current or 
calcium transients [86].  Additionally, we have reported that Rad-/- cardiac 
myocytes and whole hearts exhibit a phenotype that mirrors constitutive 
β−adrenergic activation [104, 131].   
Interestingly, β-adrenergic agonism is known to result in phosphorylation of the L-
type calcium channel complex as well as an increase in calcium current (ICa) in 
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cardiac myocytes [197, 198] .  Traditionally, these two downstream events were 
thought to be linked; that is, phosphorylation of the calcium channel CaV1.2 and 
CaVβ2a subunits was thought to induce a conformational change that allowed for 
an increase in calcium current.  Notably, however, a number of recent studies 
have indicated that the mechanism underlying the β-adrenergic increase in ICa 
may not be this simple [199-201].  Ser1928 phosphorylation within the C-
terminus of CaV1.2 was the main event thought to afford increased ICa following 
β-adrenergic stimulation, and this residue was also the first to be excluded, as 
calcium current in cardiac myocytes from CaV1.2 S1928A mutant mice retained 
responsiveness to β-adrenergic stimulation [199]. Ganesan et al. demonstrated 
that the C-terminus of CaV1.2, but not Ser1928, was necessary for β-adrenergic 
stimulation of the channel [200]; this observation is intriguing, as RGK proteins 
associate with the C-terminus of CaV1.2 [107]. Subsequently, deletion of the C-
terminal phosphorylation sites in the CaVβ2a subunit and mutations of the 
phosphorylation sites Ser1512 and Ser1570 in CaV1.2 did not abolish 
responsiveness to β-adrenergic stimulation [201].  These findings called into 
question the basic mechanism for elevated calcium current downstream of β-
adrenergic receptor activation. This new uncertainty in the mechanism for β-
adrenergic increases in ICa, coupled with the Rad-/- phenotype of tonic β-
adrenergic drive in the absence of stimulus, led to an intriguing but provocative 
model in which Rad may function as a brake on a subset of calcium channels 
that can be reversed following β−adrenergic stimulation through Rad 
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phosphorylation to allow an acute rise in ICa. In other words, Rad phosphorylation 
would be equivalent to loss of Rad function with respect to calcium current.  
The physiological significance of Rad phosphorylation and the stimuli mediating 
phosphorylation of N-terminal serine residues in Rad have not been studied. In 
this chapter, the role of Rad phosphorylation at Ser39, the N-terminal 14-3-3 
binding site, will be interrogated. Specifically, the hypothesis that β−adrenergic 
signaling promotes Rad phosphorylation and subsequent reversal of calcium 
channel inhibition will be tested. While the data presented here are still 
preliminary, I have included them in this dissertation in order to document the 
progress we have made so far in understanding the regulatory role of Rad Ser39 
phosphorylation as well as to highlight areas for future study. 
Results 
Generation of an antibody to detect Rad phosphorylation at Ser39 
In order to characterize the stimuli that may induce Rad phosphorylation, an 
antibody was raised against a peptide corresponding to Rad phosphorylated at 
Ser39.  This residue is equivalent to Rem Ser18 in terms of 14-3-3 binding [118]. 
The Rad anti-phospho-Ser39 (Rad pSer39) antibody was tested to confirm its 
specificity for phosphorylated Ser39 relative to other serine residues in the Rad 
protein, as well as its specificity for Rad relative to other RGK subfamily proteins 
(Figure 4.1).  Western blotting analysis indicates that the antibody recognizes 
Rad phosphorylated at Ser39, as the S39A phosphorylation deficient mutation 
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was not recognized (Figure 4.1). Mutation of Ser272 and Ser301 to alanine also 
reduced immunoreactivity with the Rad pSer39 antibody (Figure 4.1), suggesting 
the possibility of Ser272 and/or Ser301 phosphorylation cross-reactivity, or 
perhaps of coordinated phosphorylation of these more C-terminal residues and 
Ser39. The latter is almost certainly true in the case of Ser301, as 14-3-3 dimers 
bind to phosphorylated Ser39 and Ser301 in Rad protein; hence, Rad S301A has 
diminished binding to 14-3-3, rendering Rad phosphorylation at Ser39 less 
protected from phosphatase activity in the S301A mutant compared to wildtype 
Rad.  The Rad pSer39 antibody was specific to Rad, as it did not detect Rem, the 
long isoform of Rem2 (Rem2L), or Gem (Figure 4.1).  Finally, this analysis 
suggested that under conditions of serum starvation, there remains a basal level 
of Rad Ser39 phosphorylation in HEK293 cells (Figure 4.1). 
β-adrenergic stimulation results in phosphorylation of Rad 
The Rad pSer39 antibody was next used to examine the stimuli capable of 
regulating Rad phosphorylation.  HEK293 cells were transfected with HA-tagged 
Rad WT and serum starved prior to stimulation with various agonists.  As seen in 
Figure 4.1, treatment with isoproterenol, a β-adrenergic agonist, appears to 
increase Rad Ser39 phosphorylation in HEK293 cells. Activation of the α-
adrenergic kinase PKC using the phorbol ester PMA failed to induce 
phosphorylation of Rad (Figure 4.2) at concentrations that successfully resulted 
in Rem phosphorylation in prior studies in our laboratory (data not shown).  
Notably, robust and time-dependent phosphorylation of Rad at Ser39 in HEK293 
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cells was observed following treatment with forskolin (Figure 4.2), which 
activates adenylyl cyclase downstream of the β-adrenergic receptor and thereby 
increases intracellular cAMP levels and triggers PKA activation. Preliminary 
studies suggest that these effects of isoproterenol and forskolin are also 
observed in cardiac myocytes, as stimulation of wildtype fetal ventricular 
myocytes with either of these agonists induced a robust increase in Rad Ser39 
phosphorylation (Figure 4.3).  This experiment needs to be repeated with better 
quality total Rad immunoblotting as well as with a loading control so that 
quantification and statistical analysis can be performed. Furthermore, preliminary 
studies suggest that Rad Ser39 phosphorylation is also elevated in hypertensive 
human hearts (Figure 4.4), a condition associated with up regulation of β-
adrenergic signaling, but we acknowledge the need for a loading control in these 
studies. Together, these data suggest that Rad Ser39 phosphorylation may be 
accomplished downstream of the β- rather than α-adrenergic signaling pathway. 
Rad phosphorylation at Ser39 may weaken its association with CaVβ2a 
The impact of Rad phosphorylation at Ser39 on its interaction with the CaVβ2a 
subunit of the L-type calcium channel complex was next assessed by a series of 
co-immunoprecipitation experiments.  First, Rad Ser39 was mutated to alanine 
(S39A) so that this residue could not be phosphorylated or to aspartate (S39D) to 
mimic the size and charge of a phosphorylated serine at this position using site 
directed mutagenesis. The S39A mutation thus results in a phosphodeficient Rad 
protein with a reduced ability to bind 14-3-3 dimers [16], while the S39D mutation 
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generates a phosphomimetic protein that we hypothesized might display 
stimulus-independent 14-3-3 association.  HEK293 cells were co-transfected with 
HA-tagged Rad WT, S39A, or S39D and Flag-tagged CaVβ2a or empty vector as 
a control.  Cell lysates were subjected to Flag immunoprecipitation, and co-
immunoprecipitated HA-tagged Rad proteins were detected by Western blotting.  
Mutation of Ser39 to alanine had no effect on Rad binding to the CaVβ2a subunit 
of the calcium channel; however, the phosphomimetic S39D mutation resulted in 
a reduction in CaVβ2a association by ~50% (Figure 4.5), suggesting that 
phosphorylation of this residue may promote dissociation of Rad from the 
calcium channel complex, perhaps due to enhanced 14-3-3 binding. 
To probe the role of phosphorylation in regulation of the Rad-CaVβ association 
further, co-immunoprecipitation of Rad and CaVβ2a was assessed in the 
presence and absence of phosphatase inhibitor in the cell lysis buffer.  The lysis 
buffer used in the co-immunoprecipitations in Figure 4.5 lacked both EGTA, 
which chelates calcium ions, and β-glycerophosphate, a phosphatase inhibitor.  
In preliminary experiments, addition of EGTA to the lysis buffer had no effect on 
the Rad-CaVβ2a association; however, phosphatase inhibition using β-
glycerophosphate appears to reduce Rad association with CaVβ2a (Figure 4.6), 
further suggesting that Rad phosphorylation may reduce its association with the 
calcium channel complex either directly or through displacement by 14-3-3 
binding. 
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To probe for a role of PKA in modulating the interaction between Rad and 
CaVβ2a, HEK293 cells were pre-treated with H-89 to block PKA activity prior to 
and during transfection with HA-tagged Rad WT and Flag-tagged CaVβ2a or 
empty vector. In the setting of PKA inhibition, which decreases Rad 
phosphorylation, Rad association with CaVβ2a is enhanced (Figure 4.7).  Taken 
together, the three different co-immunoprecipitation based experiments shown 
here suggest that Rad phosphorylation at Ser39 may be inversely related to its 
relative association with CaVβ2a and that further studies are warranted to confirm 
this notion. 
Rad phosphorylation at Ser39 promotes 14-3-3 association 
The impact of Rad phosphorylation at Ser39 on 14-3-3 association was also 
probed by co-immunoprecipitation.  First, HEK293 cells were transfected with 
HA-tagged Rad WT, S39A, S39D, or empty vector as a control along with GST-
tagged 14-3-3.  Cell lysates were subjected to immunoprecipitation with anti-HA 
antibody, and co-immunoprecipitated GST-14-3-3 was detected by Western 
blotting.  Mutation of Ser39 to alanine a in a reduction in Rad association with 14-
3-3 as has been reported [16], while the S39D mutant associated with 14-3-3 
more strongly than WT (Figure 4.8). Similarly, stimulation of the cells with 
forskolin prior to harvest and immunoprecipitation resulted in an increase in Rad 
WT association with 14-3-3 but had no effect on S39A or S39D association with 
14-3-3 (Figure 4.8), representing the first report of RGK association with 14-3-3 
in response to a stimulus. These results suggest that Rad Ser39 phosphorylation 
	   102 
promotes 14-3-3 association.  Coupled with the observation that phosphorylated 
Rad seems to have a reduced interaction with CaVβ2a (Figures 4.5, 4.6, and 
4.7) suggests a potential mechanism in which 14-3-3 binding may displace 
phosphorylated Rad from the calcium channel complex. 
Enigma overexpression promotes Rad Ser39 phosphorylation  
Given the established association between Rad and Enigma (see Chapter 3) and 
a literature indicating that Enigma and related proteins bind to a variety of 
kinases through their C-terminal LIM domains [172, 176-179], I next asked 
whether Enigma might modulate Rad phosphorylation. Interestingly, 
overexpression of Enigma alone was sufficient to increase Rad Ser39 
phosphorylation without any additional stimulus (Figure 4.9). In fact, Enigma 
overexpression resulted in Rad Ser39 phosphorylation nearly as robust as that 
observed following stimulation with isoproterenol, a β-adrenergic receptor agonist 
(Figure 4.9).  
Enigma associates with CaV1.2  
The Enigma subfamily proteins Enigma homolog protein (ENH) and Cypher have 
been reported to bind to and regulate voltage-dependent calcium channels [176-
179], but the potential interaction between Enigma and CaV1.2 has not been 
previously examined. HEK293 cells were transfected with an HA-tagged CaV1.2 
C-terminal construct comprising amino acids 1507-2171 along with Flag-tagged 
EV or Enigma.  Co-immunoprecipitation analysis revealed a novel interaction 
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between Enigma and the CaV1.2 C-terminus (Figure 4.10A).  Further 
investigation of the Enigma-CaV1.2 association by co-immunoprecipitation 
narrowed down the region of CaV1.2 required for Enigma binding to amino acids 
1507-1906 and suggested that the PDZ domain of Enigma is not required for the 
interaction with CaV1.2 (Figure 4.10B). Thus, Enigma, like ENH and Cypher, 
associates with the calcium channel CaVα1 subunit, and we hypothesized that 
Enigma may therefore contribute to the regulation of Rad-mediated VDCC 
control.  
Enigma overexpression does not alleviate Rad-mediated calcium channel 
inhibition 
Since Rem phosphorylation at Ser18 was reported to reverse its calcium channel 
inhibitory activity [64], Enigma overexpression was used as a means of 
enhancing Rad Ser39 phosphorylation (Figure 4.9) to ask whether Rad-
mediated calcium current blockade may be altered by increased Rad Ser39 
phosphorylation. To this end, HEK293 cells were transfected with GFP-tagged 
CaV1.2 (calcium channel α subunit), a dual expression vector for RFP and 
CaVβ2a (allowing transfected cells to be readily identified), and either HA- and 
Flag-tagged empty vectors as a control to establish basal calcium current, HA-
tagged wildtype Rad and empty vector to reproduce published work that Rad 
overexpression blocks calcium current [12], or HA-Rad WT and Flag-Enigma to 
ask whether Enigma overexpression and increased Rad Ser39 phosphorylation 
would alter Rad-dependent current block.  While Rad overexpression resulted in 
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a complete block of calcium current, co-overexpression of Enigma failed to 
reverse channel inhibition (Figure 4.11) despite the observed increase in Rad 
Ser39 phosphorylation.  Thus, further studies of the role of Enigma in the 
regulation of Rad-mediated VDCC control, as well as more direct analysis of the 
impact of Rad phosphorylation on VDCC regulation, are needed.  
Discussion 
In addition to their regulation through expression levels, RGK subfamily proteins 
have long been known to be subject to complex phosphorylation [49], and more 
recently Rem Ser18 phosphorylation was shown to regulate Rem-dependent 
calcium current blockade in vitro [64].  The idea that phosphorylation of RGK 
proteins could provide an acute increase in calcium current in response to an 
upstream stimulus is intriguing. Given the linkage between Rad and β-adrenergic 
signaling in the literature [86, 104, 131] and the absence of a mechanism to 
explain the acute rise in calcium current following β-adrenergic receptor 
stimulation [199-201], the studies in this chapter aimed to explore the contribution 
of the β−adrenergic signaling cascade to Rad phosphorylation at Ser39 as well 
as the significance of Rad phosphorylation to protein-protein interactions and 
calcium current regulation. While many of the results are still preliminary, the 
data in this chapter suggest that β-adrenergic agonism results in Rad Ser39 
phosphorylation and that phosphorylation at this site promotes 14-3-3 binding 
while potentially weakening the association between Rad and the calcium 
channel CaVβ2a subunit.  We also find that Enigma overexpression promotes 
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Rad Ser39 phosphorylation but is not sufficient to alter Rad-mediated VDCC 
blockade; however, we do establish a novel interaction between Enigma and the 
CaV1.2 C-terminus that suggests that further study of the role of Enigma in the 
regulation of Rad and VDCCs is warranted. 
While Rem is subject to phosphorylation downstream of α-adrenergic signaling 
and PKD1 activation [64], Rad phosphorylation is more robust following 
stimulation of the β-adrenergic receptor, likely via PKA-dependent signaling, as 
shown in Figures 4.1-4.3.  This specificity of signaling is not surprising, as there 
is an overall lack of sequence conservation in the N-terminal regions of RGK 
subfamily GTPases where these serine residues are found that suggests 
differential kinase control. For instance, the PKD1 consensus motif (L-X-R-X-X-
S*) [202] is present in the sequence preceding Rem Ser18 but is not found 
upstream of Rad Ser39, as the important -5 position leucine is instead located at 
the -4 position in the Rad sequence (Figure 4.12). Notably, this idea of 
differential regulation of RGK subfamily proteins may extend to Gem and Rem2 
as well, as the degree of conservation in the sequences surrounding the N-
terminal 14-3-3 binding sites of these two RGKs are even more divergent than 
Rem and Rad (Figure 4.12). 
A series of co-immunoprecipitation experiments in Figures 4.5-4.8 suggested 
that Rad Ser39 phosphorylation may disrupt the interaction between Rad and 
CaVβ2a while enhancing the interaction between Rad and 14-3-3.  The model 
that logically extends from these data is that upon phosphorylation, 14-3-3 
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binding displaces Rad from CaVβ2a and the calcium channel complex (Figure 
4.13).  Consistent with such a model, 14-3-3 binding has been reported to 
modulate the subcellular distribution of RGK proteins [16, 109, 113]. This notion 
is complicated, however, by the many functions of the C-terminus of RGK 
proteins.  14-3-3 dimers bind to N- and C-terminal phospho-serine residues in 
RGK proteins (Ser39 and Ser301 in Rad), and 14-3-3 binding to the phospho-
Ser301 residue impedes importin binding and nuclear trafficking [116, 117].  14-
3-3 binding also interferes with PIP lipid binding and likely with plasma 
membrane targeting of RGKs as a result [106].  Hence, it is difficult to distinguish 
whether 14-3-3 binding might have a direct or indirect role.   
In contrast to our proposed model, Jhun and colleagues suggested a different 
mechanism after demonstrating that Rem Ser18 phosphorylation reversed VDCC 
blockade.  Jhun et al. instead proposed that overexpressed Rem binds to and 
sequesters VDCCs in the endoplasmic reticulum, with phosphorylation of Rem at 
Ser18 releasing VDCCs to traffic appropriately to the plasma membrane, thereby 
increasing calcium current [64]. This model set forth by Jhun et al., although 
untested, is reminiscent of reports in which RGK proteins inhibit calcium current 
by binding to and sequestering CaVβ subunits away from the CaVα1 pore-forming 
subunit to interfere with trafficking of the channel complex to the plasma 
membrane [14, 16, 64, 90, 109].  In contrast to these reports, studies in our 
laboratory and others suggest that RGK proteins can act as inhibitors of calcium 
channels resident at the plasma membrane [12, 13, 15, 103, 106, 110, 111]. We 
have also shown that RGK proteins lacking the C-terminal region that directs 
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membrane association fail to block calcium current and that addition of a 
membrane-targeting sequence to truncated RGK proteins restores VDCC current 
inhibition [110].  Furthermore, the affinity of CaVβ subunits for CaV1.2 far exceeds 
that for RGK proteins [15], and the RGK and CaV1.2 binding sites on CaVβ are 
distinct [15].  Indeed, we have demonstrated that CaVβ2a can simultaneously 
associate with both CaV1.2 and RGK proteins [15].  Coalesced, these data 
oppose the idea that Rad blocks calcium current through sequestration of CaVβ 
and dysregulation of VDCC trafficking.   
To test the model we propose in Figure 4.13 and ask whether 14-3-3 binding is 
necessary for the decrease in association with CaVβ2a following phosphorylation 
of Rad, the co-immunoprecipitation experiments in this chapter could be 
repeated using the Rad S301A mutant that is null for 14-3-3 binding.  In 
particular, a dual Rad S39D/S301A mutant could be probed for CaVβ2a 
association, with the expectation that the phosphomimetic mutation at Ser39 
would no longer result in dissociation of Rad from CaVβ2a when combined with 
the S301A mutation if 14-3-3 binding is necessary to displace Rad from the 
calcium channel.  Alternatively, this mutant would be indistinguishable from the 
Rad S39D single point mutant if, instead, Rad Ser39 phosphorylation disrupts 
association with CaVβ2a through a conformational change in Rad protein without 
the necessity of 14-3-3 binding. 
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The data in the previous chapter identified a novel interaction between Rad and 
Enigma that may modulate Rad ubiquitination and turnover, and in the present 
chapter the interaction with Enigma is also shown to enhance Rad 
phosphorylation (Figure 4.9).  Enigma and the related proteins ENH and Cypher 
bind to a variety of kinases including PKA, PKC, and PKD1 [172, 176-179]; 
hence, it follows that Enigma could serve as a scaffold for kinase recruitment to 
promote Rad phosphorylation.  Alternatively, we cannot exclude a model in which 
Enigma overexpression may result in more Rad phosphorylation at Ser39 
through binding to and protecting this phosphorylated residue from phosphatase 
activity.  This alternative model could be tested by asking whether Rad S39A 
associates with Enigma as well as wildtype Rad, with the expectation that this 
phosphorylation-deficient mutant would exhibit weaker association with Enigma if 
Enigma promotes Rad phosphorylation through protection of the phospho-serine 
residue.  A second means of testing this alternative model could utilize 
phosphatase treatment to determine whether Enigma overexpression is indeed 
protective of Rad Ser39 phosphorylation. Finally, identification of the subdomain 
of Enigma required for interaction with Rad, as was proposed in Chapter 3, would 
allow us to determine whether the Rad-Enigma association is necessary for the 
increase in Rad phosphorylation that is observed.  We could also then 
overexpress the minimal Rad binding region of Enigma to differentiate between 
the two models described above.  Namely, if Enigma acts as a scaffold for Rad 
and its kinase, overexpression of the minimal Rad binding domain of Enigma 
should abolish the increase in phosphorylation observed with Enigma 
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overexpression.  Conversely, if Enigma increases Rad phosphorylation via 
protection of this phospho-serine residue from phosphatase activity, then the 
minimal binding domain should still be effective in increasing Rad 
phosphorylation. 
A novel interaction between Enigma and CaV1.2 is reported in Figure 4.10.  The 
related PDZ/LIM proteins ENH1 and Cypher have been reported to bind to 
calcium channel CaVα1 subunits, although there has been debate as to which 
domain of these proteins is required for calcium channel association, and the 
region of the CaVα1 subunit that associates with these proteins has never been 
analyzed [176-179].  Here, Enigma is demonstrated to associate with the C-
terminal region of CaV1.2, specifically the region between amino acids 1507-
1906, in a PDZ-independent fashion.  The association between Enigma and the 
calcium channel suggested that Enigma likely has a regulatory role in the 
function of Rad in VDCC control. 
Having observed that Enigma overexpression promotes Rad Ser39 
phosphorylation, Enigma overexpression was used as a “stimulus” to probe for 
the role of Rad phosphorylation on its ability to block calcium current.  Unlike 
Rem Ser18 phosphorylation [64], inducing Rad Ser39 phosphorylation through 
Enigma overexpression had no effect on calcium current (Figure 4.11).  On one 
level, these data suggest that Rad phosphorylation may not regulate its calcium 
channel inhibitory activity; however, there are caveats to such a conclusion. First, 
the electrophysiology experiment described here required transfection of four 
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plasmids: GFP-CaV1.2, RFP/CaVβ2a, EV or Rad, and EV or Enigma.  Since each 
recording represents an individual cell, this analysis assumed that each cell 
expressed all four plasmids.  While selecting for GFP+/RFP+ cells ensured that 
every cell that was recorded should have contained a functional calcium channel 
complex, it cannot be known for certain that every cell expressed both Enigma 
and Rad, potentially confounding the results.  To ask more directly whether Rad 
Ser39 phosphorylation modulates its calcium channel inhibition, further 
electrophysiology experiments should probe whether Rad S39D/E mutants are 
as effective as Rad WT at inhibiting calcium current.  Similarly, stimulation with 
isoproterenol or forskolin or transfection of constitutively active PKA could 
provide additional means of testing this hypothesis.  Second, it is possible that 
phosphorylation of Rad at a different residue, or at multiple residues, may afford 
regulation of calcium current. Rad is subject to complex phosphorylation at a 
number of sites including threonine-2 (Thr2), Ser26, Thr27, Ser39, Thr52, Ser79, 
Ser105, Ser214, Ser257, Ser273, Ser290, Ser299, and Ser301 [49, 203-209]; 
thus, interrogation of the role of phosphorylation of one residue in the regulation 
of Rad is likely a gross over-simplification of the potential for kinase regulation in 
vivo.  While use of the RadpSer39 antibody suggested that β-adrenergic 
stimulation and Enigma overexpression promote Rad phosphorylation at Ser39, it 
is unclear whether these conditions alter phosphorylation of additional sites in the 
Rad protein.  Moreover, Ser39 was chosen for analysis as the N-terminal 14-3-3 
binding site within Rad and thus as the analogous residue to Rem Ser18 
reported in the study by Jhun et al [64].  However, Jhun and colleagues only 
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speculated but did not establish that 14-3-3 binding was important for the 
modulation of Rem-mediated channel block following Ser18 phosphorylation [64].  
While Rad Ser39 is analogous to Rem Ser18 with respect to 14-3-3 binding, an 
alignment of the amino acid sequences of Rem and Rad indicates that Rad 
Ser26 corresponds more directly to Rem Ser18.  An alternative hypothesis, then, 
is that while β-adrenergic stimulation may regulate Rad Ser39 phosphorylation 
and 14-3-3 binding, Rad phosphorylation at Ser26 could afford regulation of 
calcium channel blockade in a manner similar to Rem Ser18 phosphorylation and 
in a manner that does not require 14-3-3 binding.  In this case, the stimuli 
responsible for regulating Rad phosphorylation at Ser26, and potentially at other 
residues, would require further investigation. Electrophysiology experiments 
probing the ability of additional phosphomimetic Rad mutants to inhibit calcium 
current may provide further insight as well. Finally, the potent calcium channel 
blockade established upon Rad overexpression also makes this experiment 
difficult to interpret.  It is plausible that even in a setting in which phosphorylated 
Rad is displaced from the calcium channel and no longer an effective inhibitor of 
current, the degree of Rad overexpression is sufficient that another Rad protein 
quickly takes its place and blocks calcium current.   
In summary, the studies in this chapter provide preliminary evidence that β-
adrenergic signaling may regulate Rad Ser39 phosphorylation and that this 
phosphorylation event may modulate Rad interactions with CaVβ2a and 14-3-3.  
The experiments in this chapter should be repeated more rigorously to confirm 
these conclusions.  The functional significance of Rad phosphorylation at Ser39 
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and other residues and the role of Rad in β-adrenergic signaling remain unclear 
and require further study.  Data from our laboratory suggest that deletion of Rad 
in cardiac myocytes results in a phenotype that mirrors β-adrenergic agonism of 
the calcium channel in the absence of stimulus [104, 131].  Rad deletion also 
renders cardiac myocytes nearly insensitive to further β-adrenergic stimulation of 
the calcium channel [104], suggesting that Rad plays a functional role in this 
pathway.  Although CaV1.2 and CaVβ2a are phosphorylated downstream of β-
adrenergic activation, calcium channel phosphorylation appears to be 
dispensable for the increase in calcium current that is triggered through this 
pathway [199-201]; hence the potential role of Rad phosphorylation, re-
localization, or turnover in response to β-adrenergic signaling remains a possible 
hypothesis for the increase in calcium current downstream of β-adrenergic 
signaling.  
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Figure 4.1: Rad phospho-Ser39 antibody validation 
HEK293 cells were transfected with HA-tagged empty vector (EV) or Rad WT, 
S26A, S39A, S272A, or S301A mutants in order to validate the specificity of the 
rabbit antibody raised against Rad phospho-serine 39 in collaboration with 21st 
Century Bio.  Cells were also transfected with the β2 adrenergic receptor (β2AR) 
and stimulated with isoproterenol (ISO, 100 ng/mL) as an agonist to promote Rad 
phosphorylation.  In the last three lanes, HEK293 cells were transfected with HA-
tagged Rem, Rem2L (long isoform), and Gem in order to validate that the 
antibody does not cross-react with other RGK subfamily proteins. 
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Figure 4.2: Forskolin treatment increases Rad Ser39 phosphorylation in 
HEK293 cells 
HEK293 cells transfected with HA-tagged Rad were starved prior to stimulation 
with 1 µM phorbol 12-myristate 13-acetate (PMA) to activate PKC in the α-AR 
pathway or 1 µM forskolin to activate PKA in the β-AR pathway.  Unlike Rem, 
Rad is phosphorylated downstream of PKA, not PKC. Results are representative 
of three independent experiments.  * p<0.05 relative to unstimulated by Student’s 
t test. 
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Figure 4.3: β-adrenergic stimulation of fetal ventricular cardiomyocytes 
induces Rad Ser39 phosphorylation 
Ventricular cardiomyocytes were isolated from fetal wildtype mice at embryonic 
day 18 and stimulated with vehicle, isoproterenol (100 ng/mL), or forskolin (1 µM) 
for the indicated amounts of time. Western blotting analysis suggests that 
treatment with either of these activators of the β-adrenergic signaling cascades 
may result in an increase in Rad Ser39 phosphorylation.  
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Figure 4.4: Rad Ser39 phosphorylation is elevated in human heart samples 
from patients with a history of hypertension 
Human heart samples were homogenized, and Rad phosphorylation levels were 
assessed by Western blotting and normalized to total Rad levels.  Samples from 
patients with a history of hypertension (HTN) exhibited significantly higher levels 
of Rad Ser39 phosphorylation/total Rad relative to non-hypertensive (non-HTN) 
controls.  ** p<0.01 relative to non-HTN by Student’s t test. 
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Figure 4.5: Phosphomimetic mutation of Rad at Ser39 decreases its 
association with CaVβ2a 
HEK293 cells were transfected with Flag-tagged CaVβ2a along with HA-tagged 
Rad WT, S39A, or S39D. Co-immunoprecipitation analysis suggests that the 
phosphomimetic S39D mutation results in weaker association with CaVβ2a. 
Results are representative of three independent experiments, * p<0.05 compared 
to Rad WT by Student’s t test.  
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Figure 4.6: Phosphatase inhibition may decrease the interaction between 
Rad and CaVβ2a 
HEK293 cells were transfected with Flag-tagged CaVβ2a along with HA-tagged 
Rad WT.  Co-immunoprecipitation was performed with standard IP buffer or with 
the addition of 50 mM β-glycerophosphate to inhibit phosphatases or 2 mM 
EGTA to chelate calcium.  Addition of β-glycerophosphate appears to result in 
loss of association between Rad and CaVβ2a.  
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Figure 4.7: Inhibition of PKA may enhance Rad interaction with CaVβ2a 
HEK293 cells were transfected with HA-tagged Rad and Flag-tagged EV (lane 1) 
or CaVβ2a (lanes 2-5) and subjected to immunoprecipitation with an anti-Flag 
antibody.  Pre-treatment with the PKA inhibitor H-89 appears to result in an 
increase in the association between Rad and CaVβ2a. Results of two 
independent experiments are shown here. 
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Figure 4.8: Rad phosphorylation at Ser39 promotes 14-3-3 association  
HEK293 cells were transfected with GST-tagged 14-3-3 and HA-tagged empty 
vector (EV) or HA-tagged Rad WT, S39A, or S39D.  Cells were starved in serum-
free media and treated with 1 µM forskolin or vehicle prior to harvest.  Co-
immunoprecipitation analysis suggests that forskolin stimulation to induce 
phosphorylation of Rad WT at Ser39 or phosphomimetic mutation of Ser39 to 
aspartic acid strengthens the association between Rad and 14-3-3. Results are 
representative of three independent experiments. 
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Figure 4.9: Enigma overexpression increases Rad Ser39 phosphorylation 
HEK293 cells were transfected with HA-tagged Rad WT and Flag-tagged empty 
vector or Enigma.  48 hours after transfection, cells were serum-starved and 
treated with 100 ng/mL isoproterenol or vehicle for 15 minutes. Western blotting 
analysis indicates that Enigma overexpression is sufficient to increase Rad Ser39 
phosphorylation without an additional stimulus. Results are representative of 
three independent experiments. 
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Figure 4.10: Enigma associates with the C-terminus of CaV1.2  
Panel A) HEK293 cells were transfected with HA-tagged CaV1.2 C-terminus 
(amino acids 1507-2171) and either Flag-tagged Enigma WT, ΔPDZ, ΔLIM1-3, or 
empty vector.  Immunoprecipitation with anti-Flag antibody and Western blotting 
with biotinylated anti-HA antibody indicate that the CaV1.2 C-terminus forms a 
complex with Enigma that does not require the PDZ domain.  
Panel B) HEK293 cells were transfected with HA-tagged CaV1.2 C-terminus 
constructs (amino acids 1507-2171, 1507-1906, or 1906-2171) and Flag-tagged 
Enigma or empty vector and subjected to immunoprecipitation with anti-Flag 
antibody.  Western blotting with biotinylated anti-HA antibody indicates that the 
interaction between the CaV1.2 C-terminus and Enigma requires amino acids 
1507-1906.  Results are representative of three independent experiments. 
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Figure 4.11: Enigma overexpression does not alleviate Rad-mediated 
calcium channel blockade 
HEK293 cells were transfected with full-length rabbit GFP-tagged CaV1.2, a dual 
expression vector containing RFP and CaVβ2a, HA-tagged empty vector or Rad 
WT, and Flag-tagged empty vector or Enigma.  Cells expressing the calcium 
channel complex alone had detectable inward calcium current that was 
completely blocked by Rad overexpression.  Overexpression of Enigma with Rad 
did not rescue calcium channel blockade. N=3-8 cells per group. 
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Figure 4.12: Alignment of N-terminal 14-3-3 binding sites across the RGK 
subfamily 
The lack of conservation in the amino acid sequences surrounding the N-terminal 
14-3-3 binding sites across the RGK subfamily suggests that distinct upstream 
stimuli and kinases may mediate phosphorylation of the different GTPases in the 
family. 
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Figure 4.13: Proposed model in which phosphorylated Rad is displaced 
from the calcium channel complex via 14-3-3 binding 
Panel A) In its non-phosphorylated state, Rad binds to the C-terminus of CaV1.2 
and to the accessory CaVβ subunit of calcium channels resident at the plasma 
membrane and blocks calcium current. 
Panel B) Upon phosphorylation at Ser39 (and Ser301, the other 14-3-3 binding 
site), 14-3-3 dimers bind to phosphorylated Rad, potentially displacing it from the 
calcium channel complex.  Further studies are needed to determine whether Rad 
Ser39 phosphorylation can reverse calcium channel blockade. 
 
 
 
Copyright © Catherine N. K. Withers 2017 
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Chapter 5 
 
Rad GTPase is essential for the regulation of bone density and bone 
marrow adiposity in mice 
 
Introduction 
While frequently studied in the context of calcium channel modulation in excitable 
cells, the recent surge in reports of Rad expression changes in non-excitable cell 
types suggests that our analysis of the physiological functions of Rad should be 
expanded.  Specifically, RGK (Rad, Rem, Rem2, and Gem/Kir) subfamily 
proteins have recently been implicated in the regulation of cell differentiation [42-
45].  Rem2, an RGK family protein that is primarily expressed in the nervous 
system, is highly expressed in embryonic stem cells and plays a key role in 
ectoderm differentiation and neuronal development [42, 43].  Similarly, gene co-
regulation mapping studies have suggested a likely role for Rad in embryonic 
stem cell differentiation [45]. Importantly for the work in this chapter, Satija and 
colleagues reported that lithium treatment of human mesenchymal stem cells 
(MSCs) to enhance osteogenic differentiation elicited a robust increase in Rad 
expression [44]. Notably, siRNA-mediated Rad silencing reversed the osteogenic 
priming effect of lithium [44]; hence, Rad may play a role in the regulation of 
osteogenesis that requires further investigation. 
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Although it is often erroneously thought of as a static support structure, the 
skeleton is a living, highly dynamic tissue with a number of important functions in 
the body [141].  Best known for its roles in supporting the weight of the body and 
in facilitating movement, the skeleton also provides protection for vital organs 
including the brain, bone marrow, and spinal cord.  Moreover, the bone marrow is 
the site of blood cell production and is also the site for storage of a fat depot 
known as bone marrow adipose tissue (BMAT) [210]. Finally, the skeleton plays 
a crucial role in overall mineral homeostasis in the body, acting as a storage 
reservoir for calcium and phosphate. Remodeling of the bone tissue allows 
mobilization of these minerals as needed by the body [141]. Calcium 
homeostasis is critical to overall health, as the body uses calcium for muscle and 
heart contraction, neurotransmission, hormone secretion, and blood clotting 
[100].  
Osteoporosis is a disease of low bone mass and deterioration of bone tissue 
leading to structural fragility and increased risk of fractures [211].  According to 
the National Osteoporosis Foundation, 54 million adults age 50 and over in the 
United States are affected by osteoporosis and low bone mass, amounting to 
over half of the total US adult population in that age category [211].  Interestingly, 
many conditions that can induce bone loss, such as estrogen insufficiency, 
anorexia, disuse, and hind limb unloading, are accompanied by increased bone 
marrow adipose tissue (BMAT) [212, 213]. In patients with osteoporosis, bone 
marrow adiposity is significantly increased, and bone formation rates are 
inversely related to BMAT levels [214, 215].  BMAT has gained recent interest as 
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a distinct fat depot that appears to have roles regulating bone homeostasis, 
hematopoiesis, and metabolism, and it is well established that adipokines and 
free fatty acids released by adipocytes can modulate bone remodeling and 
hematopoiesis [210].  BMAT constitutes 70% of the adult bone marrow volume 
on average and represents about 10% of total body adipose in humans [216], yet 
its origin and physiological functions remain to be fully characterized. 	  
Mesenchymal stem cells (MSCs) present in the bone marrow are the precursors 
for osteoblasts, chondrocytes, and white and brown adipocytes [146]. One 
mechanism that has been proposed to explain the often-inverse relationship 
between bone density and bone marrow adiposity is a shift in mesenchymal 
progenitors toward more adipogenic differentiation at the expense of osteoblast 
formation, but much remains to be determined [217].  The transcriptional 
programs that drive MSCs to adopt these two cell fates are well characterized, 
with CCAAT-enhancer binding protein- α (C/EBP-α) and peroxisome proliferator-
activated receptor γ2 (PPARγ2) initiating expression of genes associated with 
mature adipocytes [218], and Runt-related transcription factor 2 (Runx2) and the 
downstream osteoblast-specific transcription factor osterix/Sp7 required for 
osteogenic differentiation [151, 219].  However, there is some debate as to 
whether bone marrow adipocytes are derived from the same precursors as 
gonadal and intramuscular adipose.  Unexpectedly, and in contrast to white and 
brown adipocytes, bone marrow adipocytes were recently found to express 
osterix/Sp7 [220], suggesting that MSCs directed toward an osteogenic fate may 
be re-allocated toward an adipogenic one. Similarly, lineage tracing studies 
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performed in mT/mG mice expressing a floxed, membrane-targeted tdTomato 
cassette (mT) upstream of an eGFP cassette (mG), which allows excision of mT 
and expression of membrane-targeted green fluorescent protein (GFP) when 
Cre-recombinase is expressed, demonstrated that bone marrow adipocytes 
traced in Osterix-cre:mT/mG mice [221].  Hence, while more studies are 
necessary, bone marrow adipocytes are unique in their expression of the 
osteoblast-specific transcription factor Osterix and thus may not follow the 
traditional adipogenic differentiation pathway.  
In addition to the report of increased Rad expression during the osteogenic 
differentiation of MSCs [44], the interaction between Rad and Enigma that was 
demonstrated in Chapter 3 also points to a potential role for Rad in osteogenesis.  
Enigma is also referred to as LIM mineralization protein (LMP) in the bone 
literature [222] and has an established function in bone mineralization as its 
name suggests. Multiple studies have demonstrated that Enigma/LMP 
overexpression induces mineralization of calvarial cells in vitro and bone 
formation in vivo [223-229].  Similarly, loss of Enigma/LMP expression prevents 
in vitro osteoblast differentiation [223] and periodontal ligament cell 
mineralization [230], and LMP-/- mice have lower bone density compared to WT 
[160].  The osteoinductive effects of Enigma/LMP are thought to involve both the 
regulation of bone morphogenetic protein (BMP) expression [231-233] as well as 
regulation of BMP responsiveness through modulation of Smad ubiquitin 
regulatory factor 1 (Smurf1) E3 ubiquitin ligase activity [184, 188].   
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Given the importance of the balance between osteogenesis and adipogenesis in 
human disease, coupled with the report of Rad up regulation during osteogenic 
priming of MSCs [44] and our observation of a novel interaction between Rad 
and Enigma/LMP (see Chapter 3), the goal of the work in this chapter is to 
characterize the effects of Rad deletion on bone homeostasis and bone marrow 
adiposity in vivo and on osteoblast function in vitro using global Rad-knockout 
(Rad-/-) mice.  I will test the hypothesis that genetic deletion of Rad results in low 
bone mass through a decrease in bone formation by osteoblasts and ultimately 
postulate that Rad might be one of the elusive upstream regulators of the switch 
between osteogenesis and adipogenesis. 
Results 
Rad-/- mice are small and weigh less than WT 
Because of a routine observation during maintenance of the Rad-/- mouse line 
that these mice tended to appear smaller in size than WT counterparts, the 
weights and lengths of these mice were quantified.   At four months of age, both 
male and female Rad-/- mice weighed significantly less than WT (Table 5.1).  The 
lengths of male mice were measured at four months of age, and Rad-/- mice were 
shorter in length than WT (Table 5.1).  Lengths and weights were also quantified 
at neonatal day one, and again Rad-/- mice weighed significantly less and were 
shorter than WT (Table 5.1). 
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No gross skeletal abnormalities in the absence of Rad 
To assess skeletal development at a gross level, skeletons were isolated from 
one-day-old WT and Rad-/- neonates and sequentially stained with Alcian blue 
and Alizarin Red S, which mark cartilage in blue and bone in reddish-purple, 
respectively.  This analysis indicated no gross abnormalities in Rad-/- skeletal 
development (Figure 5.1). 
Lower trabecular and cortical bone density in Rad-/- mouse femora 
To explore the impact of Rad deletion on bone density, WT and Rad-/- femora 
from both male and female mice were analyzed by microcomputed tomography 
(µCT) in collaboration with the µCT Core Laboratory at Rush University. Rad-/- 
femora from female mice exhibited a significantly lower trabecular bone volume 
fraction and trabecular number, with a parallel increase in trabecular spacing 
relative to WT controls (Figure 5.2 and Table 5.2).  A similar trend was observed 
in male Rad-/- femora (Figure 5.2). Trabecular thickness was not significantly 
different from WT.  Rad-/- femora also exhibited a significantly lower cortical bone 
area and thickness than WT, whereas the medullary area was significantly higher 
when compared to WT controls (Figure 5.2 and Table 5.2). Taken together, 
these data suggest that Rad GTPase contributes to the maintenance of normal 
bone density.  
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Rad-/- femora have altered mechanical properties  
To determine whether the decrease in bone density in Rad-/- femora changed the 
mechanical properties of these bones, four-point bending analysis was 
performed by our collaborators at Indiana University School of Medicine.  Rad-/- 
femora displayed a significant mechanical phenotype, including a significantly 
lower cortical bone ultimate force, stiffness, work to yield, ultimate stress, and 
elastic modulus compared to femora from WT controls (Figure 5.3 and Table 
5.3). Total displacement, toughness, and total strain were all significantly higher 
in the absence of Rad (Table 5.3). These data indicate that Rad loss results in a 
unique mechanical phenotype characterized by weaker and more elastic bones, 
which is consistent with the lower bone density evident from µCT analysis. 
Rad deletion enhances osteoclast differentiation in vitro 
A decrease in bone density and strength could occur via an increase in bone 
resorption by osteoclasts, a decrease in bone formation by osteoblasts, or a 
combination of the two.  To determine the impact of Rad deletion on osteoclast 
differentiation, mononuclear cells were isolated from the spleens of WT and   
Rad-/- mice and treated with M-CSF and RANKL to stimulate their differentiation 
toward multinucleated osteoclasts. Staining for tartrate-resistant acid 
phosphatase (TRAP) and counting TRAP+ multinucleated cells (MNCs) indicated 
that loss of Rad significantly enhanced osteoclast differentiation in vitro (Figure 
5.4). 
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Osteoclast surface is not higher in Rad-/- femora in vivo 
To examine whether the lower bone density of Rad-/- femora resulted from an 
increase in osteoclast numbers in vivo, we performed TRAP staining at the distal 
femur of 4-month-old animals.  Osteoclast surface was unchanged in male Rad-/- 
animals, and a small but significant decrease in osteoclast surface was observed 
in the distal femora of female Rad-/- mice compared to WT (Figure 5.5).  These 
data suggest that, despite the increase in in vitro osteoclastogenesis that was 
observed in Figure 5.4, the low bone density phenotype of Rad-/- mice is not 
likely to arise solely from increased osteoclast numbers. 
Lower bone formation rate in Rad-/- femora 
The reduction in osteoclast surface in Rad-/- femora, coupled with the report of a 
role for Rad in osteogenic priming of MSCs [44], suggested that altered 
osteoblast function might also contribute to the lower bone density observed in 
Rad-/- mice.  To test this notion, dynamic histomorphometry was used to 
determine the rate of bone formation in WT and Rad-/- femora in vivo.  In 
trabecular bone at the distal femur, a significantly lower mineral apposition rate 
(MAR) but a higher percent mineralizing surface (MS/BS) was observed in Rad-/- 
femora compared to WT controls (Figure 5.6 and Table 5.4).  The latter 
observation may arise in part due to the significant decrease in total trabecular 
bone surface at the distal femora of Rad-/- mice compared to WT (Figure 5.6A).  
Normalization of MAR and MS/BS results in a downward trend in bone formation 
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rate (BFR/BS) in trabecular bone of Rad-/- animals compared to WT (Figure 5.6B 
and Table 5.4).  
These parameters were also measured in cortical bone. Consistent with the µCT 
data, histology indicated a significantly lower cortical bone area at the mid-
diaphysis of Rad-/- femora compared to WT (Table 5.4).  The mineralizing 
surface (MS/BS) and bone formation rate (BFR/BS) at the periosteal surface of 
Rad-/- femur diaphyses were significantly lower than in WT, and the periosteal 
mineral apposition rate (MAR) also trended downward in Rad-/- femora (Figure 
5.6B and Table 5.4).  These same measures at the endocortical surface of the 
femur diaphysis trended downward in Rad-/- animals but did not reach 
significance (Table 5.4).  Overall, these data suggest that a decrease in 
osteoblast function may contribute to the lower bone mass observed in Rad-/- 
mice. 
Rad-/- calvarial osteoblast function is blunted in vitro 
To characterize the contribution of Rad GTPase signaling to osteoblast 
differentiation and function in vitro, the phenotype of osteoblasts derived from 
neonatal WT and Rad-/- calvariae was examined.  Immunoblot analysis confirmed 
Rad expression in this cell population (Figure 5.7A).  Consistent with the in vivo 
decrease in bone formation, osteoblast differentiation was impaired in Rad-/- 
calvarial cells as shown by a reduction in alkaline phosphatase activity, an 
enzymatic marker of osteoblast maturation (Figure 5.7B), and a significant 
decrease in mineralization as indicated Alizarin Red S staining (Figure 5.7C) 
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following osteogenic induction. Together these data indicate that osteoblast 
development and/or function is diminished in the absence of Rad.   
Higher expression of matrix Gla protein in Rad-/- calvarial osteoblasts 
To examine the molecular mechanisms underlying the decrease in osteoblast 
function upon Rad loss, microarray analysis was performed to compare the gene 
expression profile of naïve calvarial osteoblasts from WT and Rad-/- mice. 
Surprisingly, Rad deficiency had no effect on the expression of the canonical 
osteoblast marker genes Runt-related transcription factor 2 (Runx2), osteocalcin 
(Bglap), or type I collagen (Col1a1) (Figure 5.8A).  Expression of the osteogenic 
transcription factor osterix (Sp7) and of alkaline phosphatase (Alpl) trended 
downwards but did not reach significance (Figure 5.8A). Instead, the profiling 
data indicated that matrix Gla protein (Mgp), a 15-kDa secreted protein that was 
initially isolated and identified from demineralized bovine bone and has since 
been found to inhibit bone mineralization [234-236], was markedly increased in 
Rad-/- calvarial osteoblasts compared to WT (+11.28-fold) (Figure 5.8A). This 
increase in matrix Gla protein (MGP) expression in Rad-/- osteoblasts was 
confirmed by RT-PCR (Figure 5.8B) and suggests a novel means by which Rad 
loss may result in a decrease in osteoblast activity and therefore overall bone 
density.   
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Rad-/- calvarial osteoblasts show a striking adipogenic phenotype 
During the course of culturing primary calvarial cells, a dramatic increase in the 
number of cells that appeared to have lipid droplets was observed in the Rad-/- 
osteoblast preparations after 10-14 days in culture when compared to WT 
osteoblasts.  This observation, coupled with published work indicating that MGP 
not only inhibits mineralization but that its secretion increases ~30-fold during the 
in vitro differentiation of human pre-adipocytes [237], suggested that lower 
osteogenesis following Rad deletion might be linked to increased adipogenic 
differentiation. To test this possibility, WT and Rad-/- calvarial osteoblast 
monolayers were stained with Oil Red O (ORO) on day 14 to confirm that these 
structures were lipid droplets. Consistent with a potential role for Rad in inhibiting 
adipogenesis, the number of ORO-positive cells was significantly higher in Rad-/- 
calvarial cultures compared to WT (Figure 5.9). 
Adipogenic induction of WT osteoblasts causes a decline in endogenous 
Rad levels 
Rad gene expression is increased following lithium stimulation of mesenchymal 
stem cells, which enhances osteogenic differentiation, and Rad silencing has 
been shown to attenuate osteogenic priming [44]. These data prompted 
examination of Rad expression in primary calvarial cells upon adipogenic 
differentiation.  Treatment of WT calvarial osteoblasts with adipogenic media for 
one week resulted in a dramatic loss of endogenous Rad protein (Figure 5.10).  
Together with the data from Satija and colleagues [44], this observation suggests 
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that dynamic control of Rad may play a role in directing differentiation toward the 
osteogenic versus adipogenic lineages.  In addition to Rad down regulation, 
adipogenic treatment of WT calvarial cells generated a phenotype that resembled 
that of Rad-/- osteoblasts without adipogenic induction. Specifically, treatment 
with adipogenic media for one week resulted in the accumulation of ORO+ lipid 
droplets in WT calvarial cultures, a reduction in alkaline phosphatase staining, 
and a significant rise in MGP gene expression (Figure 5.11). 
Increased bone marrow adiposity at the distal femora of Rad-/- mice 
The significant increase in adipogenesis observed in primary Rad-/- calvarial 
osteoblast cultures under normal growth conditions suggested that Rad 
deficiency might alter the in vivo balance of osteoblasts and adipocytes in the 
bone marrow compartment. Von Kossa/MacNeal’s tetrachrome staining of WT 
and Rad-/- distal femora was performed to evaluate the overall cell distribution 
and revealed a significant increase in BMAT at the Rad-/- distal femur compared 
to WT (Figure 5.12).  Rad deletion resulted in significantly higher adipocyte 
numbers as well as significantly larger adipocyte size compared to WT (Figure 
5.1).  Notably, reexamination of TRAP-stained distal femora (Figure 5.4) was 
consistent, with unstained round structures resembling adipocytes frequently 
observed in Rad-/- femora. 
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Total body fat percentage is unchanged in Rad-/- mice 
To determine whether Rad loss results in a global alteration in adipogenesis, 4-
month-old WT and Rad-/- mice were weighed and subjected to EchoMRI body 
composition analysis. These analyses showed that although Rad-/- mice weigh 
less than WT littermates (Table 5.1 and Figure 5.13), there is no significant 
change in body fat percentage upon Rad deletion (Figure 5.13); thus, the 
increase in adipogenesis in Rad-/- mice appears to be specific to BMAT. 
Rad associates with C/EBP proteins 
CCAAT-enhancer binding proteins (C/EBPs) play an important role in adipocyte 
differentiation, with induction of C/EBP-β and -δ observed early in adipogenesis 
and induction of C/EBP-α necessary for terminal adipocyte differentiation [238-
240].  Rad has been reported to bind to C/EBP-δ and to impede its DNA binding 
and its function as a transcription factor in heart tissue [41], and a similar 
regulatory mechanism in osteoblast progenitors could explain the increase in 
adipogenesis observed in the absence of Rad.  Co-immunoprecipitation studies 
in HEK293 cells corroborate the finding that Rad interacts with C/EBP-δ, and 
notably, we also observe co-immunoprecipitation of Rad and the C/EBP-α and 
β isoforms (Figure 5.14), suggesting that regulation of C/EBP activity is an area 
that should be pursued as a potential mechanism for the increased adipogenesis 
and decreased osteogenesis in Rad-/- bone marrow. 
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Discussion 
Bone is a dynamic tissue that undergoes continuous remodeling throughout life 
in response to changing demands on the skeleton and in order to maintain 
mineral homeostasis. Dysregulation of the bone remodeling process is one 
characteristic of age-related osteoporosis. In addition to low bone mass, 
osteoporosis is often characterized by an increase in bone marrow adiposity 
[214].  Osteoblasts and adipocytes share a common mesenchymal stem cell 
precursor [146], but the mechanisms by which these precursors are marked for 
an adipogenic versus an osteogenic cell fate have not been fully elucidated, and 
the literature also suggests potential differences in the origin of bone marrow 
adipocytes compared to white and brown adipocytes [216]. The data in this 
chapter represent the first analysis of the bone physiology of Rad-/- mice and 
demonstrate that Rad GTPase plays an important, previously uncharacterized 
role in the regulation of bone homeostasis in mice.  Deletion of Rad in mice 
results in low bone density owing in part to a lower rate of bone formation in vivo 
and lower osteoblast function in vitro. A concomitant increase in BMAT is also 
observed within Rad-/- femora without obvious expansion of peripheral adipose 
tissue, and adipocytes spontaneously arise in primary cultures from Rad-/- 
calvaria. The work in this chapter suggests that Rad may alter osteogenic versus 
adipogenic lineage commitment, potentially via regulation of matrix Gla protein 
expression.  Endogenous Rad levels are decreased following adipogenic 
treatment of calvarial cells, complementing the previously reported increase in 
Rad expression during osteogenesis.  These observations implicate Rad 
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GTPase as a regulatory protein whose levels can be dynamically modulated to 
control the shift between osteogenesis and adipogenesis, and as such, studies 
into the mechanism of Rad action and regulation may present potential targets 
for osteoporosis research. 
Following the report of a requirement for Rad function in lithium-mediated 
osteogenic priming of MSCs [44], we hypothesized that global Rad-/- mice would 
have lower bone density than WT controls, which was confirmed by µCT analysis 
in Figure 5.2 and Table 5.2.  Further evaluation of these bones to examine their 
mechanical properties in Figure 5.3 and Table 5.3 revealed that while Rad-/- 
femora have significantly lower strength and stiffness, which would typically 
render them more susceptible to fracture, they also have significantly longer 
displacement than femora from WT controls. Hence, Rad-/- femora are 
simultaneously weaker and more elastic, bending under smaller loads than WT 
but not overtly fracturing. Both collagen and water provide plasticity to bone, and 
the contribution of these variables to the Rad-/- mechanical phenotype could be 
explored in the future.   
 
Bone dynamics are controlled by the coordinated actions of osteoclasts and 
osteoblasts, and I sought to define the cell type(s) responsible for the lower bone 
density in Rad-/- mice. Despite the observation of an increase in osteoclast 
differentiation in Rad-/- cells in vitro in Figure 5.4, the in vivo result in Figure 5.5 
Indicates that osteoclast number is not increased in the absence of Rad in 4-
month-old animals.  This observation suggests that an increase in osteoclasts 
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may not be the primary source of the low bone mass seen in Rad-/- animals. 
Further studies should investigate the serum and/or urine levels of bone 
resorption markers such as carboxy-terminal collagen crosslinks (CTX-I) or 
deoxypyridinoline (DPD) to determine whether osteoclast activity is altered in 
these mice.  In addition, investigation of the bone density and osteoclast surface 
area of WT and Rad-/- femora from younger and older mice will also better inform 
the phenotype that we have observed. 
Analysis of osteoblast function in vivo and in vitro suggested that bone formation 
is impaired in Rad-/- mice.  The bone formation rate was significantly lower at the 
periosteal surface of cortical bone and trended downwards at the endocortical 
surface as well as in trabecular bone (Figure 5.6 and Table 5.4), indicating that 
Rad loss might result in decreased osteoblast differentiation and/or function.  In 
vitro calvarial osteoblast assays corroborated this notion, as our studies in 
Figure 5.7 indicated lower alkaline phosphatase activity and decreased 
mineralization in Rad-/- calvarial cells following osteogenic induction compared to 
WT.  Further studies will be important to determine whether the loss of Rad 
impacts osteoblast differentiation, function, or both.  Specifically, isolation of WT 
and Rad-/- MSCs for analysis of their differentiation potential toward the 
osteogenic and adipogenic lineages will be informative.   
Surprisingly, we did not see a change in the expression of canonical osteoblast 
marker genes in Rad-/- calvarial cells in Figure 5.8, as would be expected if 
osteoblast development were hindered in the absence of Rad.  In part this might 
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arise from our study design, using freshly isolated calvarial cells prior to 
osteogenic induction.  It will be important to determine whether Rad deletion 
hinders this gene expression program following osteogenic induction. Our 
microarray analysis did, however, reveal a robust increase in matrix Gla protein 
expression in Rad-/- calvarial cells compared to WT (Figure 5.8).  MGP up-
regulation may provide a novel mechanism for the decrease in osteogenesis as 
well as the increase in adipogenesis observed upon Rad deletion.  MGP has 
been shown to prevent mineralization in the osteoblast-like cell line MC3T3-E1 
[235, 236]. In keeping with its role as an inhibitor of mineralization, transgenic 
mice overexpressing MGP in osteoblasts have low bone density [241], and  
MGP-/- mice exhibit profound calcification of the aorta and other arteries, as well 
as inappropriate calcification of cartilaginous structures like the growth plate and 
the tracheal rings [242, 243].  Interestingly, not only does MGP inhibit 
mineralization, but its secretion is robustly increased during adipocyte 
differentiation, second only to the body fat regulatory hormone leptin [237], and 
we observed induction of MGP gene expression following adipogenic 
differentiation of WT cells in Figure 5.11.  Thus, the elevation in MGP gene 
expression in Rad-/- osteoblasts is likely important to the overall phenotype of 
increased adipogenesis at the expense of osteogenesis.   
While calvarial cells were isolated from WT and Rad-/- mice with the purpose of 
examining osteoblast differentiation and activity, the finding of spontaneous 
adipogenesis in the absence of Rad in Figure 5.9 was unexpected and exciting.  
Moreover, the observations that endogenous Rad expression decreases during 
	   143 
adipogenesis of WT calvarial cells in Figure 5.10 and that adipogenic induction 
of WT cells phenocopies Rad-/- cells in Figure 5.11 indicate that Rad may be a 
physiological regulator of the adipogenesis process.  Specifically, our finding that 
Rad levels decrease during adipogenesis complements the report by Satija and 
colleagues that Rad expression is increased during osteogenic priming [44].  The 
observation that Rad deletion increases bone marrow adiposity but not total body 
fat percentage in Figures 5.12 and 5.13 is equally intriguing, as recent studies 
have hinted at differences in the origins of BMAT and peripheral adipose depots 
[216]. The increase in BMAT, but not of peripheral fat, in Rad-/- animals suggests 
that Rad function may serve as a novel regulator of BMAT development and 
regulation.  This possibility is supported by a study showing that Rad protein 
levels in human skeletal muscle are correlated with measures of obesity and 
resting metabolic rate [129].  Taken together, these studies lead to the 
hypothesis that Rad levels may be dynamically regulated at the level of 
expression to modulate cell fate of MSCs or potentially even redirection of 
osteoprogenitors toward an adipogenic differentiation course. We hypothesize 
that higher Rad expression promotes osteogenesis and that lower Rad 
expression promotes adipogenesis, and more specifically, BMAT production.   
Finally, while preliminary, our finding of an interaction between Rad and C/EBP-
α, β, and δ in Figure 5.14 suggests a potential mechanism for the increase in 
adipogenesis observed in the absence of Rad.  C/EBPs are critical for adipocyte 
differentiation [239], and Rad binding to C/EBP-δ in cardiac myocytes has been 
shown to decrease its DNA binding and transcriptional activity [41]. Moreover, 
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preliminary studies suggest that C/EBP protein expression may be higher in  
Rad-/- calvarial cells than WT (data not shown), suggesting that Rad may regulate 
the stability of C/EBP proteins as well.  Future studies should probe for changes 
in C/EBP promoter occupancy or transcriptional activity in Rad-/- calvarial cells 
and following ectopic Rad expression.  A reasonable hypothesis that stems from 
these data is that Rad function may be required for osteogenic differentiation of 
MSCs during adult bone homeostasis via inhibition of C/EBP family proteins, with 
the lack of Rad function promoting adipogenesis through enhanced C/EBP-
dependent transcription.  
Unraveling the pathways that regulate the bifurcation between osteogenic and 
adipogenic differentiation is critical to understanding the disease progression of 
osteoporosis and identifying new therapies, as a shift in this balance favoring 
adipogenesis at the expense of osteogenesis may contribute to the increase in 
BMAT that accompanies low bone density in osteoporotic patients.  The data in 
this chapter suggest that Rad may represent a promising target in regulating this 
balance. 
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Table 5.1: Mouse weights and lengths  
 
Age Genotype Gender Weight (g) Length (cm) 
4 months Wildtype Male 35.9 +/- 0.4 18.4 +/- 0.1 
  Female 26.5 +/- 0.9  
 RadKO Male 32.1 +/- 0.7 *** 17.0 +/- 0.1 *** 
  Female 22.2 +/- 0.4 **  
1 day Wildtype  2.67 +/- 0.06 5.66 +/- 0.06 
 RadKO  2.16 +/- 0.11 *** 5.08 +/- 0.07 *** 
 
** p<0.01, *** p<0.001 compared to WT using Student’s t test 
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Table 5.2: Trabecular and cortical geometry of 4-month-old mouse femora 
from µCT analysis 
	  
Distal Femur Wildtype (N=5) RadKO (N=5) 
TV (mm3) 3.26 +/- 0.18 4.65 +/- 0.06 *** 
BV (mm3) 0.32 +/- 0.04 0.22 +/- 0.04 
BV/TV (%) 9.60 +/- 0.88 4.81 +/- 0.80 ** 
Conn.D 109.3 +/- 8.8 27.1 +/- 6.2 *** 
SMI 2.43 +/- 0.09 3.20 +/- 0.08 *** 
Tb.Th (mm) 0.045 +/- 0.002 0.047 +/- 0.002 
Tb.N (1/mm) 3.49 +/- 0.12 2.72 +/- 0.11 ** 
Tb.Sp (mm) 0.29 +/- 0.01 0.37 +/- 0.02 ** 
Ap.Dens 278.6 +/- 9.7 204.5 +/- 11.3 ** 
BS/BV 61.3 +/- 2.2 63.4 +/- 3.3 
DA 1.34 +/- 0.04 1.35 +/- 0.03 
Femoral Midshaft Wildtype (N=5) RadKO (N=5) 
Ct.Ar (mm2) 0.96 +/- 0.02 0.79 +/- 0.02 *** 
Tt.Ar (mm2) 1.45 +/- 0.01 1.81 +/- 0.03 *** 
Ma.Ar (mm2) 0.49 +/- 0.01 1.02 +/- 0.02 *** 
Ct.Th (mm) 0.26 +/- 0.01 0.18 +/- 0.01 *** 
Ct.Ar/Tt.Ar (%) 66.3 +/- 0.8 43.7 +/- 0.6 *** 
Ct.Po (%) 7.9 +/- 0.5 11.2 +/- 0.5 *** 
 
** p<0.01, *** p<0.001 compared to WT using Student’s t test 
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Table 5.3: Whole bone structural and estimated material mechanical 
properties from femoral four-point bending  
 
Femur Wildtype (N=13) RadKO (N=15) 
Yield Force (N) 24.5 +/- 1.2 8.0 +/- 0.4 *** 
Ultimate Force (N) 28.9  +/- 1.6 17.5 +/- 0.7 *** 
Displacement to Yield (mm) 186.9 +/- 4.2 104.0 +/- 5.8 *** 
Postyield Displacement (mm) 165.9 +/- 18.4 810.3 +/- 87.6 *** 
Total Displacement (mm) 352.8 +/- 18.5 914.3 +/- 88.1 *** 
Stiffness (N/mm) 195.7 +/- 8.0 127.2 +/- 5.4 *** 
Work to Yield (mJ) 2.52 +/- 0.16 0.51 +/- 0.05 *** 
Postyield Work (mJ) 4.46 +/- 0.49 10.17 +/- 0.75 *** 
Total Work (mJ) 6.98 +/- 0.52 10.68 +/- 0.75 *** 
Yield Stress (MPa) 258.7 +/- 13.5 74.8 +/- 4.9 *** 
Ultimate Stress (MPa) 301.6 +/- 12.3 160.6 +/- 4.5 *** 
Strain to Yield (mε) 20380.8 +/- 935.8 11527.4 +/- 533.2 *** 
Total Strain (mε) 38517.2 +/- 2681.7 101673.0 +/- 9722.0 *** 
Elastic Modulus (GPa) 14.2 +/- 0.6 7.7 +/- 0.2 *** 
Resilience (MPa) 2.9 +/- 0.3 0.5 +/- 0.1 *** 
Toughness (MPa) 8.3 +/- 0.9 10.8 +/- 0.7 * 
 
* p<0.05, *** p<0.001 compared to WT using Student’s t test 
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Table 5.4: Histomorphometry 
	  
Distal Femur Wildtype (N=5) RadKO (N=5) 
Trabecular MAR (µm/day) 3.51 +/- 0.26 2.52 +/- 0.18 * 
Trabecular MS/BS (%) 36.6 +/- 1.4 45.2 +/- 0.6 ** 
Trabecular BFR/BS 
(µm3/µm2/year) 
 
470.0 +/- 41.7 
 
417.0 +/- 36.0 
Femur Diaphysis Wildtype (N=5) RadKO (N=5) 
Ct.Ar (mm) 0.92 +/- 0.02 0.74 +/- 0.01 *** 
Periosteal MAR (µm/day) 1.01 +/- 0.07 0.78 +/- 0.08 
Periosteal MS/BS (%) 55.0 +/- 4.8 39.5 +/- 2.3 * 
Periosteal BFR/BS 
(µm3/µm2/year) 
 
204.8 +/- 28.7 
 
114.3 +/- 17.1 * 
Endocortical MAR (µm/day) 1.08 +/- 0.09 0.93 +/- 0.06 
Endocortical MS/BS (%) 76.0 +/- 4.0 69.0 +/- 4.7 
Endocortical BFR/BS 
(µm3/µm2/year) 
 
299.1 +/- 32.8 
 
237.5 +/- 30.4 
 
* p<0.05, ** p<0.01, *** p<0.001 compared to WT using Student’s t test	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Figure 5.1: No gross alterations in skeletal development in Rad-/- mice 
Skeletons of one-day-old mouse pups were isolated from surrounding tissue and 
stained with Alcian Blue (cartilage, blue) and Alizarin Red S (bone, purple).  
RadKO skeletons appeared smaller than WT, but no profound differences in 
skeletal development were observed.  
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Figure 5.2: Lower trabecular and cortical bone density in Rad-/- mouse 
femora 
Panel A) Representative images from µCT analysis of trabecular bone at the 
distal femora of WT and RadKO mice with accompanying quantification of the 
trabecular bone volume fraction (BV/TV).   
Panel B) Representative images from µCT analysis of cortical bone at the mid-
diaphysis of WT and RadKO mouse femora with corresponding quantification of 
the cortical bone area (Ct.Ar). N=5-15 mice per group, 4 months of age. 
**p<0.01, ***p<0.001 compared to WT by Student’s t test. 
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Figure 5.3: Rad deletion results in altered mechanical properties 
Quantification of mechanical properties obtained from four-point bending analysis 
of WT and RadKO mouse femora. N=13-15 mice per genotype, male, 4 months 
of age. ***p<0.001 compared to WT by Student’s t test. 
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Figure 5.4: In vitro osteoclast differentiation is enhanced in the absence of 
Rad 
Representative images and quantification of tartrate-resistant acid phosphatase 
(TRAP) stained osteoclasts derived from spleen.  The number of TRAP-positive 
multinucleated cells (MNCs, at least three nuclei) was counted in each well of a 
24-well plate. N=3 animals per genotype, male, 2 months of age. *p<0.05 
compared to WT by Student’s t test	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Figure 5.5: Osteoclast surface is not higher in the absence of Rad 
Tartrate-resistant acid phosphatase (TRAP) staining of WT and RadKO distal 
femur thin sections and corresponding quantification of the percentage of the 
bone surface occupied by osteoclasts (Oc.S/BS). N=5 mice per group, 4 months 
of age. * p<0.05 by Student’s t test. 
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Figure 5.6: Lower bone formation rate in Rad-/- femora 
Panel A) Representative images of calcein double labeling in distal femur 
trabecular bone of WT and RadKO mice (10X).  
Panel B) Mineral apposition rate (MAR), mineralizing surface/bone surface 
(MS/BS), and bone formation rate/bone surface (BFR/BS) in the cortical bone 
(periosteal surface) and trabecular bone of WT and RadKO mice. N=5 mice per 
genotype, female, 4 months of age. * p<0.05, ** p<0.01 compared to WT by 
Student’s t test. 
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Figure 5.7: Rad-/- osteoblast activity is depressed in vitro  
Panel A) Representative immunoblot of WT and RadKO calvarial osteoblast 
lysates confirms Rad expression in these cells. N=3 isolations per genotype. 
Panel B) Representative images of WT and RadKO primary calvarial osteoblasts 
stained for alkaline phosphatase activity after 7 days in osteogenic media. N=4 
isolations per genotype.  
Panel C) Representative images of Alizarin Red S staining of WT and RadKO 
primary osteoblast monolayers following 21 days in mineralizing conditions. 
Staining was quantified by solubilization of the stain in acetic acid, neutralization, 
and optical density measurement at 405 nm. N=3-5 isolations per genotype. 
**p<0.01 compared to WT by Student’s t test. 
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Figure 5.8: Higher expression of matrix Gla protein in Rad-/- osteoblasts  
Panel A) Osteoblast marker gene expression from microarray analysis of WT and 
RadKO primary osteoblasts. N=2 isolations per genotype.  
Panel B) RT-PCR analysis of MGP expression confirms its expression is 
elevated in RadKO osteoblasts compared to WT. N=3 isolations per genotype. 
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Figure 5.9: Loss of Rad results in spontaneous adipogenesis of calvarial 
osteoblasts in vitro 
Representative images of wildtype and RadKO primary calvarial osteoblasts 
stained with Oil Red O (ORO) after 14 days in mineralizing conditions. The 
number of ORO-positive cells was counted for 3 random fields per isolation. N=3-
4 isolations per genotype. * p<0.05 by Student’s t test. 
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Figure 5.10: Adipogenic induction of WT osteoblasts results in a reduction 
in endogenous Rad levels 
WT osteoblasts were maintained in growth media or adipogenic media (AM) for 7 
days and harvested for Western blotting analysis of Rad and Gapdh levels. 
Quantification of Rad levels normalized to Gapdh is shown.  N=3 isolations.         
* p<0.05 by Student’s t test. 
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Figure 5.11: Adipogenic induction of WT cells results in a phenotype 
similar to Rad deletion 
Panel A) Representative images of Oil Red O staining in WT and RadKO primary 
osteoblast monolayers following 14 days in growth (GM) or adipogenic (AM) 
media. Adipogenic treatment of WT and RadKO cells resulted in a marked 
increase in ORO+ cells. N=3 isolations per genotype. 
Panel B) Representative images of alkaline phosphatase activity in WT and 
RadKO primary osteoblast monolayers following 7 days in osteogenic (OM) or 
adipogenic (AM) media. Adipogenic treatment of WT cells reduced alkaline 
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phosphatase activity to a level comparable to RadKO basally. N=3 isolations per 
genotype. 
Panel C) RT-PCR analysis of MGP expression levels normalized to 18S RNA. 
RNA was isolated from WT primary osteoblasts after 3 days in growth (GM) or 
adipogenic (AM) media. N=3 isolations. * p<0.05 by Student’s t test. 
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Figure 5.12: Higher bone marrow adiposity at the distal femur of Rad-/- mice 
Representative images of Von Kossa/MacNeal’s staining of thin sections from 
WT and RadKO femora at 5X and 20X magnification. Number of adipocytes per 
20x field and the average adipocyte diameter in pixels were quantified. N=5 mice 
per genotype, female, 4 months of age. * p<0.05, ** p<0.01 by Student’s t test. 
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Figure 5.13: No change in global adiposity in Rad-/- mice  
Echo-MRI analysis of body composition of WT and RadKO mice indicates no 
significant difference in lean or fat mass percentage. N=21 WT, 11 RadKO mice, 
4 months of age, female. 
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Figure 5.14: Rad interacts with C/EBP proteins 
HEK293 cells were transfected with C/EBP α, β, or δ along with HA-tagged Rad 
WT or empty vector as a control. Immunoprecipitation with anti-HA antibody and 
Western blotting with the appropriate C/EBP isoform antibodies indicates that 
each of these three C/EBP isoforms can associate with Rad. Results are 
representative of 2-3 independent experiments. 
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Chapter 6 
 
Discussion 
 
The studies described in this dissertation were performed with two main 
objectives.  The first goal was to identify potential mechanisms for the regulation 
of RGK (Rad, Rem, Rem2, Gem/Kir) subfamily proteins with a particular focus on 
Rad, given that these proteins act as intrinsic negative regulators of calcium 
current yet are highly expressed in excitable cell types such as cardiomyocytes 
and given the unusual characteristics of this subfamily compared to other Ras-
related small GTPases.  The second goal was to explore potential roles of Rad 
beyond voltage-dependent calcium channel (VDCC) regulation in light of the 
increasing number of reports that have found expression of this small GTPase in 
non-excitable cell types.   
Identification of Rad/RGK subfamily regulatory mechanisms: ubiquitination 
and phosphorylation 
The results described herein demonstrate that Rad associates with Enigma, a 
putative scaffolding protein with a PDZ domain and three LIM domains.  This 
Rad-Enigma interaction likely plays a regulatory function, as Enigma is known to 
associate with E3 ubiquitin ligases including Smad ubiquitin regulatory factor 1 
(Smurf1) as well as with protein kinases.  Notably, ectopic Smurf1 expression 
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resulted in ubiquitination and turnover of Rad protein (Figure 3.4), and Enigma 
overexpression resulted in an increase in Rad phosphorylation at Ser39 (Figure 
4.10), suggesting that this protein complex indeed plays a role in regulating post-
translational modifications of the Rad protein.  Two related and interesting 
questions that remain to be answered, then, are which of these proteins form a 
larger complex, and whether the processes of Rad phosphorylation and 
ubiquitination may be linked.  Our studies established that Enigma associates 
with Rad and CaV1.2 through the LIM domains (Figure 3.2 and 4.10), raising the 
possibility of steric clash.  Likewise, it is unclear whether E3 ubiquitin ligases, 
kinases, and RGK proteins may simultaneously bind to Enigma or whether 
binding of some of these components to Enigma may block association of others.  
Furthermore, the idea of sequential control of phosphorylation and ubiquitination 
requires further exploration; perhaps Rad phosphorylation is a prerequisite for 
ubiquitination (Figure 6.1A).  This idea could be tested by asking whether the 
Rad S39A mutant, or potentially other phospho-site mutants, is subject to 
Smurf1-mediated degradation. Alternatively, phosphorylation of Rad could inhibit 
ubiquitination and turnover, since 14-3-3 dimers may impede the availability of 
Rad Lys204 as a substrate for E3 ubiquitin ligases (Figure 6.1B).  Analysis of 
ubiquitination and Smurf1-mediated turnover of Rad S39D/E and other 
phosphomimetic Rad mutants could help to answer this question.  
Although Enigma overexpression had no effect on the calcium channel inhibitory 
property of Rad despite increasing Rad Ser39 phosphorylation, the interaction 
between Enigma and CaV1.2 is likely not coincidental.  A different but attractive 
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hypothesis moving forward is that Enigma may act as a scaffold that tethers Rad 
to the calcium channel, thereby enhancing its ability to block calcium current, 
potentially while also regulating turnover of Rad to fine tune calcium current. It is 
worth noting, however, that pilot echocardiography studies suggest that Enigma-/- 
mice do not display the Rad-/- cardiac phenotype and thus that Enigma is not 
essential for Rad function at the level of heart function (data not shown).  Future 
studies of the role of Enigma in regulating Rad and its control of calcium current 
are needed, particularly Enigma knock down experiments in HEK293 cells to 
determine whether Rad overexpression still abolishes calcium current.  Likewise, 
overexpression of Rad in Enigma-/- cardiac myocytes should be performed to 
determine whether Enigma is required for Rad-mediated inhibition of 
endogenous VDCCs.  Given the roles of Enigma in interacting with Rad and the 
Smurf1 E3 ligase and potentially thereby controlling Rad ubiquitination and 
turnover (Chapter 3), promoting Rad phosphorylation (Figure 4.9), and 
interacting with the calcium channel (Figure 4.10), the role of Enigma in Rad 
regulation is likely complicated.  It is conceivable that Enigma may help to 
localize Rad to the calcium channel while also scaffolding E3 ubiquitin ligases 
and kinases that might control Rad and calcium channel function. 
The findings of an interaction with Enigma and of down regulation in the context 
of ectopic Smurf1 expression were not only demonstrated for Rad, but were 
found to be consistent across the RGK subfamily of GTPases (Figures 3.1 and 
3.5).  These observations suggest that Smurf1 may contribute to proteostatic 
regulation of each of the four RGK proteins.  The subsequent studies performed 
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with Rad warrant repetition with the other RGK subfamily proteins, namely 
determining whether proteasome inhibition abolishes the Smurf1-mediated 
decline in RGK expression and whether Smurf1 overexpression results in an 
increase in ubiquitination of the other RGKs.  While ubiquitination had been 
established as a post-translational modification of Rad protein [123, 124], the 
same has not yet been reported for Gem, Rem, or Rem2.  Hence, should these 
proposed studies indicate that the other RGKs are indeed subject to Smurf1-
mediated ubiquitination, the lysine residue(s) that are involved would require 
elucidation through mass spectrometry analysis or targeted mutagenesis of 
candidate lysine residues.  
The contribution of the interaction between RGKs and Enigma to RGK-mediated 
cytoskeletal modulation is another interesting avenue for future investigation.  
Early work investigating the role of Rad indicated that Rad associates with the 
actin cytoskeleton through an interaction with the actin-binding protein β-
tropomyosin [244]. Interestingly, Enigma has also been reported to localize to the 
actin cytoskeleton and to bind directly to β-tropomyosin through its PDZ domain, 
and a role has been proposed for Enigma as an adaptor protein to guide LIM 
domain-binding proteins to muscle cell actin filaments [245].  Notably, the PDZ 
domains of PDZ-LIM family proteins are highly conserved, and several of these 
related proteins also associate with the cytoskeleton through their PDZ domains 
[246-248]. Rad and Gem modulate the actin cytoskeleton as established 
inhibitors of Rho kinase [19], and overexpression of these RGK proteins leads to 
cell flattening and disassembly of stress fibers and focal adhesions [19, 20, 22]. 
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Similarly, Enigma deletion in mouse embryonic fibroblasts inhibited stress fiber 
formation [249].  While it is unclear whether the roles of RGK proteins and of 
Enigma in the regulation of actin stress fibers are linked, it is notable that Enigma 
deletion, which we observed was correlated with an increase in Rad expression 
in the heart (Figure 3.3), results in a similar phenotype of impaired stress fiber 
formation as does Rad overexpression. Enigma is not the only PDZ-LIM family 
protein associated with the regulation of stress fiber assembly; CLP36 (PDLIM1), 
a protein with a PDZ domain and only one LIM domain, localizes to actin stress 
fibers [248], and its knock down results in the loss of stress fibers and focal 
adhesions with rescue of this phenotype requiring both the PDZ and LIM 
domains [250].  Furthermore, both Rad and Enigma have independently been 
reported to have roles in the translocation of glucose transporters to the plasma 
membrane and glucose uptake in response to insulin, a process that is known to 
involve rearrangement of the actin cytoskeleton [140, 251]. Notably, 
overexpression of full-length Enigma inhibited insulin-stimulated glucose 
transport, while deletion of the LIM domains, which are not required for 
cytoskeletal association but are involved in RGK association (Figure 3.2), 
abolished this effect [251].  In vivo, Rad overexpression in muscle resulted in 
more severe insulin resistance [252], which is consistent with the in vitro 
observation of decreased insulin-stimulated translocation of glucose transporters. 
Rad has also been reported to inhibit glucose transporter translocation in cancer 
cells [24-27]. Taken together, these reports in the literature suggest that the 
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interaction between Rad and Enigma may play a role in the regulation of Rad-
mediated cytoskeletal remodeling in addition to calcium channel modulation.   
Another key untested notion is that ubiquitin-mediated turnover might contribute 
to Rad regulation in the heart, particularly of Rad-mediated VDCC control. 
Should Enigma and Smurf1 play an important role in the regulation of Rad in 
cardiac myocytes, it will be important to consider the role of alternative splicing of 
Enigma in Rad activity.  Full-length Enigma, or LIM mineralization protein-1, 
consists of an N-terminal PDZ domain and 3 C-terminal LIM domains as we have 
described here; however, alternative splicing can result in the generation of a 
shorter LIM mineralization protein-3 isoform that lacks the three LIM domains 
[170].  Since the data suggest that Rad associates via the LIM domains of 
Enigma, the implication is that this alternatively spliced isoform may exclude Rad.  
Interestingly, the related protein Enigma homolog (ENH) is alternatively spliced 
during heart development as well as cardiac hypertrophy [253].  Should the same 
be true for Enigma, this could explain the altered regulation of Rad protein levels 
in heart failure.  In a similar vein, recent studies have reported increases in BMP-
4 and 6 expression and signaling in heart failure [254, 255], presenting another 
potential means for Rad down regulation in this context.  Bone morphogenetic 
protein-2 (BMP-2) was also shown to be required for cardiac contractility [256], 
which is in keeping with the phenotype of enhanced contractility that we observe 
in Rad-/- hearts [104].  While it remains unclear whether the down regulation of 
Rad in the context of heart failure is pathological or compensatory and whether 
proteostatic mechanisms are relevant to this regulation, understanding how Rad 
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levels are modulated and the role of Enigma and Smurf1 in this process could 
afford a potential therapeutic strategy for heart failure patients.  Other interesting 
questions along these lines include whether Enigma or Smurf1 levels are altered 
in heart failure and whether and how the interaction between Rad and Enigma is 
regulated.   
The studies in Chapter 4 of this dissertation suggest that β-adrenergic signaling 
promotes downstream Rad phosphorylation at Ser39 (Figures 4.1-4.4).  While 
we were unable to demonstrate a change in Rad-mediated VDCC blockade in 
response to Rad Ser39 phosphorylation (Figure 4.11), co-immunoprecipitation 
studies suggested that Rad Ser39 phosphorylation may decrease its association 
with the CaVβ2a subunit of the calcium channel and increase its association with 
14-3-3 (Figures 4.5-4.8), and we have proposed studies in the Discussion 
section of Chapter 4 for further analysis of the potential regulatory role of 
phosphorylation in Rad-mediated calcium channel modulation. 
The hypothesis that Rad Ser39 phosphorylation downstream of β-adrenergic 
signaling may abolish its calcium channel inhibitory properties is particularly 
attractive in light of the recent studies showing that mice with calcium channel 
knock-in mutations that eliminate phosphorylation of the channel complex 
through β-adrenergic signaling retain β-adrenergic responsiveness [199-201].   
To determine whether Rad phosphorylation plays a key role in the acute increase 
in calcium current observed following β-adrenergic receptor stimulation, we could 
use CRISPR/Cas9 gene editing technology to mutate the endogenous Rad 
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Ser39 to alanine in mice, as we have successfully used this system recently to 
generate a floxed Rad mouse and a Flag-tagged Rad knock-in mouse (data not 
shown). If Rad phosphorylation at Ser39 is necessary for the β-adrenergic 
increases in calcium current, then the Rad S39A knock-in mouse would no 
longer be responsive to isoproterenol.  In contrast, knocking in an S39D/E 
mutation into mice may be expected to generate a cardiac phenotype that mimics 
β-adrenergic activation in the absence of stimulus, similar to what we have 
reported in Rad-/- mice [104, 131]. 
While our preliminary results in Chapter 4 demonstrate Rad Ser39 
phosphorylation downstream of β-adrenergic receptor and adenylyl cyclase 
activation using isoproterenol and forskolin, respectively (Figures 4.1-4.3), the 
endogenous kinase(s) responsible for Rad phosphorylation at this residue have 
not yet been identified. Namely, it is unclear whether PKA directly phosphorylates 
Rad or whether PKA signaling indirectly modulates Rad phosphorylation through 
regulation of downstream kinase(s) or phosphatase(s) that then act upon Rad.  In 
vitro kinase assays would allow determination of a direct role for PKA, while a 
kinase siRNA library could be employed to identify kinase(s) that act upon Rad at 
Ser39. 
Finally, the impact of β-adrenergic stimulation and Rad Ser39 phosphorylation on 
the subcellular localization of Rad has not yet been investigated.  It is worth 
noting that our observation that Rad Ser39 phosphorylation enhances 14-3-3 
binding reproduces what has been previously published [16, 118], but also 
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extends those studies as the first report of 14-3-3 association in response to a 
stimulus.  RGK mutants deficient for 14-3-3 binding have altered subcellular 
distributions, and overexpression of 14-3-3 results in cytoplasmic redistribution of 
wildtype RGK proteins [16, 109, 113]. As mentioned above, we have recently 
generated a mouse with a Flag tag introduced in frame at the N-terminus of the 
endogenous Rad gene, and this mouse will be useful in studying the subcellular 
distribution of endogenous Rad protein in different cell types and in response to 
different stimuli, including isoproterenol and forskolin.  In addition, anti-Flag 
immunoprecipitation from heart tissue from these mice coupled with mass 
spectrometry would allow analysis of the endogenous proteins that interact with 
Rad, with the expectation that we would observe co-immunoprecipitated Enigma 
and potentially other protein partners that may give further insight into Rad 
regulation. 
Roles of Rad beyond calcium channel regulation: regulation of bone 
homeostasis 
In Chapter 5, we demonstrated that genetic loss of Rad GTPase results in low 
bone mass accompanied by a dramatic expansion in bone marrow adipose 
tissue (BMAT) that is similar to the presentation of age-related osteoporosis in 
humans.  We also showed that Rad is significantly down regulated during the 
adipogenic differentiation of primary calvarial cells, suggesting that Rad signaling 
may play a previously unrecognized role in directing osteogenic versus 
adipogenic differentiation. 
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An interesting area of future investigation will be the contributions of the known 
functions of Rad GTPase as well as the new insights made about Rad regulation 
in Chapters 3 and 4 of this dissertation to Rad-mediated regulation of bone 
homeostasis (Figure 6.2).  Specifically, Rad-mediated calcium channel inhibition, 
Rad-mediated cytoskeletal modulation through regulation of Rho/ROK signaling, 
the interaction between Rad and Enigma, and the regulation of Rad 
phosphorylation through β-adrenergic signaling could each play a potential role in 
the Rad-/- phenotype of low bone density that we have reported in Chapter 5. 
Does calcium channel regulation contribute to Rad’s role in bone? 
First, the role of Rad as an intrinsic negative regulator of calcium current has not 
yet been probed as a potential mechanism for Rad modulation of bone 
homeostasis.  Importantly, both osteoblasts and osteoclasts express L-type 
VDCCs [257, 258].  Specifically, both mRNA and protein for the CaV1.2 subunit, 
the predominant CaVα subunit in the heart, have been detected in osteoblasts 
[259, 260].  However, since increased calcium current is correlated with an 
increase in bone density and a decrease in bone resorption [257], and we see a 
decrease in bone density in Rad-/- mice where we would expect increased 
calcium current, we do not expect calcium current to play a key role in the low 
bone density phenotype of Rad-/- mice.  Nevertheless, calvarial osteoblasts from 
WT and Rad-/- mice could be isolated and subjected to voltage clamp analysis to 
determine whether calcium current is elevated in the absence of Rad in these 
cells, as we have established for cardiac myocytes [104].  In Chapter 5 of this 
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dissertation, we were unable to ask whether the Rad-/- phenotype might be 
complemented upon reintroduction of Rad protein.  In preliminary studies, Rad 
overexpression not only failed to improve the deficit in calcium deposition in   
Rad-/- calvarial cells, but Rad overexpression in WT calvarial cells severely 
inhibited calcium deposition (data not shown). We postulate that Rad 
overexpression in these cells blocked calcium current and therefore interfered 
with osteoblast mineralization, and that Rad deletion likely impairs osteoblast 
differentiation and/or activity through a mechanism that is distinct from calcium 
channel regulation. We have previously demonstrated that the C-terminus of 
RGK proteins is required for calcium channel blockade [12], so we could ask 
whether introduction of Rad ΔΔCT might rescue the mineralization defect in Rad-/- 
calvarial cells.  
Does cytoskeletal reorganization contribute to Rad’s role in bone? 
While work in our laboratory has focused on the function of Rad in VDCC 
regulation [12, 104], the other key physiological role that has been documented 
for Rad is in regulation of cytoskeletal remodeling through regulation of Rho/Rho 
kinase signaling [19] as described in Chapter 1.  Interestingly, Rho signaling 
plays a critical role in osteoclast-mediated bone resorption [261].  During bone 
resorption, osteoclasts undergo ordered cycles of migration and attachment that 
depend upon podosome assembly and disassembly [261].  Podosomes have an 
actin-rich core that is highly sensitive to actin regulatory pathways, including Rho 
signaling, and these structures cluster in a ring around the cell periphery [262].  
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Constitutively active Rho stimulates podosome formation, osteoclast motility, and 
bone resorption, while dominant negative Rho prevents these processes [263].   
Hence, given the role of Rad as an inhibitor of Rho/ROK signaling [19], one 
hypothesis may be that loss of Rad results in enhanced Rho signaling to promote 
osteoclast-mediated resorption and lower bone density.  While such a 
mechanism would fail to explain the decrease in bone formation observed in  
Rad-/- mice, it may be a contributing factor to the overall low bone density 
phenotype.  In Chapter 5, we demonstrated that Rad deletion resulted in 
enhanced osteoclast differentiation in vitro that did not correlate to an increase in 
osteoclast surface area in vivo.  However, future studies are necessary to probe 
the effects of Rad loss on osteoclast activity through either serum or urine 
ELISAs of bone resorption markers.  If these markers are elevated in Rad-/- mice, 
altered Rho/ROK signaling should be considered as a likely contributor.  Finally, 
Rho signaling has been implicated in the cytoskeletal rearrangements necessary 
for mononuclear precursors to migrate and fuse to form multinucleated 
osteoclasts during late stages of osteoclast differentiation [264], so enhanced 
Rho signaling in Rad-/- mononuclear cells could contribute to the increase in 
osteoclast differentiation observed in vitro. 
Does the interaction with Enigma contribute to Rad’s role in bone? 
As outlined in the introduction to Chapter 5, the novel Rad-interacting protein 
Enigma/LIM mineralization protein (LMP) (Chapter 3) has an established role in 
osteoblast differentiation and bone homeostasis that may provide insight into the 
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role of Rad in these processes.  Multiple studies have found that overexpression 
of Enigma/LMP enhances bone formation in vitro and in vivo [223-229]. Notably, 
there are three endogenous splice isoforms of Enigma/LMP [170].  The full-
length, 457 amino acid Enigma-1/LMP-1 protein has a PDZ domain and 3 LIM 
domains [170] and was utilized for the studies in this dissertation.  Enigma-
2/LMP-2 is a 423 amino acid splice variant whose PDZ and LIM domains are 
intact but whose overexpression fails to induce bone formation [222].  
Interestingly, Enigma-3/LMP-3 has only 153 amino acids and lacks all three LIM 
domains, yet it retains the property of bone formation upon overexpression [222].  
Hence, the LIM domains of Enigma/LMP are dispensable for its stimulation of 
bone formation [222].  Since our analyses in Figure 3.2 suggested that the LIM 
domains are required for Rad association with Enigma/LMP, it is possible that 
overexpression of the truncated Enigma-3/LMP-3 protein induces efficient bone 
formation through loss of regulation of Rad turnover.  Studies of these three 
splice isoforms has indicated a 36 amino acid region within the Enigma/LMP 
protein that is necessary for the induction of bone formation [222].  We could ask 
whether the native splice isoform Enigma-2/LMP-2, which is unable to bind to 
Smurf1, also fails to bind to Rad.  Our initial hypothesis is that overexpression of 
full length Enigma (LMP-1) induces bone formation through its ability to bind to 
both endogenous Rad and Smurf1, thereby sequestering these proteins from one 
another on separate Enigma scaffolds upon gross Enigma overexpression 
(Figure 6.3A).   Likewise, overexpression of truncated Enigma lacking the LIM 
domains (LMP-3) may induce bone formation through binding to Smurf1 but not 
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to Rad, again effectively reducing the efficiency of Rad ubiquitination and 
turnover (Figure 6.3C).  In contrast, overexpression of LMP-2 may fail to induce 
bone formation if it cannot bind to either Rad or Smurf1; hence, binding of Rad 
and Smurf1 to endogenous Enigma scaffolds would be unperturbed and Rad 
turnover would not be altered (Figure 6.3B). 
Similarly, the Smurf1 E3 ubiquitin ligase that binds to Enigma and that we have 
demonstrated to regulate Rad ubiquitination and turnover in vitro (Chapter 3) 
plays a critical role in the regulation of osteogenesis through altering BMP/Smad 
signaling [187, 190].  Indeed, the potential contribution of Smurf1-mediated 
regulation of Rad turnover to the Rad-/- low bone density phenotype we have 
observed in Chapter 5 is highlighted by the observation in Figure 5.10 that 
adipogenesis of WT calvarial cells results in a profound decrease in Rad protein 
levels.  Further work is necessary to determine whether this decrease in Rad 
expression is at the transcriptional level, the post-transcriptional level, or a 
combination of the two.  To address this issue, WT calvarial cells could be 
cultured in growth media or adipogenic media as described, followed by RNA 
isolation and qRT-PCR analysis to ask whether Rad mRNA levels are altered in 
this context.  If adipogenic differentiation does not reduce Rad mRNA levels, then 
the decrease in Rad protein levels that we have observed is likely mediated 
through a post-transcriptional mechanism. Administration of proteasome inhibitor 
to WT calvarial cells in combination with the adipogenic media would aid in 
determining whether the decrease in Rad levels during adipogenesis is due to 
increased protein turnover. If proteasome inhibition would render protection of 
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Rad levels during adipogenesis, then we would conclude that Rad is likely 
subject to ubiquitination and proteasomal degradation during adipogenic 
differentiation.  In such a case, the potential role of Smurf1 in regulating Rad 
protein ubiquitination and turnover during the physiological process of 
adipogenesis is an intriguing idea that could be tested by knocking down Smurf1 
expression in these cells and asking whether Rad protein levels are reduced to 
the same extent during adipogenesis.  Similarly, to test the role of Enigma as a 
scaffold that facilitates this process, calvarial osteoblasts should be isolated from 
LMP-/- mice and treated with adipogenic media to ask whether the same decline 
in Rad protein expression is observed.   
Does β-adrenergic signaling contribute to Rad’s role in bone? 
The β-adrenergic signaling pathway also has established effects on bone 
homeostasis [265].  Both osteoblasts and osteoclasts express type 2 β-
adrenergic receptors (β2ARs) [266, 267].  Studies in rodents suggest that β-
adrenergic activation results in an increase in osteoclastogenesis and bone 
resorption [267-270], as well as a decrease in osteoblast proliferation [271, 272].  
Conversely, global deletion of the three known β-adrenergic receptor subtypes 
results in an increase in bone mass [273], and β-adrenergic antagonism reduces 
bone loss following ovariectomy [274, 275], the chronic mild stress model of 
depression [276], and mechanical unloading [277].  In humans, some studies 
have correlated βAR-blocker treatment with increased bone density and a 
reduction in the risk of bone fractures [278-280], although not all studies have 
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yielded consistent results making overall conclusions about the effectiveness of 
beta-blockers difficult [281, 282].  Notably, patients with asthma or chronic 
obstructive pulmonary disease (COPD) using βAR agonists had an increased 
risk of bone fracture [283], and a study of pre- and post-menopausal women 
found an inverse correlation between sympathetic activity and bone density 
[284].  These studies collectively suggest that β-adrenergic signaling modulates 
bone homeostasis and raises the question of the role that proteins downstream 
of the β-adrenergic receptor may play in regulating bone formation and 
resorption.  Administration of β-adrenergic agonists or antagonists to WT and 
Rad-/- mice followed by assessment of bone density may provide insight into the 
potential role that this signaling pathway may have in generating the Rad-/- low 
bone density phenotype we have observed. Measurement of circulating 
catecholamine levels in WT and Rad-/- mice by serum ELISA would also provide 
insights into whether sympathetic drive may contribute to the observed 
phenotype.  Finally, the floxed Rad mouse that we have recently generated could 
be used to knock out Rad expression specifically in bone cells to determine 
whether the low bone density phenotype is intact; conversely, if the sympathetic 
nervous system is playing a critical role in generating the phenotype, then 
deletion of Rad specifically in osteoblasts, osteoclasts, adipocytes, or even MSC 
progenitors would be expected to have no effect on bone mineral density.  
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Parathyroid hormone signaling and matrix Gla protein 
While β-adrenergic signaling is one candidate, the upstream pathways involved 
in regulating Rad signaling in bone still require elucidation.  Future studies should 
also aim at determining whether signaling pathways known to direct bone 
marrow mesenchymal cell fate, such as parathyroid hormone (PTH), bone 
morphogenetic protein (BMP), and Wnt signaling, impact Rad expression levels 
and/or Rad function.  Notably, the parathyroid receptor (PTH1R), like the β-
adrenergic receptor, is a G-protein coupled receptor (GPCR) that signals through 
PKA [285].  PTH has complex effects in bone depending on the dose and the 
frequency of administration.  Namely, continuous PTH treatment has a catabolic 
effect in bone through decreased osteoblast activity and increased bone 
resorption by osteoclasts, while intermittent PTH treatment results in increased 
bone formation [286].  PTH been reported to enhance osteoblast differentiation, 
potentially through enhanced BMP signaling [287, 288], and overexpression of 
PTH1R results in an increase in bone formation and a decrease in BMAT [289, 
290].  More recently, Fan et al. has demonstrated that MSC-specific deletion of 
PTH1R results in a phenotype of increased BMAT and decreased bone density 
[291] that bears a resemblance to the Rad-/- bone phenotype described in 
Chapter 5.  PTH administration to WT and Rad-/- calvarial cells, followed by 
assessment of mineralization, alkaline phosphatase activity, and adipogenesis, 
would provide a reasonable pilot study for the role of Rad in PTH-mediated 
osteogenesis.  In addition, serum PTH levels in WT and Rad-/- mice could be 
assessed, as could plasma membrane expression of PTH1R in WT and Rad-/- 
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calvarial cells.  Furthermore, if Rad is required for the increase in osteogenesis 
downstream of PTH signaling, then overexpression of PTH1R in Rad-/- calvarial 
cells would be expected to fail to induce mineralization compared to WT.   
As mentioned above, continuous PTH treatment has an opposing, catabolic 
effect on bone.  Underscoring the potential relevance of altered PTH signaling to 
the Rad-/- bone phenotype, PTH treatment of the osteoblast-like cell line 
MC3T3E1 inhibited mineralization through induction of matrix Gla protein (MGP) 
expression [235, 236].  MGP is a 15-kDa secreted protein that was initially 
isolated and identified from demineralized bovine bone and whose name is 
derived from the presence of several mineral-binding γ-carboxyglutamic acid 
residues within the protein [234].  These modified amino acids, also present in 
osteocalcin or bone Gla protein, are generated via the action of a vitamin K-
dependent γ-carboxylase enzyme on glutamic acid residues [292-294].  These 
Gla residues can bind to calcium and hydroxyapatite [292-294], but the precise 
mechanism by which MGP blocks mineralization remains unclear.  We observed 
significant up regulation of MGP in Rad-/- calvarial osteoblasts at base line and in 
WT calvarial osteoblasts following adipogenic differentiation in Figures 5.8 and 
5.11, suggesting that the role of Rad in PTH signaling should be further explored 
as expressed above.  It would be worthwhile to ask whether PTH stimulation 
might alter Rad phosphorylation and/or ubiquitination and turnover in HEK293 
cells and in primary calvarial osteoblasts.  To probe the importance of the 
elevation in MGP expression to the Rad-/- phenotype of lower mineralization and 
spontaneous adipogenesis in calvarial osteoblast cultures, future studies should 
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aim at knocking down MGP expression in these primary cells to determine 
whether normalization of MGP expression to WT levels may rescue the observed 
phenotype.  Conversely, we could ask whether elevated MGP expression is 
sufficient to drive the Rad-/- phenotype by overexpressing MGP in WT calvarial 
cells and asking whether adipogenesis is enhanced at the expense of 
mineralization. 
Finally, the increase in the expression of MGP, an extracellular matrix protein, in 
Rad-/- calvarial cells is also intriguing in light of recent work suggesting that Rad 
deficiency can lead to increased cardiac fibrosis [41], which arises from excess 
deposition of extracellular matrix (ECM) in the heart. Specifically, loss of Rad 
enhanced C/EBP-δ activity and resulted in an increase in the expression of the 
target gene connective tissue growth factor and an increase in ECM deposition 
[41].  Taken together with our data, this study suggests that one role for Rad 
beyond calcium channel control may be regulation of the ECM.  Indeed, altered 
ECM deposition may explain the unique mechanical phenotype of weaker but 
more elastic bones in Rad-/- mice (Figure 5.3 and Table 5.3).   
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Does Rad regulate transcription? 
Our data that Rad associates with R-Smad proteins (Figure 3.7) and C/EBP 
proteins (Figure 5.14), coupled with the reports that Rad associates with and 
regulates the transcriptional activity of the RelA subunit of NF-kB [40] and 
C/EBP-δ [41] and that Rad resides in the nucleus in certain settings [16, 40, 117], 
suggest that the function of Rad in transcriptional regulation should be further 
explored.   
One intriguing hypothesis that could be tested is that Rad may bind to and 
sequester C/EBP proteins in the cytosol.  In such a model, loss of Rad would 
increase basal C/EBP activity to promote adipogenesis.  Billiard et al. 
demonstrated stimulus-dependent translocation of C/EBP-δ from the cytosol to 
the nucleus in osteoblasts [295].  Notably, this nuclear shuttling of C/EBP-δ 
required PKA activity, but C/EBP-δ was not itself a substrate for PKA [295].  
Conversely, early in vitro kinase assays to characterize Rad phosphorylation 
indicated direct phosphorylation of Rad by PKA at an unknown site [49], and our 
studies in Chapter 4 of this dissertation indicate phosphorylation of Rad at serine-
39 downstream of PKA signaling.  Hence, we propose the idea that Rad may 
sequester C/EBP-δ in the cytoplasm, but that PKA activation may result in Rad 
phosphorylation and disassociation from C/EBP proteins, releasing C/EBPs to 
enter the nucleus and regulate target gene expression. Alternatively, 
phosphorylated Rad may remain associated with C/EBP proteins and may enter 
the nucleus along with C/EBPs, given the presence of NLS sequences within the 
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Rad protein and the reports in the literature of Rad nuclear shuttling [11, 16, 40, 
117].  A first step in testing this model would be to determine whether the 
interaction between Rad and C/EBP-δ is direct or indirect. Next, the co-
immunoprecipitation studies of Rad and C/EBP-δ in HEK293 cells (Figure 5.14) 
should be repeated using a stimulus such as isoproterenol or forskolin to activate 
PKA activity and induce Rad phosphorylation. If PKA-dependent phosphorylation 
of Rad triggers disassociation from C/EBP-δ, then we would expect these stimuli 
to reduce the co-immunoprecipitation of C/EBP-δ  with Rad. Similarly, co-
immunoprecipitation and/or binding of Rad WT with C/EBP-δ could be compared 
to that of phosphodeficient and phosphomimetic Rad mutants at S39 as well as 
other serine residues to establish the effects of Rad phosphorylation on C/EBP 
association as well as which phosphorylation sites are pertinent.  To determine 
the relevance of C/EBP binding in vivo, we could probe for an interaction 
between endogenous Rad and C/EBP isoforms in calvarial cells and determine 
whether adipogenic treatment might abrogate this interaction to promote C/EBP-
dependent gene expression.  Finally, to determine the effects of Rad on C/EBP 
transcriptional activity, chromatin immunoprecipitation experiments could be 
performed to determine the promoter occupancy of C/EBP in WT versus Rad-/- 
calvarial cells, and C/EBP luciferase reporter assays could be utilized as well.  
We could also use the newly generated mouse line with Flag-tagged 
endogenous Rad to ask whether Rad is present at the promoter regions of 
C/EBP-regulated genes as well as to probe the subcellular localization of Rad 
and C/EBP-δ basally and in response to stimuli.  
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Clarifying the Rad-/- low bone density phenotype using conditional Rad-
knockout mice 
While the Rad-/- phenotype of low bone density and high bone marrow adiposity 
is quite striking, the deletion of Rad globally in these mice makes it difficult to 
draw conclusions about the underlying mechanism that drives the phenotype.  
Moreover, our observations that Rad deletion enhances osteoclast differentiation 
(Figure 5.4) and also decreases osteoblast mineralization in vitro (Figure 5.7) 
suggests that changes in both osteoblast and osteoclast activities may contribute 
to the low bone mass in these mice.  We have recently used CRISPR/Cas9 to 
insert loxP sites around exons 2 and 3 of the RRAD gene to generate conditional 
Rad-knockout mice that can be combined with tamoxifen-inducible Cre 
recombinase expression globally or tissue specifically.  These conditional Rad-
knockout mice will allow selective loss of Rad in distinct cell types or lineages to 
probe the contributions of these cell types to the phenotype we have observed.  
For instance, Rad could be selectively deleted in osteoblasts by expressing Cre 
recombinase under the control of the type I collagen promoter (Col1a1-Cre) 
[296], while selective loss of Rad in osteoclasts could be achieved using tartrate-
resistant acid phosphatase- or cathepsin K-driven Cre recombinase expression 
(TRAP-Cre or Ctsk-Cre, respectively) [297]. These mice would facilitate 
interrogation of the individual roles of osteoblasts and osteoclasts in generating 
the phenotype that we observe in the global Rad-/- mouse.  Specifically, we could 
ask whether deletion of Rad in osteoblasts or osteoclasts alone is sufficient to 
recapitulate the low bone mass phenotype that we report in Chapter 5 to 
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determine whether the phenotype results from a decrease in bone formation, an 
increase in bone resorption, or a combination of the two. 
Additionally, the conditional Rad-knockout mice could also be utilized in order to 
characterize the impact of Rad loss on osteogenic and adipogenic differentiation 
of mesenchymal stem cells (MSCs).  Deletion of Rad in MSCs can be achieved 
by crossing the floxed Rad mice with Prx1-Cre animals [298].  We would then 
assess the bone density and bone marrow adiposity of these animals, with the 
expectation that if Rad loss indeed alters the differentiation potential of MSCs to 
favor adipogenesis, then we should observe a similar phenotype of low bone 
mass and high marrow adiposity as with global Rad deletion.  We could also 
isolate MSCs from these animals and assess osteogenic versus adipogenic 
differentiation potential in vitro.  Furthermore, MSC-specific Rad deletion could 
be compared to osteoblast-specific ablation of Rad expression to distinguish 
between the possible effects of Rad on osteoblast differentiation versus mature 
osteoblast function.  Finally, tamoxifen injection of mice at various ages and 
stages in development to induce Cre expression and thus turn off Rad 
expression would allow us to look at the role of Rad in bone development as well 
as in aging. 
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Conclusions 
In this dissertation, we have presented a novel interaction between Rad and 
Enigma that may regulate Rad ubiquitination and turnover, we have 
characterized Rad phosphorylation and altered protein interactions downstream 
of β-adrenergic signaling, and we have demonstrated that Rad deletion in mice 
perturbs bone homeostasis and the bone-fat balance.  Given that Rad, unlike 
most Ras-related small GTPases, has not been shown to be controlled by 
classical GTP/GDP cycling, other mechanisms such as phosphorylation, 
ubiquitination, and alterations in Rad expression levels may represent key means 
of regulation. 
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Figure 6.1: Models to integrate Rad phosphorylation and ubiquitination 
Panel A) In the first model, Rad phosphorylation at Ser39 or other residues may 
facilitate Smurf1-mediated ubiquitination of Rad. 
Panel B) In the second model, Rad phosphorylation at Ser39 (and Ser301), 
which is known to promote 14-3-3 binding, may impede Smurf1-mediated 
ubiquitination of Rad. 
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Figure 6.2: Potential contributors to the Rad-/- phenotype of low bone 
density and high bone marrow adiposity 
A summary of many of the potential mechanisms that may contribute to the 
phenotype of low bone density and high bone marrow adiposity that we have 
reported in Rad-/- mice indicates that more work is needed to understand the role 
of Rad in regulating the bone-fat balance. 
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Figure 6.3: Proposed model for the role of Rad in the osteogenesis induced 
by overexpression of various LMP splice isoforms 
Panel A) Enigma/LMP-1 overexpression induces mineralization.  We propose 
that overexpression of LMP-1 may allow sequestration of Rad and Smurf1 on 
distinct LMP scaffolds to reduce the efficiency of Rad ubiquitination and turnover. 
Panel B) Enigma/LMP-2 overexpression does not induce mineralization and does 
not bind to Smurf1.  We propose that if LMP-2 also fails to bind to Rad, then Rad 
turnover may not be impacted by overexpression of this isoform, as Rad and 
Smurf1 would remain correctly localized to endogenous Enigma/LMP. 
Panel C) Enigma/LMP-3 overexpression induces mineralization, despite the 
absence of LIM domains.  We propose that overexpression of LMP-3 results in 
loss of regulation of Rad turnover through binding to Smurf1 but not Rad, 
sequestering the E3 ubiquitin ligase away from its substrate Rad.  
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Appendix 
List of Abbreviations 
 
AID: CaVα interaction domain 
ALP: Alkaline phosphatase 
AM: Adipogenic medium 
Ap.Dens: Apparent density 
AR: Adrenergic receptor 
ARS: Alizarin Red S 
ATP: Adenosine triphosphate 
BCIP: 5-bromo-4-chloro-3’-indolyphosphate 
BFR/BS: Bone formation rate/bone surface 
BMAT: Bone marrow adipose tissue 
BMP: Bone morphogenetic protein 
BMPRI/II: Bone morphogenetic protein receptor I/II 
BV: Bone volume 
BV/TV: Bone volume fraction 
CaMKII: Ca2+/Calmodulin-dependent protein kinase II 
cAMP: Cyclic adenosine monophosphate 
cDNA: Complementary deoxyribonucleic acid 
C/EBP: CCAAT-enhancer binding protein 
Co-IP: Co-immunoprecipitation 
Conn.D: Connectivity density 
	   192 
Co-Smad: Common partner Smad 
CRISPR: Clustered regularly interspaced short palindromic repeats 
Ct.Ar: Cortical bone area 
Ct.Ar/Tt.Ar: Cortical area fraction 
CTGF: Connective tissue growth factor 
Ct.Th: Cortical thickness 
DA: Degree of anisotropy 
DAG: Diacylglycerol 
DEPC: Diethyl pyrocarbonate 
dLS: Double labeled surface 
DMEM: Dulbecco’s Modified Eagle Medium 
DNA: Deoxyribonucleic acid 
DNase: Deoxyribonuclease 
ECM: Extracellular matrix 
EDTA: Ethylene diamine tetraacetic acid 
EGTA: Ethylene glycol tetraacetic acid 
ELISA: Enzyme-linked immunosorbent assay 
ENH: Enigma homolog 
EV: Empty vector 
FBS: Fetal bovine serum 
GAP: GTPase activating protein 
Gapdh: Glyceraldehyde 3-phosphate dehydrogenase 
GDP: Guanosine diphosphate 
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GEF: Guanine exchange factor 
Gem: Gene expressed in mitogen-stimulated T-cells 
GM: Growth medium 
GFP: Green fluorescent protein 
Gmip: Gem-interacting protein 
GPCR: G-protein coupled receptor 
GK: Guanylate kinase 
GSK-3: Glycogen synthase kinase-3 
GST: Glutathione S-transferase 
GTP: Guanosine triphosphate 
HA: Hemagglutinin 
HEK: Human embryonic kidney 
HTN: Hypertension 
HVA: High voltage-activated 
ICa: Calcium current 
IP3: Inositol 1,4,5-trisphosphate 
ISO: Isoproterenol 
kD: Kilodaltons 
Kir: Tyrosine kinase-inducible Ras-like 
LIM: Lin11, Isl-1, Mec-3 
LMP: LIM mineralization protein 
LVA: Low voltage-activated 
Ma.Ar: Medullary area 
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MAPK: Mitogen-activated protein kinase 
MAR: Mineral apposition rate 
Mat.Dens: Material density 
M-CSF: Macrophage colony-stimulating factor 
µCT: Microcomputed tomography 
MEM: Modified Eagle Medium 
MGP: Matrix Gla protein 
MNC: Multinucleated cells 
MRI: Magnetic resonance imaging 
mRNA: Messenger RNA 
MS/BS: Mineralizing surface/bone surface 
MSC: Mesenchymal stem cell 
NBT: Nitro blue tetrazolium 
NFκB: Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLS: Nuclear localization signal 
NMDA: N-methyl D-aspartate receptor 
noLS: Unlabeled surface 
Oc.S/BS: Osteoclast surface/bone surface 
OD: Optical density 
OM: Osteogenic medium 
ORO: Oil Red O 
Osx: Osterix 
PBS: Phosphate buffered saline 
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PCR: Polymerase chain reaction 
PDZ: PSD95, Dlg1, zo-1 
PIP: Phosphatidyl inositol phospholipids 
PIP2: Phosphatidylinositol 4,5-bisphosphate 
PKA: Protein kinase A 
PKC: Protein kinase C 
PKD1: Protein kinase D1 
PMA: Phorbol 12-myristate 13-acetate 
PTH: Parathyroid hormone 
PTH1R: Parathyroid hormone receptor 
Rad: Ras associated with diabetes 
RadpS39: Rad phospho-serine-39 
RANKL: Receptor activator of nuclear factor kappa-B ligand 
Rem(2): Rad- and Gem-like (2) 
RFP: Red fluorescent protein 
RGK: Rad, Rem, Rem2, Gem/Kir 
RNA: Ribonucleic acid 
ROK: Rho kinase 
R-Smad: Receptor-associated Smad 
RT-PCR: Reverse transcriptase-polymerase chain reaction 
Runx2: Runt-related transcription factor 2 
SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM: Standard error of the mean 
	   196 
SH3: Src homology 3 
sLS: Single labeled surface 
SMI: Structural model index 
Smurf: Smad ubiquitin regulatory factor 
SR: Sarcoplasmic reticulum 
Tb.N: Trabecular number 
Tb.Sp: Trabecular spacing 
Tb.Th: Trabecular thickness 
TGF-β: Transforming growth factor-β 
TRAP: Tartrate-resistant acid phosphatase 
Tt.Ar: Total cross-sectional area 
TV: Total volume 
Ub: Ubiquitin 
VDCC: Voltage-dependent calcium channel 
VKM: Von Kossa/MacNeal’s stain 
WB: Western blot 
WT: Wildtype 
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